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Abstract of Thesis 
 
The development of drug resistance, notably multidrug resistance (MDR) and adverse 
side effects due to treatment with current anticancer drugs are considerable obstacles in 
cancer therapy and together with dose-limiting toxicity lead to therapeutic failure in the 
cancer clinic. The aim of this study is to design and deliver new anticancer agents 
selectively to the tumour site to increase efficacy and reduce toxic side effects to normal 
cells, thereby increasing the therapeutic index; this would afford significant improvement 
for patients. The P-glycoprotein (P-gp; p-170) efflux pump is the most notable factor 
contributing to MDR. In one approach, a series of novel ester-linked aminoanthraquinone-
triphenylphosphonium (AQ-TPP) conjugates, structurally related to the DNA-binding, 
Pgp- substrate anticancer drug mitoxantrone, was, synthesised and characterized by 
mass spectrometry, 1H and 13C NMR spectroscopy. AQ-conjugates of the lipophilic 
cation TPP+ were designed and shown to utilize the large mitochondrial membrane 
potential (ΔΨm) in cancer cells to drive drug accumulation inside the mitochondria and 
concomitantly circumvent Pgp-mediated resistance. Correspondingly, enhanced DNA-
binding affinity and cytotoxicity were achieved for the AQ-TPP conjugate series compared 
with unconjugated precursors, exemplified by conversion of the non-DNA binding, non-
cytotoxic hydroxyalkylanthraquinone NU:UB 238 to its TPP conjugate SH1; that bound 
strongly to DNA (Kapp 0.1×107M-1) and was equitoxic in the highly resistant Pg-p 
expressing HCT 15 colon carcinoma and sensitive MCF7 breast carcinoma cell lines. 
[IC50 (µM) 9.48 ± 0.32 and 9.69 ± 3.35, respectively, by MTT assay]. Confocal 
microscopy live cell imaging in HCT116 colon cells, using MitoTrackerFM tracer dye 
showed significant colocalisation of cationic and lipophilic SH1 (Log D: 2.68 ± 0.04) to 
mitochondria and not to lysosomes, whereas precursor NU:UB 238 (Log D:1.97 ± 0.12) 
was not taken up by cells, establishing proof of principle.  
In another approach to achieve selective targeting of anthraquinone-based cytotoxics to 
cancer cells, a novel theranostic (therapeutic and diagnostic) anticancer prodrug Rho-
Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) and FRET substrate of the endoprotease 
legumain, highly overexpressed in cancer, was designed and synthesized, using solution 
ii 
 
phase and solid phase peptide synthesis, to incorporate experimental anticancer drug 
NU:UB 51, a cytotoxic bis-hydroxylated, propyl-spaced, aminoanthraquinone glycine 
conjugate with in vivo activity to confer cancer cell selectivity by legumain-mediated 
prodrug OM50 activation in the tumour microenvironment. The active drug was attached 
to the C-terminal asparagine (Asn) residue of the peptide substrate to exploit the unique 
proteolytic cleavage specificity of the enzyme for the acid terminus of Asn. Incubation of 
OM50 (10 μM) with rh-legumain (0.40 ng/μL) at 37 °C for 2 h in MES assay buffer (pH 
5.0) afforded a time-dependent increase in relative fluorescence intensity, monitored at 
the emission wavelength (λem 583 nm) of rhodamine-labelled peptide, confirming proof 
of principle for activation of the prodrug and direct release of the active anthraquinone 
NU:UB 51.  
The above approaches offer the prospect of improved methods for selectively targeting 
the anthraquinone class of cytotoxics to cancer cells with therapeutic potential.      
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4FDT                  Fluorinated docetaxel 
ABC                    ATP-binding cassette 
ADP                   Adenosine diphosphate 
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CsA                      Cyclosporine A 
CT DNA                  Calf thymus DNA 
DCC                       1,3-Dicyclohexylcarbodiimide 
DCU                        N,N-dicyclohexylurea 
DIPEA                     N,N-diisopropylethylamine 
DMAP                     N,N-Dimethylpyridine-4-amine 
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IMS                       Intermembrane space 
Kapp                                  DNA binding constant 
M                          Molar 
MDR               Multidrug resistance  
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MitoQ10                Mitoquinone Q10 
mmol                   Millimole(s) 
MOMP                 Mitochondrial outer membrane permeabilization 
MPPs                   Mitochondria-penetrating peptides 
MS                       Mass spectrum 
MSD                    Membrane-spanning domains 
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nDNA        Nuclear DNA 
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PDT                 Photodynamic therapy 
PE                      Phosphatidylethanolamine 
PEG                   polyethylene glycol 
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P-gp                   P-glycoprotein  
PLL                    Poly-L-lysine 
Pro                 Proline  
PyBOP               Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
PyClock              6-Chloro-benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium  
                           hexafluorophosphate               
QD                      Quantum dots 
Rf                         Retention factor 
Rho B                  Rhodamine B  
ROS                    Reactive oxygen species 
rRNA                   Ribosomal RNA 
SPPS                  Solid phase peptide synthesis 
TAMRA               Carboxytetramethylrhodamine 
TCA                     Tricarboxylic acid cycle 
TFA                     Trifluoroacetic acid 
TLC                     Thin-layer chromatography 
xxvi 
 
Top                      Topoisomerase 
Top2cc                Top2 cleavage complexes 
TPMP                  Triphenylmethylphosphonium 
TPP                     Triphenylphosphonium  
tRNA                   Transfer ribonucleic acid 
Trt                       Triphenylmethyl (trityl) 
UV                       Ultraviolet  
VDAC                  Voltage dependent anion channel 
ZnPc                    Zinc phthalocyanine 























Results from this research programme have been reported in part in the following 
publication: 
Mohammed, O., Turnbull, A., MacCallum, J. and Mincher, J. D.  (2016) Design, 
synthesis and evaluation of novel and clinically used anti-cancer agents targeted to 





During this research, different series of novel compounds have been synthesised to 
specifically target anticancer drugs inside the cancer cells. The structures below show 
examples of the compounds designed and synthesised in this study in their simplest 
format. 





           
  
 
The numbering system (blue colour) was used in this research for the anthraquinone 
chromophore, to support the NMR characterization (i.e. the compounds were 






Figure A1: Structural representation of TPP-aminoanthraquinone [TPP-butyl-AQ(4-OH)] 
The abbreviation AQ was used for the anthraquinones. The vector tryphenylphosphonium 
has been represented by the standard abbreviation TPP. The spacer in the TPP-
conjugate compounds has been further abbreviated for convenience; for example, the 
spacer -HO-(CH2)4-NH- (hydroxybutylamino) is presented as Butyl in Figure A1. In other 
instances, for example, the spacer -OH-(CH2)2-O-(CH2)2-NH- (hydroxyethoxyethylamino) 



















Figure A2: Structural representation of rhodamine B prodrug [Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-
di-OH)] 
In addition, in the rhodamine B prodrug, the spacer group [-HN-(CH2)3-NH-] 
(aminopropylamino) has been further abbreviated to APA. Gly-APA-AQ(4,8-di-OH) has 
been further abbreviated to NU:UB 51 (active agent component of the prodrug). The 
peptide is described using standard 3-letter codes Pro-Ala-Asn Figure A2. The 

























1 Chapter 1  
 
 
1.1 Aim and Hypothesis  
 
Aim 
The principal aims of this project are the synthesis and characterization of a series of 
novel anti-cancer drugs targeted selectively to mitochondria. Specifically, to develop 
novel compounds containing the mitochondrial carriers triphenylphosphonium (TPP) and 
rhodamine, ester-linked with anthraquinone derivatives structurally related to the 
topoisomerase inhibitor mitoxantrone. Furthermore, to evaluate the DNA-binding, 




The higher membrane potential (ΔΨm) of cancer cells compared with healthy cells can 
be exploited to achieve selective delivery of anticancer drugs to mitochondria using 
specific lipophilic cations, with the potential to avoid drug resistance, reduce side effects 










1.2 Introduction  
 
 Mitochondrial structure and function 
The observation that mitochondria are vital organelles in eukaryotic cells has been 
highlighted more than one Century ago. They were originally described as ‘‘bioplasts”, 
then were soon renamed due to their threadlike appearance during spermatogenesis 
(mitos = thread, chondros = granule). Mitochondria are known as a powerhouse by 
playing a central role in energy generating processes [adenosine triphosphate (ATP)] via 
oxidative phosphorylation and produce more than 90% of intracellular ATP in healthy 
eukaryotic cells (Galluzzi et al., 2010). However, mitochondria are also involved in 
secondary cellular functions such as the production of nicotinamide adenine dinucleotide 
(NADH) and guanosine triphosphate (GTP) in the citric acid cycle, synthesis of 
phospholipids for membrane biogenesis (Kühlbrandt, 2015) , fatty acid oxidation, amino 
acid metabolism and tricarboxylic acid and urea cycle (Duchen, 2004; Smith et al., 2012; 
Smith et al., 2011). All these functions make mitochondria an organelle to target in cancer 
therapy.  
Mitochondria consist of an outer mitochondrial membrane (OMM) and an inner 
mitochondrial membrane (IMM) with folded cristae that separate two aqueous 
compartments; the intermembrane space (IMS), which is the space between OMM and 
IMM, and the inner mitochondrial matrix, which is surrounded by the inner mitochondrial 
membrane  (Endo and Yamano, 2010) Figure 1.1. The OMM is porous and freely passed 
by small, uncharged molecules and ions through pore-forming membrane proteins 
(porins), such as the voltage dependent anion channel VDAC, which regulates the entry 
of different cellular components into the mitochondria. Any larger molecules, such as 
proteins, have to be transferred by special translocases. Because of its porosity, there is 
no membrane potential across the outer membrane (Kühlbrandt, 2015). The outer 
membrane also plays an important role in cell apoptosis by process called mitochondrial 




release of proteins normally found in the space between the inner and outer mitochondrial 
membranes such as cytochrome C (Green and Kroemer, 2004).  
However, the inner mitochondrial membrane (IMM) is highly folded into cristae and it is 
the most important part of mitochondria because it involves in the formation of ATP under. 
The IMM contains the components of the electron transport chain in which the 
oxidation/reduction reaction generates a proton that is used by ATP synthase to 
phosphorylate adenosine diphosphate (ADP) to ATP. Mitochondrial cristae folds allow a 
greater amount of enzymes and ATP synthase included in electron transport chain to be 
packed into the mitochondrion (Paumard, 2002). 
 
 
Figure 1.1: mitochondria structure 
 
However, mitochondria are known to be dynamic organelles in which the shape and size 
of mitochondria are highly variable and are controlled by fusion and fission. Also, the 
internal structure (inner membrane) of mitochondria can change in response to their 
physiological state (Detmer and Chan, 2007). Many cristae are found in mitochondria 
from tissues where energy demand is high, whereas  tissues with low energy have 
insignificant cristae (Higgs and Peterson, 2005). In addition, the mitochondrial inner 
membrane is not only morphologically different but also seems to have different functional 




through the inner membrane, are enriched in the inner boundary membrane close to the 
outer membrane, whereas proteins that are involved in oxidative phosphorylation are 
enriched in the cristae membranes. Also, the mitochondrial membrane structure is linked 
to the metabolic state of mitochondria. Mitochondria, which have limited respiration and 
are characterized by narrow cristae and few cristae junctions per cristae compartment 
have low ADP. Whereas, the mitochondria that have high respiratory activity and are 
characterized by larger cristae and several cristae junctions per cristae compartment 
have high ADP (Detmer and Chan, 2007). Therefore, these changes in mitochondrial 
structure and function make mitochondria dynamic organelles. 
 
 Mitochondrial membrane potential (ΔΨm) 
Mitochondrial membrane potential (ΔΨm) is an electrochemical gradient that is generated 
across the inner mitochondrial membrane (IMM). The origin of this gradient is a 
consequence of the transfer of electrons through mitochondrial enzyme complexes I, III, 
and IV, coupled to the pumping of protons from the mitochondrial matrix into the 
intermembrane space. The ΔΨm has a critical role in apoptosis, production of reactive 
oxygen species, energy translation, stability of mitochondrial encoded, protein synthesis 
and activation and translation of nuclear encoded proteins across mitochondrial 
membranes. However, ΔΨm is dynamic and changes in response to apoptotic signals, 
changes in the microenvironment, location of an individual cell during growth and 
localization of particular mitochondria within a cell (Heerdt et al., 2005).  
Furthermore, mitochondria can create a transmembrane electric potential of 
approximately -180 mV in comparison with the plasma membrane which can produce 
approximately -60 mV (Rin Jean et al., 2014). However, the most notable difference 
between healthy cells and cancer cells is that mitochondrial membrane potential (ΔΨm) 
is higher in cancer cells than healthy cells (Constance and Lim, 2012). Therefore, as the 
(ΔΨm) increases, more intracellular cationic species will penetrate the mitochondria 




accumulation of cationic drugs inside mitochondria and leading to cellular death Figure 
1.2. 
 
Figure 1.2: Mitochondrial membrane potential (ΔΨm) and accumulation of lipophilic cationic-
conjugates inside the mitochondrial matrix of a cancer cell. 
 
 Mitochondrial DNA and topoisomerases  
Each human cell contains nuclear DNA (nDNA) and a mitochondrial genome DNA 
(mtDNA). Mitochondria are the only cellular organelles containing DNA outside the 
nucleus (Khiati et al., 2014). mtDNA was first discovered in 1963 by (Nass and Nass, 
1963), they showed conclusively that chick embryo mitochondria contained DNA using 
electron microscopy. The mtDNA sequence was first published in 1981 as being 16,569 
base pairs long (Anderson et al., 1981). mtDNA is a circular double-stranded DNA 
molecule, capable of transcription, translation and protein assembly which are present at 
a high copy number per cell, and the number varies with the cell type. Human mtDNA 
encodes 13 polypeptides involved in respiration and oxidative phosphorylation, as well as 




(Chatterjee et al., 2006). mtDNA has special features including high copy number, 
matrilineal inheritance, a higher evolutionary turnover rate when compared with nDNA 
and lack of recombination (Van Oven and Kayser, 2009). In addition, compared with 
nDNA, mtDNA is more susceptible to damage due to insufficient DNA repair capacity, the 
lack of protective histones, and a high rate of reactive oxygen species (ROS) generation 
in mitochondria. Because all of the genes in mtDNA are important for the bioenergetic 
and biogenesis function of mitochondria, any mtDNA change may result in impairment of 
oxidative phosphorylation and enhanced ROS production, therefore may accelerate the 
rate of mtDNA mutations, this has been linked to the early stages of carcinogenesis (Yu 
et al., 2007).  
On the other hand, mtDNA, like nuclear DNA, require DNA topoisomerases for 
transcription and replication (Wang et al., 2002). DNA topoisomerases are ubiquitous 
enzymes that modify DNA topology by breaking the DNA phosphodiester backbone and 
resealing it, allowing DNA double helices or stands to pass though or rotate around each 
other. Hence, DNA topoisomerases play an essential role in modifying, maintaining and 
monitoring the topology of DNA transcription, replication, recombination, and repair of 
DNA (Zhang et al., 2007).  
DNA topoisomerases have been divided into two main types, type I and type II 
topoisomerases. Type I topoisomerases, which break one DNA strand at a time have 
been divided into two main groups: type IA and type IB. Type IA topoisomerases 
subdivided into (Top3α and Top3β) and Type IB subdivided into (Top1 and Top1mt). 
whereas, type II topoisomerases, which cut both strands of the DNA double helix (IIA) 
subdivided into (Top2α and Top2β) Figure 1.3 (Zhang et al., 2001). Mitochondria have 
type I topoisomerase (top I mt), which is similar to nuclear top I, composed of four 
domains: An N-terminal localization domain, a linker domain, a core domain, and a C-
terminal domain containing the catalytic tyrosine. Type I topoisomerases have been 
classified type IA and IB according to the polarity of the cleavage reaction and the 
relaxation mechanism. Type IA enzymes have an opposite polarity that bind to the 5` end 
of the cleaved DNA by covalent linkage and then relaxation of DNA by strand passage 




and forming a tyrosyl-DNA covalent catalytic intermediate at 3` end of the DNA breaks 
(Zhang et al., 2007). Furthermore, nuclear top 2 is known to translocate from the nucleus 
to mitochondria and therefore can present another drug target in addition to mt-Top1. 
Mitochondrial DNA and topoisomerases have been the subject of a very recent review 
(Goffart et al., 2019). 
 
 
Therefore, targeting drugs to mitochondrial DNA by inhibiting the activity of 
topoisomerases is a promising therapy to kill cancer cells. Many topoisomerase inhibitors, 
known as poisons, work by binding at the enzyme-DNA interface therefore trapping 
topoisomerase cleavage complexes which in turn, if not repaired, lead to cell death (Khiati 
et al., 2014). These inhibitors poison Top2 cleavage complexes (Top2cc) by two 
mechanisms; by inhibiting DNA relegation, in a similar manner as etoposide, teniposide, 
the DNA intercalators doxorubicin, daunorubicin and amsacrine and by enhance the 
formation of Top2cc such as quinolones, ellipticines, azatoxins and the natural flavonoid 
genistein. These drugs not only poison Top2-mediated DNA double-strand breaks but 




also single-strand breaks. Furthermore, doxorubicin poisons Top2cc at low drug 
concentrations due to its ability to inhibit Top2 catalytic activity without trapping cleavage 
complexes at drug concentrations that alter DNA structure, thereby preventing Top2 from 
binding to DNA or from forming Top2cc (Pommier et al., 2010) Figure 1.4.  
 
 




 Mitochondria and cancer 
Mitochondria play a crucial role in the regulation of cellular function, metabolism, and cell 
death in cancer cells. Several functional changes to cancer cell mitochondria are involved 
in tumour formation including decreased oxidative phosphorylation, increased production 
of reactive oxygen species (ROS) and increase in glycolysis. However, in cancer cells, 
mutations in mitochondrial genomes can change the biochemical behaviour of 
mitochondrial and nuclear protein complexes which in turn increase reactive oxygen 
species (ROS), thereby enabling tumour growth. In healthy cells, the glycolysis process 
in which ATP is generated is mainly by oxidative breakdown of pyruvate following non-
oxidative breakdown of glucose (Verschoor et al., 2013). In contrast, cancer cells 
constitutively upregulate glucose metabolism, even in the presence of high oxygen, thus 
cancer cell synthesize ATP through ‘aerobic glycolysis’, which is a metabolic process in 
which glucose breaks down in the absence of oxygen to produce lactic acid and increase 
the acidity of cancer cells which may facilitate tumour invasion. On the other hand, 
increased glucose breakdown provides building blocks for the synthesis of nucleotides 
and amino and fatty acids (Kroemer, 2006). The differences in the ratio of glycolysis and 
respiration in healthy and cancer cells is known as the Warburg effect (Warburg, 1956).  
Furthermore, it was discovered that the mitochondria of cancer cells are often resistant 
against the induction of mitochondrial outer membrane permeabilization (MOMP), which 
is a crucial process during apoptosis due to the release of proapoptotic factors such as 
cytochrome c from the mitochondrial intermembrane space to the cytosol, which in 
turnmediate the pathway of apoptosis. The inhibition of MOMP resulting in disabled 
apoptosis which is important for the development of solid tumours (Kroemer, 2006). 
However, several growth advantages of cancer cells provided by aerobic glycolysis 
include growth of cells in unfavourable microenvironments, affording precursors for 
biosynthetic reactions and generation of substrates for glycosylation reactions. The 
metabolism of glycolytic enzymes has independent functions which in turn provide 
additional function to cancer cells such as resistance to apoptosis, transcriptional and 
malignancy regulation and invasiveness. Besides aerobic glycolysis, the malignant 




biosynthesis, and glutamine-dependent anaplerosis [renewal of tricarboxylic acid cycle 
(TCA cycle) intermediates]. These changes in metabolism are important in rapid cell 
proliferation. Furthermore, many forms of cancer reveal mitochondrial DNA (mtDNA) 
mutations that include, mutations deletions, duplications, copy number changes and 
insertions, which can cause inhibition of oxidative phosphorylation, an increase reactive 
oxygen species generation, and can lead in tumour adaptation under adverse conditions. 
Alterations in cancer mtDNA include, increase invasive metastatic potential, drug 
resistance and poorer prognosis of cancer cells have been observed and related with the 
type and range of mtDNA mutations (Pathania et al., 2009). 
 
 Mitochondrial targeting for cancer therapy 
Targeting compounds to mitochondria represents a promising approach in cancer 
chemotherapy due to its vital functions in survival of eukaryotic cells through energy 
production (ATP) via oxidative phosphorylation and its crucial role in regulation of 
apoptosis (Galluzzi and Kroemer, 2008). However, (Diehn et al., 2009) demonstrated that 
modifications in the levels of reactive oxygen species (ROS) have been linked to the 
intrinsic chemotherapy resistance of cancer stem cells. These changes and functions 
make these organelles attractive drugs targets for cancer therapy.  
The mitochondria of tumour cells are structurally and functionally different from those of 
normal cells. Tumour cells have extensive metabolic reprogramming that make cancer 
cells more liable to mitochondrial disorder than healthy cells. In addition, mitochondrial 
adaptations that take place in cancer range from simple to intense dysfunction, therefore 
any difference between healthy and tumour cells is an opportunity to be therapeutically 
targeted (Constance and Lim, 2012). On the other hand, to deliver active drugs to 
mitochondria, it is important first to understand the chemical properties of molecules that 
selectively localize inside mitochondria. Two generalized requirements for mitochondrial 
localization are: delocalized positive charge and lipophilicity Figure 1.5 (Horobin et al., 




through mitochondrial membrane and cellular membrane, which have a negative 




Figure 1.5: General concept for TPP Carrier-Drug Targeting of mitochondria 
 
1.2.5.1  Examples of drugs targeted to mitochondria 
Impermeability of mitochondria against a wide range of molecules, makes the design of 
an efficient mitochondria-targeting cell permeable compound a difficult challenge. 
Delocalized positive charge is important to control the uptake of delivery vectors through 
mitochondrial membrane and cellular membrane, which have a negative membrane 
potential. An example of a vector containing drug with a positive charge to increase its 
uptake by mitochondria is gamitrinib (a mitochondrial matrix inhibitor) Figure 1.6. 
Geldanamycin, which is the therapeutically active portion of gamitrinib, was conjugated 
with triphenylphosphonium (TPP) to increase the uptake by mitochondria. Two main 




negative potential of inner mitochondrial membrane (IMM) are: the positive charge 
reduces the activation energy related with de-solvating the ion that should occur to 
advance its uptake through the hydrophobic inner mitochondrial membrane (IMM) and 
reduction of the interaction of this molecule with surrounding water molecules due to the 
spreading of positive charge over a large surface area, increasing its ionic radius (Kang 
et al., 2009; Kelley et al., 2011). 
 
 
Figure 1.6: Gamitrinib-TPP structure 
 
Furthermore, delocalized positive charge is not enough to make it cross the hydrophobic 
IMM, therefore introducing lipophilicity to the molecule will drive it to pass the hydrophobic 
IMM of mitochondria and accumulate. A hydrophobic nitrooxy-doxorubicin was designed 
to include a nitric oxide-releasing phenyl group that sufficiently increased its 
hydrophobicity compared with doxorubicin alone Figure 1.7. This strcture modification 
drives the molecule to be localized in membrane-rich organelles such as mitochondria 
instead of localized in the nucleus (Riganti et al., 2013). Moreover, mitochondria-targeted 




metabolically active cells such as heart and brain (Rin Jean et al., 2014). For this reason, 
by attaching mitochondrial targeting vectors, the anticancer active drugs will accumulate 
inside the mitochondria, which in turn reduces the side effects on normal cells. 
 
 
Figure 1.7: Nitrooxy-doxorubicin structure 
 
1.2.5.2 Triphenylphosphonium bromide (TPP) vector targeted to                  
mitochondria  
The delivery of drugs to mitochondria is a promising avenue for therapeutics in many 
human diseases but specifically in cancer treatment. It improves the therapeutic efficacy 
of anticancer drugs through accumulation of the drug inside the mitochondria and 
reduction of the undesirable effects of its off-target subcellular localization. By designing 
specific targeted delivery systems to mitochondria certain characteristics of the drugs may 
be improved, such as decreasing drug resistance, increasing bioavailability, and poor 
solubility. However, as the mitochondria have crucial implications in human 
pathophysiology, design and construction of carrier vectors for efficient selective drug 
delivery inside the mitochondria by crossing several membranes to reach its final 
destination inside the mitochondrion is the main and current focus of molecular 
pharmacological research. In addition, passive targeting to mitochondria is difficult due to 




to conjugation to lipophilic cations, including encapsulation in liposomes and incorporation 
into mitochondria-targeted peptides (Apostolova and Victor, 2015).  
The large membrane potential of mitochondria (−150 to –180 mV) provides a sufficient 
force for the selective targeting of lipophilic cations and accumulation inside the 
mitochondria. The distinct negative membrane potential present in mitochondria is not 
found in any other subcellular compartment and offers a unique molecular delivery 
opportunity for selectively targeting the mitochondrion (Hoye et al., 2008). The delivery of 
lipophilic cations inside the cell was first shown with the lipophilic cation rhodamine 123 
in combination with the anticancer drug cisplatin (Teicher et al., 1987) Figure 1.8. On the 
other hand, the most notable and widely employed lipophilic cation for mitochondrial 
targeting is (4-carboxybutyl)triphenylphosphonium bromide (TPP) Figure 1.9. The 
lipophilic nature and delocalized positive charge of TPP, allows TPP to permeate lipid 
bilayers easily and accumulate within mitochondria with 100-500 fold difference in the 
accumulation of TPP in the cytoplasm (Bielski et al., 2015). The selective uptake of TPP 
by mitochondria should greatly increase the specificity and efficacy of targeting molecules 
to mitochondria and moreover decreasing unwanted side effects (Smith et al., 2003).  
 
 







Figure 1.9: Triphenylphosphonium (TPP) structure (a mitochondrial vector) 
 
1.2.5.3 Examples of TPP conjugates targeted to Mitochondria 
Consequently, a number of TPP conjugates compounds have been designed to target 
the mitochondria for improve therapeutic index and reduce side effects. To improve this 
view, Chakraborty and Jana, (2015) synthesised quantum dots (QD) and iron oxide-
based nanoprobes and they conjugated these compounds with TPP. They found that QDs 
distributed all over the cells, but QDs with TPP were found to be localized inside cells. 
Moreover, they reported that co-localization study for QD with or without TPP using 
mitotracker and lysotracker probes showed that the nanoprobes clearly co-localized 
inside the mitochondria but did not co-localize in lysosomes, thus QD-TPP produces high 
toxicity in comparison with QD due to their excessive binding with mitochondria and thus 
disturbing their function (Chakraborty and Jana, 2015).  
In addition, Han et al., (2014) synthesised doxorubicin (DOX) derivatives; doxorubicin has 
a similar mechanism of action to mitoxantrone (the model compound in this research) as 
both are DNA binding topoisomerase II inhibitors. They conjugated TPP directly to DOX 
by an amide bond to investigate mitochondrial targeting of DOX Figure 1.10. Han et al., 
(2014) studied mitochondrial targeting, intracellular accumulation, cytotoxicity and 
resistance to DOX-TPP in human cancer cells and compared these with free DOX. They 
reported that cellular uptake of free DOX was lower than that of DOX-TPP in MDA-MB-
435/DOX breast cancer cell line, due to the possibility of bypass of Pgp and other 




localization of free DOX when compared with DOX-TPP in MDA-MB-435/WT and MDA-
MB-435/DOX cell lines showed the localization of free DOX in the nucleus of MDA-MB-
435/WT cells without any observed presence in mitochondria or cytoplasm and in MDA-
MB-435/DOX cells, free DOX was excluded from the nucleus. DOX-TPP showed similar 
distribution in both cell lines and colocalized with Mitotracker in mitochondria and no 
notable distribution in cytoplasm or nucleus in both cell lines, determining that TPP makes 
DOX more targeted to mitochondria, thus increases the preferential accumulation of DOX 
inside the mitochondria and not in the nucleus or cytoplasm leading to cellular death (Han 
et al., 2014). 
 
Figure 1.10: Doxorubicin-triphenylphosphonium (DOX-TPP) structure 
 
However, to improve the activity and targeting efficiency of TPP, several modifications of 
the hydrophobicity of the TPP−drug conjugate system have been studied and 
investigated. Hu et al., (2017) studied the effect of TPP phenyl substitution on the 
mitochondrial uptake properties of TPP. They indicated that increasing both the 




different positions of the TPP phenyl rings remarkably enhanced the partitioning of the 
modified TPP cation in a hydrophobic environment and improved the accumulation of 
conjugated cargo within the mitochondria. Hu et al., (2017) conjugated TPP with 
hexachloro-fluorescein Figure 1.11 for photodynamic therapy (PDT), which is the light 
irradiation of photosensitizer-stained cancer cells in the presence of molecular oxygen to 
produce reactive oxygen species that are capable of damaging and killing cells (Agostinis 
et al., 2011). Hu et al., (2017) prepared three hexachloro-fluorescein TPP-conjugates. 
First conjugate has no methyl substitution on phenyl rings of TPP, the second conjugate 
has one methyl substitution and the third conjugate has two methyl substitutions. They 
demonstrated that the accumulation level of the modified TPP species in the mitochondria 
of HeLa cells and FU97 gastric cancer cells increased significantly upon substitution of 
the phenyl rings. However, unconjugated fluorescein does not accumulate notably in the 
mitochondria and therefore does not display any PDT effect, while TPP-conjugates 
permeate both plasma and mitochondrial membranes and accumulate in the 
mitochondria. The more hydrophobic TPP cationic carrier with two methyl substituents on 
phenyl groups facilitates a better mitochondrial uptake of conjugated hexachloro-
fluorescein which leads to a 2 fold improvement in PDT efficacy upon light irradiation (Hu 
et al., 2017). 
 
Figure 1.11: Structures of the (hexachloro-fluorescein)-TPP  and TPP modified  conjugates: 
(hexachloro-fluorescein)−triphenylethylphosphonium (1a), (hexachloro-fluorescein)−tri-p-




In addition, TPP density plays a significant role in the mitochondrial targeting when the 
number of TPP conjugates increases, which has been improved by (Bielski et al., 2015). 
Bielski et al., (2015) conjugated TPP with poly(amidoamine) (PAMAM) dendrimers. 
Dendrimers have highly reproducible pharmacokinetic profiles because of their structure 
and they are relevant strategies to deliver a combination therapy (Li et al., 2013). Bielski 
et al., (2015) designed two main TPP conjugates, they linked TPP directly to 4 PAMAM 
G4NH2 dendrimer (G4NH2-TPP) Figure 1.12 (A) and they used a polyethylene glycol 
PEG linker (G4NH2−PEGTPP) Figure 1.12 (B). Three TPP loadings were used; no (0 
TPP), low (5 TPP) and medium (10 TPP) for G4NH2−TPP and same density for 
G4NH2−PEGTPP. They reported that both strategies make a significant enhancement in 
mitochondrial targeting compared with unconjugated compound. Direct TPP conjugation 
exhibited a direct correlation between targeting and TPP number density (G4NH2−10TPP 
is higher than that of G4NH2−5TPP which were both higher than G4NH2−0TPP, while 
indirect conjugation resulted in high targeting for all TPP densities with no effect on 
targeting by the degree of PEGylation. Furthermore, the density of TPP showed a direct 
correlation with the toxicity.  Bielski et al., (2015) measured the IC50 for three densities 
which showed that G4NH2−10TPP has an IC50 of 2.95 μM, while G4NH2−0TPP’s IC50 
was found at significantly higher concentrations (more than 20 μM) and the IC50 for 
G4NH2−5TPP does not affect the toxicity profile of the conjugate. Therefore, the 
maximum density of TPP is limited by its toxicity effect, which seems that the conjugate 
with 5 TPP represents the ideal number of TPP  residues with significant improvement in 
targeting while the toxicity of the conjugate is not changed (Bielski et al., 2015). 
The alkyl chain between the TPP and its conjugate also have a significant effect in 
accumulation of the TPP-conjugates inside the mitochondria. Mitoquinone (MitoQ10) 
Figure 1.13, is a TPP bound version of ubiquinone Q10.  The cellular uptake of MitoQ is 
more rapid than that of methylTPP, because the hydrophobicity of MitoQ is higher than 
that of methylTPP, which in turn reduces the activation energy available for passage 
across the plasma membrane. MitoQ10, has a 10-carbon atom-alkyl chain, which shows 
optimum activity and acumulation in the mitochondria (Apostolova and Victor, 2015). This 















Figure 1.13: Chemical structure of mitoquinone (MitoQ10)  
 
In addition, Rin Jean et al., (2014) reported that TPP conjugates in general have low 
toxicity and high level of uptake in vivo. However, (Guzman-villanueva et al., 2015) 
reported that TPP has high cellular toxicity levels, which have limited its therapeutic use 
due to an excessive accumulation of TPP cation within mitochondria. However, to reduce 
the cytotoxicity of TPP, (Guzman-villanueva et al., 2015) synthesised CTPP-PE by 
hydrophobization with two-tail phospholipid phosphatidylethanolamine (PE) via a 
carboxyl-to-amine conjugation reaction to reduce the cytotoxic effect of TPP Figure 1.14. 
They reported that CTPP-PE liposomes were less toxic than TPP and its derivatives at 
high concentration, and that the accumulation of TPP within the mitochondria was high, 
therefore the functionality of TPP cations was not altered by the hydrophobization 
reaction. This may be a benefit when using TPP to target cancer cells as the accumulation 
of TPP inside the cancer cells may cause cytotoxicity. 
 




1.2.5.4 Examples of other vectors targeted to mitochondria 
However, there are other vectors that can deliver anticancer drugs to mitochondria such 
as, nanoparticle, liposomes, cationic peptide and rhodamine B. Nanoparticle (NP) can be 
modified for mitochondrial targeting by attaching positively charged TPP carrier on the 
outer surface or within its structure (Weissig et al., 2006). For example, Wang et al., 
(2013) synthesised a novel nanoparticle system and conjugated it with TPP to enhance 
its activity. They used poly-L-lysine (PLL), which is a cationic nanocarrier that promotes 
cellular incorporation through adsorptive endocytosis via non-specific electrostatic 
association with an anionic membrane and helped their escape from endolysosomal 
compartments by the osmotic effect. The medium-sized PLL (MH-PLL) is considered to 
be the optimum one. TPP was conjugated to MH-PLL-NPs (TPP-MH-PLL-NPs) through 
a carbodiimide reaction process for selective mitochondrial targeting Figure 1.15. TPP-
conjugates were found to be effectively taken up by cells and selectively accumulated in 
the mitochondria (Wang et al., 2013). This indicated that the combination between two 





Figure 1.15: Chemical structure of TPP-MH-PLL-NPs 
 
On the other hand, liposomes are another nanoparticle system that are used to deliver 




liposomes are their biocompatibility and biodegradability, varied range of compositions 
and ability to carry and protect wide rang of biomolecule (Torchilin, 2009). However, there 
are some limitations for using this carrier including complex synthesis, their toxicity in vivo 
and possible immune response (Filion and Phillips, 1998). To improve this, Biswas et al., 
(2012) synthesised a novel polyethylene glycol-phosphatidylethanolamine (PEG-PE) 
attached with a TPP group (TPP-PEG-PE) and this conjugate was incorporated into the 
liposomal lipid bilayer. Liposome-TPP-conjugates were studied for the mitochondrial 
targeting, toxicity and potency delivering paclitaxel (PTX) to cancer cells in vitro and in 
vivo. They demonstrated that modified liposomes with novel polymer TPP-PEG-PE are 
non-toxic and effectively target mitochondria in cancer cells (Biswas et al., 2012).  
Peptide vectors have also been shown to provide efficient carriers for mitochondrial cargo 
delivery. The advantages of this vector include low toxicity, high specificity and an 
increase in the variety of interactions such as protein–lipid, protein–DNA and protein–
protein, that are difficult to target with small molecules. However, peptide vectors can face 
some difficulties in delivery, such as rapid clearance, degradation by proteases 
(Constance and Lim, 2012) and cannot deliver cargo with high molecular weight (Rin Jean 
et al., 2014). Horton et al., (2008) engineered a type of cell-permeable peptide that 
expeditiously enters human cells and has specific mitochondrial localization. They 
indicated that these mitochondria-penetrating peptides (MPPs) have a characteristic 
favourable to use as a delivery vector because of straightforward synthesis and 
biocompatibility. Therefore, the MPPs may represent a class of transporters that 
effectively deliver cargo to mitochondria which are very suitable to cross an organelle 
membrane that is difficult to penetrate (Horton et al., 2008).  
Additionally, rhodamine B was also used as a carrier and fluorophore targeting to 
mitochondria. Rhodamine B is a member of delocalized lipophilic cations and it has been 
used as a carrier for molecules targeting to mitochondria because of preferential 
accumulation in this organelle (Muli et al., 2014). Ngen et al., (2009) reported that 
accumulation of conjugate dyes is higher than the unconjugated one due to the 
delocalized positive charge of rhodamine B. Also, they reported that the molecule 




unconjugated TPP-OH or rhodamine B. Moreover, Xie et al., (2013) synthesis and 
developed a fluorinated docetaxel derivative (4FDT) from docetaxel (DTX). Xie et al., 
(2013) developed a novel anticancer prodrug targeted to mitochondria in which a 
fluorinated docetaxel derivative (4FDT) and rhodamine B were conjugated via a 
biodegradable ester bond Figure 1.16. They reported that the cytotoxicity of 4FDT-RhB 
is much lower than DTX and 4FDT and that the toxicity of the prodrug increased with time 
and IC50 at 72 hours was 10 times more toxic of that at 48 hours in HepG2 cells, meaning 
that the prodrug needed time to release active drug. Also, the prodrug was specifically 
delivered to mitochondria and was stable in plasma or whole blood. It can be concluded 
that rhodamine B can also be used as a vector for molecules targeted to mitochondria 
(Xie et al., 2013). 
 
 





 Drug resistance  
The failure of cancer patients to respond to specific therapeutic treatment can happen 
because of the host factor which is the general and most common factor leading to failure 
in cancer therapy. Host factors include rapid metabolism or poor absorption or excretion 
of a drug, resulting in low serum levels (Pluen et al., 2001). However, each cancer cell 
responds to cytotoxic agents in their own way because each cancer cell has a different 
genetic make-up depending on the tissue of origin, the pattern of activation of oncogenes, 
variations in gene expression and inactivation of tumour suppressors, in turn resulting in 
a different array of drug-resistance gene expression by every cancer cell therefore leading 
to overgrowth of drug-resistant variants by many cancers (Gottesman, 2002). However, 
cancer cells can become resistant to anticancer agents by one of these mechanisms: 
specific metabolism of a drug, loss of a cell surface receptor or transporter for a drug and 
modification by mutation of the specific target of a drug, these mechanisms result in 
resistance to a single class of drugs (Longo-Sorbello and Bertino, 2001). However, cells 
express mechanisms of resistance that give simultaneous resistance to different classes 
of drugs that have unrelated structure and function. This phenomenon is known as 
multidrug resistance (MDR) (Sauna et al., 2001). 
There are five families of efflux-pump proteins that are correlated with MDR but the most 
notable and popular efflux-pump is the ATP-binding cassette (ABC) superfamily. MDR 
efflux pumps are classified based on the energy source that the pump uses, the number 
of components that the pump has (single or multiple), the types of substrate that the pump 
exports and the number of transmembrane-spanning regions of transporter protein 
(Piddock, 2006). Additionally, cellular multidrug resistance usually happens due to the 
resistance of cells to many substances, often hydrophobic drugs, which is known as 
classical multidrug resistance. This type of resistance results from expression of ATP-
dependent efflux pumps with wide drug specificity. These pumps belong to the ATP-
binding cassette (ABC) transporter family and have similar sequences and structure 
(Dean, Hamon and Chimini, 2001). Human ABC transporters consist of 48 family 
members, with well-studied members: P-glycoprotein (ABCB1), breast cancer resistance 




(MRP1/ABCC1 and MRP2/ABCC2) (Katayama et al., 2014). The resistance of this family 
to a wide range of drug occurs because of their ability to increase drug efflux and 
decrease drug influx resulting in reduced intracellular drug concentrations.  Many 
structurally unrelated drugs are affected by this family of ABC transporters, such as, vinca 
alkaloids (vinblastine and vincristine), anthracyclines (doxorubicin and daunorubicin), the 
microtubule-stabilizing drug paclitaxel and RNA transcription inhibitor actinomycin-D 
(Ambudkar et al., 1999).  
Furthermore, MDR also can be mediated by decreased drug uptake. Water soluble drugs 
might fail to accumulate inside the cells even without increased efflux. Example of these 
drugs include, antifolate methotrexate, cisplatin and nucleotide analogues (Shen et al., 
2000). MDR can also result from the activation of regulated detoxifying systems, such as 
DNA repair and the cytochrome P450, which in turn induces the P-glycoprotein (P-gp) 
transporter. Additionally, MDR can result from blocked apoptosis pathways, this might 
happen due to a malignant transformation, leading to decreased ceramide levels 
(Gottesman, 2002).  
However, the majority of MDR is caused by the over expression of an energy dependent 
drug efflux pump, known as P-glycoprotein (P-gp). P-gp was the first ATP-dependent 
system discovered that was involved in MDR (Sauna et al., 2001). P-gp is encoded by 
the multidrug resistance 1 (MDR1) gene, which is located on chromosome 7q21 and it is 
vastly over-expressed in many human cancers, including cancers of the gastrointestinal 
tract (small and large intestine, pancreatic cancer and liver cancer), cancers of the 
genitourinary system (kidney, ovary, testicle), cancers of the hematopoietic system 
(myeloma, lymphoma, leukemia), and childhood cancers (neuroblastoma, fibrosarcoma) 
(Goldstein et al., 1989; Katayama et al., 2014). P-gp has a molecular weight of 170 kDa 
and it contains two nucleotide-binding domains (NBDs) and three membrane-spanning 
domains (MSDs). The two NBDs are recognized by the presence of ATP-binding 
cassettes that are responsible for hydrolysis of ATP required to transport the solute 
outside the cells. Each MSDs contains 5-6 transmembrane segments which form the pore 




P-gp can detect and bind a large number of hydrophobic natural product drugs when they 
cross and enter plasma membranes. These drugs include the commonly used natural 
anticancer drugs such as doxorubicin and daunorubicin, taxol, vinblastine and vincristine 
(Bogman et al., 2001). When these drugs bind to P-gp, this results in activation of one of 
the ATP-binding domains and hydrolysis of ATP resulting in a large change in P-gp 
conformation, which in turn releases the drug into the extracellular space. Hydrolysis of a 
second ATP is required to restore P-gp to its original state (Gottesman, 2002) Figure 
1.17. On the other hand, tumours that are derived from tissues that normally express P-
gp usually express the highest level of P-gp resulting in high resistance to some cytotoxic 
agents. In contrast, the expression of P-gp may be low at the time of diagnosis in some 
tumours, but after chemotherapy, P-gp is induced resulting in the development of MDR 
(Thomas and Coley, 2003).  
 
 





Furthermore, it was reported that P-gp is not present in mitochondria. Paterson and 
Gottesman, (2007) presented data to show that P-gp is not localized to mitochondria. 
They used KB-V1 cells selected for resistance to vinblastine and MCF-7 cells selected 
for resistance to adriamycin that both express high levels of P-gp. They demonstrated 
that although P-gp is present in the crude mitochondrial fraction, further purification found 
that P-gp is not present in mitochondrial membranes, and its presence in the crude 
mitochondrial fraction was due to plasma membrane contamination (Paterson and 
Gottesman, 2007). However, Shen et al., (2012) investigated the presence or absence of 
P-gp in mitochondria using Rhodamine123 as a mitochondria marker and cyclosporine A 
(CsA) as a mitochondria tracker and Pgp inhibitor in mitochondria isolated from MCF-7 
and doxorubicin-resistant MCF-7 (MCF-7/ADM) cells. They indicated that the 
accumulation of Rho123 in MCF-7/ADM without the addition of CsA is dramatically lower 
than that of MCF-7 because of the localization of P-gp at the membrane of mitochondria 
in MCF-7/ADM. However, after pre-incubation of the mitochondria with CsA, they found 
a marked increase in the accumulation of Rho123 in mitochondria because P-gp was 
inhibited by CsA and there was no significant change in MCF-7 mitochondria following 
the addition of CsA. Shen et al., (2012) suggested that Rho123 was pumped out of the 
mitochondria by an active transport process due to differences in concentration. To 
confirm this, they tested Rho123 in MCF-7/ADM mitochondria with lower accumulation 
and they placed it in solution without Rho123. They found that the remaining Rho123 in 
MCF-7/ADM was significantly lower than that in MCF-7 mitochondria before incubation 
with CsA and after incubation with CsA, Rho123 export was inhibited in MCF-7/ADM and 
no significant changes were found in MCF-7. However, this is the only study that shows 
the expression of P-gp at the mitochondrial membrane.  
On the other hand, using drugs that can escape from ABC transporters and are not 
substrates of ABC transporters such as, alkylating drugs (cyclophosphamide), 
anthracycline modified drugs (anamycin and doxorubicin-peptide) and antimetabolites (5-
fluorouracil) could circumvent drug resistance and allow the anticancer drug to 
accumulate inside the targeting cell (Choi, 2005). Another method to circumvent 
resistance to anticancer drugs is to administer nontoxic drugs that have the ability to 




anticancer drugs are called MDR modulators, MDR inhibitors and MDR reversal agents 
or chemosensitizers (Liscovitch and Lavie, 2002). Hence, the combination of anticancer 
drugs together with an MDR inhibitor can be used to circumvent MDR. Two factors that 
should be determined in order to use this combination include, first, to identify the ABC 
transporter protein involved in drug resistance and to employ an MDR inhibitor and 
anticancer drug that should match the transporter protein to be inhibited. The second 
factor is to detect the plasma concentrations and in vivo activity of MDR inhibitor in order 
to determine the effective inhibitory concentration is attained in vivo (Ozben, 2006).  
 
 
Figure 1.18: The mechanism of P-gp inhibitor XR9576 inhibiting the activity of ATPase which is 
required to open P-gp, therefore decrease efflux and increase accumulation of anticancer drugs. 
 
In another approach, Settanni et al., (2012) designed and synthesised a mitochondria-
targeting carrier QCy7HA and conjugated it with doxorubicin (DOX). The conjugate has 
the ability to limit the effects of (P-gp) efflux pumps of MDR cells on DOX, indicating that 




resistant cancers. They designed a fluorogenic probe AcQCy7 for specific mitochondria 
labelling. They attached the hexanoic acid linker to the phenolic oxygen of the Cy7-like 
moiety of AcQCy7 through an ether bond to give QCy7HA. Both QCy7HA and AcQCy7 
are hydrophobic and have cationic properties (two positive charges on each molecule), 
which make it a potential mitochondria-targeting conjugate. Settanni et al., (2012) 
conjugated DOX with QCy7HA because DOX has two practical advantages: first, it has a 
free –NH2 functional group that can easily react with the activated carboxylic acid group 
on the carrier QCy7HA to form the DOX- QCy7HA conjugate. Second, DOX is fluorescent 
thus allowing for visualizing its intracellular localization by fluorescence microscopy. They 
studied the co-localization of QCy7HA-DOX conjugate. They indicated that QCy7HA-
DOX conjugate was completely co-localized in mitochondria, whereas DOX (without 
carrier) was kept in cell nucleus over mitochondria or other subcellular, demonstrating 
that QCy7HA is able to deliver the conjugated DOX to mitochondria effectively (Settanni 
et al., 2012).  
Furthermore, two cell lines were chosen by  (Settanni et al., 2012) to determine the effects 
of the P-gp efflux pumps on the cytotoxicity of QCy7HA-DOX and free DOX, which is 
drug-sensitive human uterine sarcoma MES-SA cells and its multidrug-resistant subline 
MES-SA/Dx5. They indicated that the free DOX exhibited toxicity against MES-SA lines 
with 21-fold greater potency than MES-SA/Dx5 lines, whereas only a 6-fold difference 
was observed for mitochondria- targeting QCy7HA-DOX. Those results demonstrated 
that the toxicity of free DOX was reduced by P-gp efflux pumps when  compared with 
mitochondria-targeting QCy7HA-DOX which was much less effected by P-gp efflux 
pumps (Settanni et al., 2012). Therefore, specific targeting of anticancer drugs to 
mitochondria by using specific carriers could limit the power of P-gp efflux pumps, thus 
increasing the accumulation of anticancer drugs inside the mitochondria.  
 
 Anthraquinones and anthracyclines 
Mitoxantrone (1,4-dihydroxy-5,8-bis{[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-




antitumour  antibiotic with significant efficiency in the treatment of different human cancers  
and multiple sclerosis (Enache et al., 2015). In general, anthracyclines include some of 
the most potent anticancer drugs ever developed and they play an essential role in the 
treatment of a wide variety of solid tumours and haematological malignancies, alone or in 
combination with other cancer drugs (Mordente et al., 2012). Anthracyclines have diverse 
cytotoxicity mechanisms against cancer cells including: inhibition of macromolecular 
biosynthesis by the inhibition of DNA replication and RNA transcription, generation of 
reactive oxygen species (ROS), resulting in DNA damage and/or lipid peroxidation, 
inhibition of topoisomerase II, direct membrane damages, DNA adduct formation, 
interference with DNA strand separation or DNA unwinding (Gewirtz, 1999). However, 
the exact mechanism of how anthracyclines kill tumour cells is still poorly understood, but 
the evidence of nuclear localization and high DNA affinity of anthracyclines suggest that 
their anticancer activity is linked to their ability to intercalate between nuclear DNA base 
pairs thus poisoning topoisomerase activity, leading to the death of dividing cancer cells 
(Swift et al., 2006; Nitiss, 2009; Pommier et al., 2010). On the other hand, the therapeutic 
activity of anthracyclines is limited by their toxicity for myocardial tissue, resulting in a 
progressive cardiomyopathy which can develop into congestive heart failure (CHF) 
(Mordente et al., 2012). 
In order to minimize the side effects relating with the naturally occurring anthracyclines 
doxorubicin and daunorubicin, mitoxantrone - a member of the anthracenedione class 
was designed as a simplified analogue of the anthracyclines (Feofanov et al., 1997) to 
reduce cardiotoxicity associated with the anthracycline antibiotics (Parker et al., 2004). 
Structurally, mitoxantrone is symmetrical and consists of a tricyclic planar chromophore 
and two basic side chains containing nitrogen that are positively charged at physiological 
pH 7.4 Figure 1.19. The two side chains of mitoxantrone are critical for intercalation into 
DNA and the role of the positively charged N-containing side chains is to stabilize the 
insertion of the ring between base pairs by forming electrostatic interactions with the 
negatively charged phosphate backbone of DNA (Varadwaj et al., 2010). Several studies 
on the mechanism of mitoxantrone action have shown that nuclear DNA is the main target 
for the mitoxantrone where its function is as a potent topoisomerase II inhibitor (Cornbleet 




inhibits DNA replication and RNA transcription by binding with DNA and causes DNA 
condensation, cross-linking and strand breakage (Panousis and Phillips, 1994). 
Mitoxantrone shows activity against solid tumours, lung cancer, melanoma, advanced 
breast cancer, acute non-lymphocytic leukemia, non-Hodgkins lymphoma. In addition, 
mitoxantrone has similar activity with less toxicity in comparison with other active 
available agents used in treatment of advanced breast cancer (Cornbleet et al., 1984; 
Feofanov et al., 1997). 
 
 
Figure 1.19: Mitoxantrone structure 
 
Mitoxantrone became a widespread drug due to its lower risks of cardiotoxic effects 
compared with doxorubicin and daunorubicin (Kapuscinski et al., 1981). However, it is 
now known that mitoxantrone can also induce cardiotoxicity which is dose-dependent, 
irreversible and it may occur after a long period of treatment (Ehninger et al., 1990; Seiter, 
2005). Furthermore, Rossato et al., (2014) studied the effect of mitoxantrone on the 
cardiac mitochondria and they indicated that therapeutic concentrations of mitoxantrone 
(100 nM and 1 µM) caused an energetic variation by hyperpolarization of the membrane 
potential of mitochondria, and a decrease in ATP levels and increase in the intracellular 
calcium levels after 24, 48, and 96 hours of mitoxantrone incubation in a H9c2 cells 
(cardiomyoblast cell model). Mitoxantrone also caused inhibition of ATP-synthase 




96 hours incubation at the same concentrations (100 nM and 1 µM). Therefore, they 
revealed that mitoxantrone overlapped with mitochondrial functionality, resulting in an 
imbalance in the mitochondrial function and therefore late ATP depletion which in turn 
leads to heart dysfunction and impaired cardiac performance (Rossato et al., 2014). 
However, due to the severe side effects such as cardiotoxicity, myelosuppression and 
extravasation of mitoxantrone specially and anthracyclines in general, considerable 
efforts have been employed to enhance their curative effect and reduce the side effects. 
These enhancements include modification of the original anthraquinone backbones and 
variations in side chains which result in biological improvements (Mansour et al., 2010). 
To improve this concept, Wang et al., (2012) synthesised anthraquinone–polyamine 
conjugates to order to increase the cytotoxicity and reduce side effects of anthraquinones 
like mitoxantrone. Several compounds have been synthesised but the most notable 
compounds were 9b and 9c. Compound 9b contained a terminal aminobutyl scaffold in 
the side chain, whereas 9c contained a terminal aminopropyl scaffold Figure 1.20. Wang 
et al., (2012) indicated that both compounds have high cytotoxicity on solid human cancer 
HepG2 and were less toxic on normal hepatic QSG7701 cells in an in vivo study, 
confirming that the presence of a polyamine motif will increase the tumour specific 
capability of the polyamine-conjugate drugs (Wang et al., 2012).  Furthermore, Mansour 
et al., (2010) studied the effect of side chain length and the presence of primary and 
secondary amine in the side chain on the formation of DNA adducts and anticancer 
efficacy produced by these drugs. They demonstrated that pixantrone, which is a novel 
2-aza-anthracenedione having a primary amino group in its side chain, has significant 
anticancer efficacy but fails to induce any detectable cardiotoxicity in comparison with 
mitoxantrone Figure 1.21. Pixantrone is similar to mitoxantrone in that it can be activated 
by formaldehyde to give formaldehyde-mediated adducts with DNA, due to its primary 
amino groups in the side chain, however these DNA adducts are formed much more 
effectively than mitoxantrone. They found also that the side chain length is not a major 
factor in adduct formation but the presence of a primary amino group is the most important 
factor because a primary amine is more reactive than secondary amine to form greater 
concentrations of reactive drug-Schiff base precursors. This complex is more stable than 




other hand, the pyridine ring present in the backbone of pixantrone makes it less effective 
than the corresponding mitoxantrone compound (Mansour et al., 2010).  
 
 
Figure 1.20: Structure of 9b and 9c compounds 
 
 
Figure 1.21: Structure of pixantrone 
 
 Lysosomal sequestration 
Lysosomes are single membrane organelles that are found in all eukaryotic cells and 
were first described by Christian de Duve about 60 years ago. Lysosomes are the major 
digestive organelles in cells which degrade intracellular components and extracellular 
materials taken up by the cell including other organelles, proteins and lipids. These 
materials enter the lysosomes via endocytosis from outside the cell or via autophagy from 




lysosome or are transported by lysosomal proteins to the cytosol for reuse by the cell 
(Mrschtik and Ryan, 2015). Lysosomes have more than 50 hydrolase enzymes, including 
glycosidases, proteases, nucleases, lipases, phospholipases, phosphatases, and 
sulfatases. Lysosomes are characterized by low acidic pH 4.5-5 which is maintained by 
vacuolar H+-ATPase. The acidic pH of lysosomes is essential for the maximum activity of 
hydrolase enzyme (Boya, 2012). In addition, lysosomes are involved in exocytosis, 
endocytosis, cholesterol homeostasis, macroautophagy, chaperone-mediated 
autophagy, promote tumourigenesis and trigger apoptosis and cell death. Furthermore, 
the lysosomes in cancer cells are relatively large and more fragile in comparison with 
normal lysosomes. Also, cancer cells are more vulnerable to lysosomal mediated cell 
death than normal cells which can be exploited in the design of new effective anticancer 
drugs that enhance lysosomal cell death by inhibition of caspase dependent cell death 
(Halaby, 2015).  
Despite their important role in the cell, lysosomes can alter the accumulation of lipophilic 
amine drugs from their target site by sequestering or trapping them inside the acidic 
lysosomes by a process known as lysosomal sequestration or lysosomal trapping. One 
of the most important physiological parameters that predicted the degree of lysosomal 
accumulation is the pH of lysosomes relative to the pH of the cytosol. Because the larger 
the lysosome-to-cytosol pH gradient, the larger the extent of lysosomal sequestration is, 
therefore the considerable trapping of weak bases in lysosomes can greatly reduce drug 
target interaction which can in turn reduce drug activity (Ndolo et al., 2012). However, 
because the lipophilic weak amine base drugs diffuse through cell membranes at 
physiological pH via passive diffusion, once they are inside the lysosomes, they become 
protonated and accumulate in lysosomes in their cationic state. Certain hydrophobic weak 
base chemotherapeutics found to be highly accumulated in lysosomes include the 
doxorubicin, mitoxantrone, daunorubicin, imidazoacridinones and sunitinib Figure 1.22. 
On the other hand, treating the cell with lysosome alkalinizing agents such as bafilomycin 
A1 and vesicular H+-ATPase inhibitor, could eradicate lysosomal drug sequestration and 
decrease the accumulation of drug in lysosomes, therefore increase cytotoxic drug 






Figure 1.22: Structure of sunitinib 
 
With regard to this, Gotink et al., (2011) investigated resistance mechanisms for sunitinib, 
which is a antiangiogenic tyrosine kinase inhibitor. They found that resistance to sunitinib 
is mediated by lysosomal sequestration. They hypothesized that sunitinib might 
preferentially accumulate in acidic lysosomes because it is hydrophobic (log P = 5.2) can 
easily cross plasma membranes and other intracellular membranes. Also, sunitinib is a 
weak base with pKa = 8.95, therefore decreasing the pH below 9, it will be protonated 
and thereby losing its ability to cross membranes. At pH 5 or below such as in lysosomes, 
all sunitinib will be protonated and would not be able cross the membranes, therefore will 
be trapped in lysosomes. To improve this, Gotink et al., (2011) studied the co-localization 
of sunitinib in acidic lysosomes. They found clear co-localization of sunitinib in acidic 
lysosomes and there was no co-localization with other intracellular organs, indicating that 
resistant cells are able to sequester sunitinib from their cytoplasmic compartment into 
acidic lysosomes and provide a novel mechanism of resistance (Gotink et al., 2011). In 
contrast, lysosomes can employ as a novel emerging target for anticancer treatment 
through different processes of lysosomal disruption by lysosomotropic agents such as 
mefloquine Figure 1.23 (Sukhai et al., 2013). Zhitomirsky and Assaraf, (2015), suggested 
that tumour cells that are rich in lysosomes and are resistant to many hydrophobic weak 




response to treatment by targeting lysosomes in malignant cells by induction of lysosome-
mediated apoptosis, disruption of lysosomes by lysosomotropic agents such as 
mefloquine and lysosomal photodestruction by lysosome accumulating photosensitizes 
such as imidazoacridinones (Zhitomirsky and Assaraf, 2015). This view was proved by 
(Petersen et al., 2013), which they targeted lysosomes in cancer cells both in vitro and in 
vivo. They showed that lysosomes in cancer cells can be selectively targeted by targeting 
lysosomal membrane permeabilization and subsequent cell death, which may prove to 
be a valuable method in cancer treatment. They targeted acid sphingomyelinase (ASM) 
inhibition to destabilize lysosomes in cancer cells using lysosome-destabilizing 
experimental anticancer agent siramesine. Siramesine interferes with the binding of ASM 
to its essential lysosomal cofactor, bis(monoacylglycero)phosphate, leading to reduced 
tumour growth in vivo, reversion of multidrug resistance MDR, and cancer-specific 
































1.3 Results and discussion 
This chapter describes the design, synthesis and evaluation of novel anticancer drugs 
targeted intracellularly, specifically targeted to mitochondria. The mitochondrial targeted 
drugs were specifically designed to accumulate inside the mitochondria by targeting the 
high membrane potential (ΔΨm) of mitochondria in cancer cells. The following sections 
in this chapter explain the rational design and synthetic strategy of novel compounds. The 
synthesis, purification and characterization are also explained in detail followed by 
biological evaluation in vitro assays for the mitochondrial compounds. These assays 
include: DNA binding assays, distribution coefficient assays, cell viability (MTT) assays, 
cellular uptake and localization and morphology studies of the targeted compounds.  
 
 Rational design  
In the last years, there was an improvement in the cancer diagnosis and treatments due 
to a better understanding of tumour biology (Pelicano et al., 2006). These treatments 
include chemotherapy, radiation therapy and surgical intervention or a combination of 
these treatments (Aftab et al., 2018). Most of the traditional chemotherapy works by 
interfering with DNA synthesis and mitosis leading to the death of cancer cells (Hosoya 
and Miyagawa, 2014). However, these anticancer drugs are nonselective and can also 
damage healthy normal tissue and have poor delivery to cancer cells which leads to 
undesirable side effects such as vomiting, nausea and becoming immunocompromised 
(Nurgali et al., 2018). Also, the failure of the remedial treatment of cancer patients usually 
occurs by drug resistance of the tumour to chemotherapeutic agents (multidrug 
resistance) due to the drug being effluxed by the P-glycoprotein (P-gp) trans-membrane 
pumps that are overexpressed in cancer (Tanabe et al., 2001; Callaghan et al., 2014).  
Therefore, the therapeutic effect of anticancer drugs can be maximized, whilst also 
making the drug more selective resulting in more precise delivery of the drug to the tumour 





In this programme of research, a prodrug system has been designed and developed to 
deliver novel experimental anticancer agents to the specific targeting site (mitochondria). 
Mitochondria are sometimes known as a power house and also have intrinsic 
mitochondrial DNA (mtDNA) and lack P-gp (Chatterjee et al., 2006; Paterson and 
Gottesman, 2007; Fulda et al., 2010). Therefore, specific delivery of an anticancer drug 
to mitochondria could avoid drug resistance and by interfering with mtDNA synthesis, lead 
to cell death and give the drug more selectivity. This prodrug system contains an active 
drug that is toxic and connected via a biodegradable linker to a targeting vector (either 
triphenylphosphonium TPP or rhodamine B) that takes the prodrug to the targeting site 
(mitochondria). The biodegradable vector will be cleaved by normal metabolic processes 
such as, specific enzyme-mediated hydrolytic cleavage or under specific conditions such 
as pH Figure 1.24. 
 
 
Figure 1.24: The general design of a mitochondrial targeting prodrug system 
 
In this study, aminoanthraquinone derivatives, which are structurally related to clinically 
used mitoxantrone (topoisomerase II poison), were chosen as the potential active drugs 
for targeted delivery to mitochondria. For many years now, there has been a particular 
interest in our laboratory in aminoanthraquinones, both as topoisomerase inhibitors and 
DNA binding agents.  
In the earliest studies, a series of anthraquinone-amino acid conjugates were synthesised 
in which the amino acid was linked via the N-terminus to the anthraquinone nucleus at 





One compound (designated CAM 1 or, later, NU:ICRF 505), was shown to act as a clean 
topoisomerase I poison (although less potent than camptothecin) without affecting the 
catalytic activity of either DNA topo I or II and had promising in vivo activity against human 
lung and colon cancer xenograft models (Cummings et al., 1996). NU:ICRF 505 was, 
however, and in common with the majority of compounds in the series, poorly soluble in 
aqueous media and poor bioavailability precluded its further development.  
In order to overcome problems observed with the conjugates of this type, another series 
of spacer-linked anthraquinone-amino acid conjugates [designated NU:UB, Figure 1.25] 
was developed (Mincher, 1999; Turnbull, 2003) that possessed the following structural 
alterations: 
1) The amino acid motif was reversed resulting in improved water solubility from 
possible amine salt formation. 
2) A spacer group was inserted between the anthraquinone skeleton and the acid 




Figure 1.25: Structure of the NU:UB series of anthraquinone-amino acid conjugates 
 
In contrast to the anthracenediones mitoxantrone and ametantrone, the vast majority of 
the NU:UB library was restricted to anthraquinones that are substituted by a single side-
arm substituent, ‘the spacer’. Importantly, it was observed that the nature of the spacer 
group itself was an important determinant of topoisomerase inhibitory properties; 
conformationally flexible spacers have a large degree of rotational freedom and are able 
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to adopt many conformations, facilitating their ability to bind to DNA and interact with 
topoisomerases. Leading members from the NU:UB series were found to inhibit DNA 
topoisomerases, have shown broad-spectrum activity in vitro at low micromolar 
concentrations in panels of human and animal tumour cell lines, including those of the 
NCI 60 cell line anticancer drug screen, and are active in vivo in experimental colon 
cancer (Mincher et al., 1999).   
Turnbull, (2003) designed and synthesized novel DNA topoisomerase inhibitors NU:UB 
73 and NU:UB 76, which are both structurally related to AQ-Butyl-TPP (SH1) synthesized 
in this research project. Both NU:UB 73 and 76 contain the same aminobutanol spacer 
as in SH1 Figure 1.26. Additionally, the studies showed that the AQ-aminobutanol is 
inactive and once it was attached with L-alanine (NU:UB 73) and D-alanine (NU:UB 76) 
it became active in vivo. In vivo Chemosensitivity against MAC15A colon 
adenocarcinonoma of NU:UB 73 and 76 produced the greatest reduction of tumour 
volume of any of the conjugates tested at toxic doses and a greater growth delay  
compared with mitoxantrone which produces growth delay but does not shrink tumours 
Figure 1.27 (Turnbull,. 2003; Mincher., 1999). Therefore, Taking the advantage of this 
study AQ-aminobutanol (NU:UB 238) which is inactive was conjugated with 
triphenylphosphonium bromide (TPP), which in turn make the compound active in vitro. 
 





Figure 1.27: In Vivo Chemosensitivity against MAC15A colon adenocarcinonoma: Comparison of 
NU:UB 73 (194), NU:UB 76 (196) and Mitoxantrone (7) 
 
Furthermore, confocal microscopy studies on the subcellular localisation of selected 
lipophilic spacer-linked anthraquinone conjugates from the NU:UB series showed that 
they were rapidly taken up into cells (Pettersson, 2004). It was also suggested that a 
positive charge along with a degree of lipophilicity influenced whether or not the 
anthraquinones were recognised by P-gp and were able to overcome MDR, in line with 
observations by Lampidis et al., (1997), that, with decreased affinity for binding DNA, 
related lipophilic anthracyclines shift in their primary localisation from nuclear to 
mitochondrial. Thus, as lipophilicity increased and nuclear DNA binding properties of the 
NU:UB compounds decreased, the analogues seemed to distribute in mitochondria 
(Pettersson, 2004), suggesting that mitochondria may pose an anthracycline target for 
the NU:UB compounds, notably, this was not the case for doxorubicin which showed no 





Based on these findings, in this programme of research, both aminoanthraquinone 
derivatives from the NU:UB series and novel aminoanthraquinones were used as a point 
of attachment for mitochondrial targeting vectors. 
Additionally, the ability of the chosen vector, TPP to enter mitochondrial membranes 
depends on hydrophobicity or lipophilicity properties, the functional group of TPP and 
linker unit (alkyl chain) length (Ross et al., 2008; Reily et al., 2013). However, the 
hydrophobicity properties play an important role for TPP to enter mitochondria and in the 
accumulation of charged TPP inside the mitochondria, which is related to the 
octanol/water partition coefficient of a given compound. 
 
 Synthetic strategy  
In this research programme, several different model TPP conjugates have been 
synthesised containing different side-arms including the same side arm as in 
mitoxantrone Figure 1.29. These molecules have been synthesized by linking the 
aminoanthraquinone with a spacer. Molecules have a different spacer with different length 
in order to study the effect of these spacers on the cytotoxicity, DNA binding and 
localization of novel compounds in mitochondria. It has been reported that the presence 
of amino groups in the spacer of mitoxantrone and the presence of hydroxyl group in the 
anthraquinone chromophore have a crucial role in binding with DNA and also their role in 
stability of drug-DNA complexes (Bailly et al., 1996). Therefore, different series of novel 
compounds were designed and synthesized in order to investigate the role of structural 
changes on the toxicity, DNA binding and localization of the compounds inside the 
mitochondria or inside the lysosomes.   
The aminoanthraquinone-spacers were further ester linked with the mitochondria carriers 
using 1,3-dicyclohexylcarbodiimide (DCC) as the coupling (dehydrating agent) and 4-
dimethylaminopyridine (DMAP) as acylation catalyst. The choice of these coupling agents 
were based on previous studies that demonstrates their role in the formation of ester 




effect of using DCC on the formation of ester bonds. They found that in the presence of 
DCC and with carboxylic acids as acylation agents, the esterification reaction after 10 
hours proceeded smoothly with high to excellent yield. However, they demonstrated that 
without DMAP the esterification did not occur even after long period of time (Zhu et al., 
2008). Neises and Steglich, (1978), illustrated that the using of 3-10 mol% of DMAP with 
DCC would accelerate the esterification of carboxylic acid with alcohol giving a good yield 
at room temperature (Neises and Steglich, 1978). Furthermore, Han et al., (2014), used 
DCC and N-hydroxysuccinimide (NHS) to successfully conjugate TPP with doxorubicin, 
where the amide bond was formed between the TPP and doxorubicin. Therefore, herein, 
DCC and DMAP were used to form the ester bond between the hydroxyl group of the 
spacer and the carboxylic acid group of the TPP. 
In addition, rhodamine B was used as a mitochondrial targeting vector due to the 
presence of cationic charge and the lipophilic properties of rhodamine B which make it a 
selective vector to accumulate inside the mitochondria (Muli et al., 2014). However, the 
locked form (nonfluorescent) and unlocked form (fluorescent) of rhodamine was the main 
consideration to choose a linker that can keep the Rhodamine in the open ring form and 
avoid cyclization. Therefore, it was important to prepare and link a photolabile groups 
(cage compounds)  that can keep the rhodamine in its open-ring form to keep its 
fluorescence for further studies (Lavis and Raines, 2008). It has been reported that the 
formation of a tertiary amide with Rhodamine and/or functionalized rhodamine B with 
piperazine could inhibit the spirolactam formation of Rhodamines (Nguyen and Francis, 
2003). Nguyen and Francis, (2003), reacted the lactone form of rhodamine B with 
piperazine which resulted in the formation of tertiary amide and kept the Rhodamine in its 
unlocked form (fluorescent) (Nguyen and Francis, 2003) Figure 1.28. Xie et al., (2013) 
synthesized a Rhodamine mitochondrial targeting prodrug in which the rhodamine B and 
4FDT (anti-hepatoma drug) were linked via a biodegradable linker through a β-alanine in 
which the rhodamine B and β-alanine were linked with a biodegradable amide bond to 
keep the open-ring form of rhodamine and a β-alanine was linked with 4FDT via 
biodegradable ester bond. They found that the prodrug was active and completely 




piperazine was used to inhibit the spirolactam of the rhodamine B and keep its 
fluorescence.  
 
Figure 1.28: synthesis of rhodamine B tertiary amide by reacting rhodamine B with piperazine 
 
Therefore, the aminoanthraquinone-spacers (structurally related to mitoxantrone) were 
synthesized and firstly were ester linked with the carriers Rho-β-ala-OH, Rho-piperazine-
succinate and (4-carboxybutyl) triphenylphosphonium bromide (TPP). Second, NU:UB 
65, a 2 armed mitoxantrone derivative was attached with TPP. Third, attempts were made 
to ester link mitoxantrone with TPP and Rho-piperazine-succinate vectors. Finally, 
ametantrone was synthesised and ester-linked with TPP Figure 1.29. 
 
Figure 1.29: Structures of model compounds and the attachment showing the site of the 
subsequent Boc-protection and site(s) for attachment of carriers upon esterification. Where 










































Due to the increased negative membrane potential of mitochondria in cancer cells 
(Constance and Lim, 2012), it was hypothesized that the attachment of the TPP group to 
mitoxantrone derivatives would increase the lipophilic properties of these compounds in 
order to improve the ability to pass through cell membranes. Also, it is hypothesized that 
the cationic, lipophilic TPP and rhodamine B carriers will allow the active molecule to 
accumulate in the mitochondria. Cleavage of the biodegradable ester link by esterases 
should release the cytotoxic drug which could potentially bind to DNA and subsequently 
inhibit the intrinsic DNA-topoisomerase or bind to mtDNA of mitochondria. 
 
 Synthesis of the mitoxantrone derivatives-TPP 
conjugates 
 
1.3.3.1 Synthesis of HO-EAE-AQ(4-OH) (OM1) 
The synthesis of the library of aminoanthraquinones, which were intended for use as 
active drugs targeted to mitochondria, was started by the amination of leucoquinizarin 
with N-(2-hydroxyethyl)ethylenediamine in dichloromethane (DCM), to afford 
anthraquinone-spacer compounds which were further ester-linked with mitochondrial 
vectors.  
According to Kikuchi et al., (1982), leucoquinizarin reacts with primary amines to give 
mono-amino and diaminoanthraquinone derivatives for which the percentage yields are 
condition dependent. The amination of leucoquinizarin is believed to proceed by an 
addition-elimination mechanism Figure 1.30, which is the addition of amine to a carbonyl 
group of a keto tautomer (a) leading to ionic intermediate (b) which is further transformed, 
after dehydration to (c) (Kikuchi et al., 1982). However, in another study, Morris et al., 
(1986) synthesized 5-hydroxyquinizarin and aminoanthraquinones from leuco-5-
hydroxyquinizarin. They found that if the leuco-intermediates were stirred with 
trimethylamine in dichloromethane and aerial oxidation, the aminoanthraquinones were 
formed. However, if the intermediates were oxidized and then hydrolyzed using HCl or 





Figure 1.30: Reaction scheme showing the amination of leucoquinizarin 
 
It is reasonable to assume that upon formation (C) would tautomerize to the 1-alkylamino-
α-hydroxy tautomer preventing a bis-amination. By applying these methodologies in this 
project, HO-EAE-AQ(4-OH) (OM1) was synthesized by reaction of leucoquinizarin with 
N-(2-hydroxyethyl)ethylenediamine, for 1 hour at 50ºC, to produce an intermediate 
(greenish-brown colour), which on oxidation (aeration) and addition of triethylamine 
produced (OM1) (purple colour) Figure 1.31. The change of colour from greenish-brown 
to purple demonstrated evidence of the oxidation of the intermediate leuco-form of the 
product to the target aminohydroxyanthraquinone ring system. The progress of the 
reaction was monitored by thin-layer chromatography on silica plates (TLC test) (4:1 
chloroform: methanol) which showed a purple spot of presumed anthraquinone-spacer 
(OM1). The monoamination of leucoquinizarin with spacer was performed under specific 
conditions (1 hour at 50ºC) to produce 4-hydroxylated aminoanthraquinone (purple 
compound) and to avoid formation of a diaminoanthraquinone (the 1,4- diaminated blue 
compound). Solvent extraction and evaporation afforded crude OM1. The introduction of 
a hydroxyl group into the anthracenedione ring generally improves cytotoxic potency, as 
in the case of mitoxantrone, due to stronger binding to DNA and slower dissociation 
kinetics therefore, an increase in the cytotoxicity due to the presence of the hydroxy 




chain of OM1 should be protected to avoid any side reaction of the secondary amine in 
further reactions (because of the reactive lone electron pair of the amine) which would 
compete with the free hydroxyl group intended for the site of attachment of the TPP 
carrier. 
 
Figure 1.31: Reaction of leucoquinizarin (1) with N-(2-hydroxyethyl)ethylenediamine (2). (a) N-(2-
hydroxyethyl)ethylenediamine, dichloromethane, 50ºC 1 h. (b) triethylamine, O2, 4 h 
 
1.3.3.2 Synthesis of HO-EAE-Boc-AQ (4-OH) (OM2) 
Introducing a protecting group to the secondary amino group in the side chain is a 
challenge because the protection group should be: 
I. Easy to introduce 
II. Stable to a wide range of reaction conditions 
III. Safely removed at the end of reaction process or when required 
IV. The removal should be fast and free of side reactions 
By considering all these characteristics, it was decided the tert-butyloxycarbonyl (Boc2O) 




(Boc2O)  with a secondary amine in the side chain and safe to remove by adding 
trifluoroacetic acid (TFA) to the protected compound (typically for 30 minutes at room 
temperature (Isidro-Liobet et al., 2009). 
HO-EAE-Boc-AQ (4-OH) (OM2) was prepared by the reaction of OM1 with Boc2O in cold 
methanol Figure 1.32. The mixture was kept over ice and the reaction continued for an 
hour. Purification of the crude product, firstly by solvent extraction using chloroform/water 
(to destroy the unreacted Boc2O with water), then column chromatography, using 
chloroform at the beginning to get rid of all unreacted leucoquinizarin (orange). The 
polarity of the solvent was increased using 4:1 chloroform: ethyl acetate + 2-5% methanol 
to give an analytically pure sample of the title compound (OM2) Figure 1.32. The structure 
of OM2 was confirmed by its high resolution electrospray (+) mass spectrum which 
showed a clear signal at m/z 427.1864 [M + H]+ which corresponded to the expected 
molecular mass of the 426.1791. Furthermore, there was a good correlation between the 
observed data and the theoretical isotope model for C23H26N2O6. This showed that the 








1.3.3.3 Synthesis of TPP-EAE-Boc-AQ-(4-OH) (OM22-Boc)  
The ester bond to link the model compounds or active drug with mitochondrial vectors 
because the ester bond is the most common linkage in prodrug design, being easy to 
synthesize from compounds having a functional group such hydroxy and carboxyl acid 
group that are widely available in many drugs. As esterases are widely distributed in the 
body, after administration the ester bond can be hydrolyzed by esterases at the targeted 
site (Mahato et al., 2011). Clearly, the ester bond requires a suitable half-life in vivo and 
should be stable enough to reach its target.  
The TPP-conjugate TPP-EAE-Boc-AQ-(4-OH) (OM22-Boc) was synthesised by reaction 
of HO-EAE-Boc-AQ (4-OH) (OM2) (pre-dissolved in dichloromethane) with 4-
(carboxybutyl-triphenylphosphonium bromide (TPP) (1.1 eq). The coupling agent, DCC 
(2.4 eq) and catalyst DMAP, were dissolved in dichloromethane with TPP and added to 
OM22-Boc and allowed to react for 1 hour. After 1 hour, the TLC showed that the starting 
compound OM2 was still in abundance, therefore a further half amount of TPP (0.55 eq) 
and coupling agents (DCC 1.2 eq) were added and allowed to react for another 1 hour 
and checked for purity by TLC, which demonstrated that only one compound was present 
in the mixture and all OM2 was reacted. After that, some white crystals of N,N’-
dicyclohexylurea (DCU) were filtered off from the reaction solution. The rest of the 
reaction solution was extracted with water and chloroform. Chromatographic purification 
on silica gel using firstly dichloromethane as eluent to get rid of non-polar impurities and 
unreacted of TPP and DCC, then 9:1 dichloromethane: ethyl acetate with an increasing 
gradient of methanol (1-5%) were used to give the title compound (OM22 Boc) Figure 
1.33.  The structure of (OM22-Boc) was confirmed by its high resolution electrospray (+) 
mass spectrum which showed a clear signal at m/z 771.3177 for [C46H48N2O7P]+ which 
corresponded to the expected molecular mass of the cation. Furthermore, there was a 
good correlation between the observed data and the theoretical isotope model for 








Figure 1.33: Reaction of OM2 with TPP. (a) TPP, DCC, DMAP, dichloromethane, 1 h 
 
1.3.3.4 Synthesis of TPP-EAE-AQ(4-OH) (OM22 TFA) 
Deprotection of the N-protected compound (OM22-Boc) was carried out by adding 
trifluoroacetic acid (TFA) for 30 minutes to OM22-Boc. A precipitate of the consequent 
salt (OM22 TFA) was obtained from an ether solution Figure 1.34. The structure of OM22 
TFA was confirmed by high resolution mass spectrometry which showed a clear signal at 
m/z 671.2658 which corresponded to the expected molecular mass of the cation [M - 
TFA]+. Furthermore, there was a good correlation between the observed data and the 
theoretical isotope model for C41H40N2O5P [M - TFA]+ Figure 1.35. This showed that the 
Boc group was successfully removed from OM22-BOC to form OM22 TFA. 
 







Figure 1.35: The ESI (+) mass spectrum of OM22 TFA 
 
In addition, the structure of TPP-EAE-AQ(4-OH) OM22 TFA was characterized and 
confirmed by its 1H NMR spectrum (in DMSO), which showed, a triplet signal at 10.20 
ppm which was assigned to the amino proton at C-1 of the anthraquinone and a singlet 
signal at 13.54 ppm was assigned to the hydroxy proton at C-4 of the anthraquinone. The 
protons of the protonated amine of the anthraquinone spacer were found as a singlet 
signal at 9.03 ppm. Signals in the 1H NMR spectrum between 1.51-1.81 ppm were 
assigned to the four protons of methylene spacer of TPP and another four protons of TPP 
spacer were found at 2.45 ppm (triplet) and 3.64 ppm (triplet). The methylene groups of 
anthraquinone spacer were found at 3.19-3.32 ppm, 3.82 ppm and 4.27 ppm (triplet). The 
fifteen aromatic protons of TPP and two of the anthraquinone were assigned between 
7.73 ppm and 7.99 ppm. The signals at 7.39 ppm (doublet) and 7.61 ppm (doublet) were 




H-5 and H-8 were assigned between 8.23-8.28 ppm Figure 1.36 and Figure 1.37. These 






















The proton-decoupled, 13C NMR spectrum showed signals for all carbon environments. 
A DEPT experiment differentiated the eight methylene CH2 carbons, twenty one methine 
CH carbons (AQTPP and AQAR) and twelve quaternary carbons. Signals between 21.10 
ppm and 59.41 ppm were assigned to eight methylene carbons. The two anthraquinone 
carbonyl groups and carbonyl group in the spacer were assigned at 172.30 ppm, 181.34 
ppm and 186.96 ppm. Signals at 125.21-128.63 ppm, 133.28 ppm and 134.88 ppm were 
assigned to 6 methine CH carbons of the anthraquinone. Three aromatic methine carbon 
signals, corresponding to the ortho, meta and para carbon atoms of the TPP aromatic 
group were found in their expected positions at 130.14-130.31 ppm (meta), 133.47-
133.61 pm (ortho) and 134.88 ppm (para) Figure 1.38, Figure 1.39 and Figure 1.40. 
Detection of all carbon atoms of OM22 TFA was possible confirming the successful 
synthesis of OM22 TFA. 
 
 















1.3.3.5 Synthesis of OH-Butyl-AQ (4-OH) (NU:UB 252)  
OH-Butyl-AQ (4-OH) (NU:UB 252) was synthesised which shared similar anthraquinone 
structure with difference in the spacer length. NU:UB 252 has a butyl-spacer compared 
with OM22 which has ethylaminoethyl spacer. Also, NU:UB 252 lacks the secondary 
amino group in the spacer which is known for its role in the binding with DNA and 
stabilising the drug-DNA complex (Bailly et al., 1996). Therefore, NU:UB 252 was 
synthesised and linked with TPP in order to evaluate the effect of structural changes on 
the localisation and toxicity of TPP conjugates.  
To synthesise OH-Butyl-AQ (4-OH) (NU:UB 252), leucoquinizarin was reacted with 4-
amino-1-butanol in dichloromethane, at reflux for 1 hour at 50ºC (water bath). The product 
was then oxidized overnight by aeration with the addition of triethylamine (Et3N) Figure 
1.41. The progress of the reaction was monitored through TLC. Solvent extraction was 
carried out with chloroform/water. The crude product was purified by column 
chromatography, using firstly chloroform as eluent to remove nonpolar impurities. The 
polarity of the solvents was increased using chloroform + 2% ethyl acetate. The eluted 
fractions containing the pure product were filtered to remove silica and evaporated to 
dryness. Addition of diethyl ether gave a precipitate of NU:UB 252, which was filtered off 
and dried.  
 
 
Figure 1.41: Synthesis of NU:UB 252 by reaction of Leucoquinizarin  (1) with 4-amino-1-butanol. 






The structure of NU:UB 252 was characterized and confirmed by its 1H NMR spectrum 
(in DMSO), which showed, a singlet signal at 10.16 ppm and this was assigned to the 
amino proton at C-1 of the anthraquinone. Signals in the 1H NMR spectrum between 1.50-
1.73 ppm were assigned to four protons of the methylene spacer of the anthraquinone. 
The methylene closest to the amino group of the anthraquinone was found at 3.35 ppm, 
whereas, the methylene close to the hydroxyl group was found at 3.48 ppm (triplet). All 
aromatic protons of the anthraquinone were assigned; 7.21 ppm (1H, H-2, doublet), 7.35 
(1H, H-3, doublet), 7.74-7.90 (2H, H-6 and H-7, multiplet) and 8.13 (2H, H-5 and H-8, 
multiplet). The signal for the aromatic hydroxyl was assigned at 13.57 ppm (1H, singlet) 















The proton-decoupled 13C NMR spectrum showed signals for all carbon environments. A 
DEPT experiment differentiated the four methylene CH2 carbons, six methine CH carbons 
AQAR and eight quaternary carbons. Signals between 25.67 ppm and 60.32 ppm were 
assigned to four methylene carbons. Signals at 125.22 ppm, 125.78 ppm, 126.15 ppm, 
128.60 ppm, 132.67 ppm and 134.44 ppm were assigned to 6 methine CH carbons of the 
























1.3.3.6 Synthesis of TPP-Butyl-AQ(4-OH) (OM30) 
OH-Butyl-AQ (4-OH) (NU:UB 252) was reacted with TPP (1.5 eq) using the coupling 
agents DCC (3.6 eq) and DMAP to give TPP-Butyl-AQ(4-OH) (OM30). The reaction 
mixture was left to stir for 1 hour Figure 1.47. The reaction progress was monitored by 
TLC which showed after 1 hour that there was some of NU:UB 252 not reacted, therefore 
additional amounts of TPP (0.75 eq) and DCC (1,8 eq) were added. The white crystals of 
N,N’-dicyclohexylurea (DCU) were filtered off from the reaction solution, followed by 
solvent extraction with water and chloroform. However, there was an unknown pink 
compound in the reaction solution, therefore the reaction was left under water overnight 
to get rid of unknown pink impurity. The product was further purified by column 
chromatography using firstly chloroform as eluent to get rid of polar impurities and 
unreacted of TPP and DCC, then 9:1 dichloromethane: ethyl acetate with an increasing 
gradient of methanol to 3% were used to get the title compound OM30. The pure fractions 
from the chromatography were filtered off and dried and were precipitated under diethyl 
ether. The structure of OM30 was confirmed by its high resolution electrospray (+) mass 
spectrum which showed a clear signal at m/z 656.2546 which corresponded to the 
expected molecular mass of the 656.2546 Da [M-Br]+ Figure 1.48. Furthermore, there 




Figure 1.47: Synthesis of OM30 by of reaction of NU:UB 252 with TPP. (a) TPP, DCC, DMAP, 







Figure 1.48: The ESI (+) mass spectrum of OM30 
 
The structure of OM30 was characterized and confirmed by its 1H NMR spectrum (in d6- 
DMSO), which showed, signals between 1.50-1.80 ppm which were assigned to eight 
protons of the methylene spacer of TPP and anthraquinone. The methylene close to 
carbonyl group in the spacer was found at 2.41 ppm (triplet) whereas, the methylene close 
to the amino group of the anthraquinone was found at 4.05 ppm. The methylene group 
close to the phosphonium group of TPP was found at 3.62 ppm (triplet). In addition, a 
signal at 4.05 ppm was assigned to the methylene group close to oxygen in the spacer. 
The fifteen aromatic protons of TPP and two of the anthraquinone were assigned between 
7.71 ppm and 7.95 ppm. The signals at 7.33 ppm (doublet) and 7.48 ppm (doublet) were 
assigned to the anthraquinone protons of H-2 and H-3. The two protons for H-5 and H-8 
were assigned between 8.17-8.25 ppm. At 10.25 ppm a signal was assigned to the amino 
proton at C-1 of the anthraquinone whereas, the hydroxyl proton of anthraquinone give a 



















The proton-decoupled 13C NMR spectrum showed signals for all carbon environments. A 
DEPT experiment differentiated the eight methylene CH2 carbons, twenty one methine 
CH carbons (AQTPP and AQAR) and twelve quaternary carbons. The eight methylene 
carbons gave signals between 20.25 ppm and 63.45 ppm. The two anthraquinone 
carbonyl groups were assigned at 180.74 ppm and 186.66 ppm. Signals at 125.46 ppm, 
125.96 ppm, 126.25 ppm, 128.83 ppm, 132.94 ppm and 134.67 ppm were assigned to 
the six methine CH carbons of the anthraquinone. Three aromatic methine carbon 
signals, corresponding to the ortho, meta and para carbon atoms of the TPP aromatic 
group were found in their expected positions at 130.13-130.29 ppm (meta), 133.46-


























1.3.3.7 Synthesis of HO-pentyl-AQ(4-OH) (OM28) 
HO-pentyl-AQ(4-OH) (OM28) was synthesised, which has the longer spacer (pentyl-
spacer) compared with TPP-EAE-AQ(4-OH) (OM22) and TPP-Butyl-AQ(4-OH) (OM30). 
HO-pentyl-AQ(4-OH) (OM28) was synthesised to compare the cytotoxicity and 
localisation in comparison with previous compounds.  
Leucoquinizarin was reacted with 5-amino-1-pentanol in dichloromethane. The reaction 
mixture was refluxed for 1 hour at 50ºC over a water bath to give OM28. After 1 hour, the 
reaction mixture was oxidized overnight by aeration with the addition of triethylamine 
(Et3N) Figure 1.54. The progress of the reaction was monitored through TLC. Solvent 
extraction was carried with chloroform/water. However, the organic layer was not 
separated well from the water during the extraction, therefore the water and the organic 
layer were evaporated and the reaction mixture was oxidized again. Solvent extraction 
was carried again with chloroform/water. The product was purified by column 
chromatography using chloroform first to get rid of polar impurities, then chloroform + 2% 
ethyl acetate were used to get the title compound OM28. The fractions were filtered off 
and dried. OM28 was precipitated under diethyl ether. The structure of OM28 was 
confirmed by its high resolution electrospray (+) mass spectrum which showed a clear 
signal at m/z 326.1389 [M + H]+ which corresponded to the expected molecular mass of 
the 326.1387 Da  for the molecule. Furthermore, there was a good correlation between 
the observed data and the theoretical isotope model for [M + H]+. 
 
 
Figure 1.54: Synthesis of OM28 by reaction of Leucoquinizarin  (1) with 5-amino-1-pentanol. (a) 5-





1.3.3.8 Synthesis of TPP-Pentyl-AQ(4-OH) (OM31) 
OM31 was synthesized by the reaction of HO-pentyl-AQ(4-OH) (OM28) pre-dissolved in 
dichloromethane with TPP using DCC and DMAP as a coupling agent. The reaction 
mixture was left to stir over ice for 1 hour Figure 1.55. The reaction progress was 
monitored by TLC. The white crystals of N,N’-dicyclohexylurea (DCU) were filtered off 
from the reaction solution, followed by solvent extraction with water and chloroform. 
OM31 was purified by column chromatography using chloroform at the beginning followed 
by using more polar solvent systems, chloroform + 3% ethyl acetate, 9:1 chloroform: ethyl 
acetate; 4:1 chloroform: ethyl acetate, 4:1 chloroform: ethyl acetate + 5% methanol, 
chloroform + 5% methanol and 4:1 chloroform: methanol. The purest fractions of OM31 
were collected, filtered and dried. Diethyl ether was added to precipitate the product and 
left overnight in cold place (4oC). However, there was also an unknown red compound 
which was collected for further determination.  The structure of OM31 was confirmed by 
high resolution electrospray (+) mass spectrum which showed a clear signal at m/z 
670.2698 which corresponded to the expected molecular mass of the 670.2698 Da cation 
Figure 1.56. Furthermore, there was a good correlation between the observed data and 
the theoretical isotope model for the C42H42NO5P cation. 
 
 
Figure 1.55: Synthesis of OM31 by reaction of OM28 with TPP. (a) TPP, DCC, DMAP, 







Figure 1.56: The ESI (+) mass spectrum of OM31 
 
OM31 structure was characterized and confirmed by its 1H NMR spectrum (in d6-DMSO), 
which showed, a signal between 1.35-1.49 ppm which was assigned to the two protons 
of the methylene group in the middle of the spacer, whereas the eight protons of TPP and 
anthraquinone spacer were found between 1.5-1.81 ppm. The methylene closest to the 
carbonyl group in the spacer was found at 2.93 ppm (triplet) whereas, the methylene 
closest to the amino group of the anthraquinone was found at 3.42 ppm (quartet). The 
methylene group closest to the phosphonium group of TPP was found at 3.61 ppm 
(triplet). In addition, a signal at 4.01 ppm was assigned to the methylene group closest to 
oxygen in the spacer. The fifteen aromatic protons of TPP and two of the anthraquinone 
were assigned between 7.71 ppm and 7.95 ppm. The signals at 7.36 ppm (doublet) and 
7.51 ppm (doublet) were assigned to the two anthraquinone protons, H-2 and H-3. The 
two protons for the anthraquinone, H-5 and H-8 were assigned at 8.24 ppm. At 10.3 ppm 
the signal was assigned to the amino proton at C-1 of the anthraquinone whereas, the 
hydroxyl proton of anthraquinone give a singlet signal at 13.67 ppm Figure 1.57 and 


















The proton-decoupled 13C NMR spectrum showed signals for all carbon environments. A 
DEPT experiment differentiated the nine methylene CH2 carbons, twenty one methine CH 
carbons (AQTPP and AQAR) and twelve quaternary carbons. The nine methylene carbons 
gave signals between 20.22 ppm and 63.57 ppm. The two anthraquinone carbonyl groups 
were assigned at 180.72 ppm and 186.66 ppm. Signals at 125.58 ppm, 126.01 ppm, 
126.27 ppm, 128.95ppm, 132.94 ppm and 134.73 ppm were assigned to the six methine 
carbons of the anthraquinone. Three aromatic methine carbon signals, corresponding to 
the ortho, meta and para carbon atoms of the TPP aromatic group were found in their 
expected positions at 130.13-130.29 ppm (meta), 133.45-133.59 ppm (ortho) and 134.90 


























1.3.3.9 Synthesis of HO-EOE-AQ(4-OH) (OM29) 
HO-EOE-AQ(4-OH) (OM29) was designed and developed specifically to study the effect 
of the oxygen group in the spacer on the cytotoxicity and localization of OM29 once 
attached with TPP in mitochondria or lysosomes and to compare the activity of this 
compound with previous synthesised compounds.  
Leucoquinizarin was reacted with 2-(2-aminoethoxy)ethanol in dichloromethane. The 
reaction mixture was refluxed for 1 hour at 50ºC over a water bath to give OM29. After 1 
hour, the reaction mixture was oxidized overnight by aeration with the addition of 
triethylamine (Et3N) Figure 1.62. The progress of the reaction was monitored through 
TLC. Solvent extraction was carried with chloroform/water. OM29 was purified by column 
chromatography using chloroform at the beginning followed by using chloroform with an 
increased percentage of methanol up to 6%. However, after the first purification, there 
were some impurities with OM29, therefore a second purification was performed using 
chloroform at the beginning then chloroform + 4% methanol to get the title compound 
OM29. The pure fractions were evaporated and dried. Diethyl ether was added to 
precipitate OM29. The structure of OM29 was confirmed by high resolution electrospray 
(+) mass spectrum which showed a clear signal at m/z 328.1181 [M + H]+ which 
corresponded to the expected molecular mass of the 327.1181. Furthermore, there was 
a good correlation between the observed data and the theoretical isotope model for 
C18H17NO5 [M + H]+. 
 
 
Figure 1.62: Synthesis of OM29 by reaction of Leucoquinizarin  (1) with 2-(2-aminoethoxy)ethanol. 




1.3.3.10 Synthesis of TPP-EOE-AQ(4-OH) (OM32) 
HO-EOE-AQ(4-OH) OM29 was reacted with TPP (1.2 eq) in dichloromethane using DCC 
(2.4 eq) and DMAP as a coupling agent. The reaction mixture was left to stir over ice for 
1 hour Figure 1.63. The reaction progress was monitored by TLC. However, OM29 was 
not fully reacted with TPP, therefore additional amounts of TPP (0.6 eq) and DCC (1.2 
eq) were added and allowed to react for 1 hour. The white crystals of N,N’-
dicyclohexylurea (DCU) were filtered off from the reaction solution, followed by solvent 
extraction with water and chloroform. Column chromatography was performed using to 
chloroform first then more polar solvents were used, chloroform + 5% ethyl acetate, 9:1 
chloroform: ethyl acetate, 4:1 chloroform: ethyl acetate: 4:1 chloroform: ethyl acetate + 
5% methanol, chloroform + 5% methanol and 9:1 chloroform: methanol. The pure 
fractions were collected, filtered and dried. Diethyl ether was added to precipitate the 
product OM32. The structure of OM32 was confirmed by high resolution electrospray (+) 
mass spectrum which showed a clear signal at m/z 672.2501 which corresponded to the 
expected molecular mass of the 672.2501 Da cation Figure 1.64. Furthermore, there was 





Figure 1.63: Synthesis of OM31 reaction of OM29 with TPP. (a) TPP, DCC, DMAP, 







Figure 1.64: The ESI (+) mass spectrum of OM32 
 
OM32 structure was characterized and confirmed by its 1H NMR spectrum (in d6-DMSO), 
which showed, signals between 1.47-1.79 ppm which were assigned to four protons of 
the methylene groups in the TPP spacer. The methylene closest to the carbonyl group in 
the spacer was found at 2.41 ppm whereas the methylene closest to the amino group of 
the anthraquinone was found at 3.34 ppm. Furthermore, the methylene protons around 
the oxygen atom in the spacer and the two protons of the methylene group closest to the 
phosphonium group of TPP where found between 3.5-3.73 ppm. In addition, a signal 
between 4.12-4.18 ppm was assigned to the methylene group closest to OH in the spacer. 
The fifteen aromatic protons of TPP and two anthraquinone protons were assigned 
between 7.71 ppm and 7.95 ppm. The signals at 7.37 ppm (doublet) and 7.55 ppm 
(doublet) were assigned to the anthraquinone protons of H-2 and H-3. The two protons 
for H-5 and H-8 were assigned between 8.20-8.27 ppm. At 10.37 ppm a triplet signal was 
assigned to the amino proton at C-1 of the anthraquinone whereas, the hydroxyl proton 























The proton-decoupled, 13C NMR spectrum showed signals for all carbon environments. 
A DEPT experiment differentiated the eight methylene CH2 carbons, twenty one methine 
carbons and twelve quaternary carbons. Signals between 20.28 ppm and 68.12 ppm were 
assigned to the eight methylene carbons. The two anthraquinone carbonyl groups were 
assigned at 180.81 ppm and 186.78 ppm. Signals at 125.81 ppm, 126.02 ppm, 126.25 
ppm, 128.71 ppm, 133.00 ppm and 133.61 ppm were assigned to six methine CH carbons 
of the anthraquinone. Three aromatic methine carbon signals, corresponding to the ortho, 
meta and para carbon atoms of the TPP aromatic group were found in their expected 
positions at 130.12-130.28 ppm (meta), 133.48-133.56 ppm (ortho) and 134.90 ppm 
(para) Figure 1.67, Figure 1.68 and Figure 1.69. 
 
 






















1.3.3.11 Synthesis of OH-butyl-AQ (NU:UB 238) 
The reason behind the synthesis of NU:UB 238 was to evaluate the effect of (-OH) and (-
NH2), which present in TPP-EAE-AQ(4-OH) (OM22) and not in NU:UB 238 after attaching 
the TPP on the localization and if they still retained activity or were less active without the 
(-OH).  
NU:UB 238 was synthesized by reaction of 1-chloroanthraquinone with 4-amino-1-
butanol in DMSO, and then the reaction mixture was heated over a boiling water bath 
with a condenser for 30 minutes. The reaction solution was cooled and added to a large 
excess of water (500 mL) to give red solid precipitate which was filtered off, dried and 
used for subsequent reactions without further purification Figure 1.70. The structure of 
NU:UB 238 was confirmed by its high resolution electrospray (+) mass spectrum which 
showed a clear signal at m/z 296.1284 [M + H]+ which corresponded to the expected 
molecular mass of the compound. Furthermore, there was a good correlation between 
the observed data and the theoretical isotope model for C18H17O3NH [M + H]+. This 
confirmed the correct structure of NU:UB 238. 
 
 
Figure 1.70: Synthesis of NU:UB 238 by reaction of 1-chloroanthraquinone (1) with 4-amino-1-






1.3.3.12 Synthesis of (TPP-Butyl-AQ) (SH1) 
SH1 was synthesized as it shares the same aminobutanol spacer as NU:UB 73 and 
NU:UB 76 (Section 1.3.1) but in SH1, the ester bond linking TPP to the spacer is likely 
to be more stable than the ester bond to L- and D- alanine in NU:UB 73 and NU:UB 76, 
respectively . Both NU:UB 73 and 76 were active in vivo once the AQ- aminobutanol 
spacer (NU:UB 238) was linked with L-alanine [NU:UB 73] and D-alanine [NU:UB 76], 
whereas the spacer alone was inactive both in vitro and in vivo.  
SH1 (AQ- aminobutanol linked with TPP) was synthesized by the reaction of OH-butyl-
AQ (NU:UB 238) pre-dissolved in dichloromethane with TPP using DCC and DMAP as a 
coupling agents. The reaction mixture was left to stir for 1 hour Figure 1.71. The reaction 
progress was monitored by TLC. The white crystals of N,N’-dicyclohexylurea (DCU) were 
filtered off from the reaction solution, followed by solvent extraction with water and 
chloroform. Column chromatography was performed using dichloromethane at the 
beginning followed by using more polar solvent systems, 9:1 dichloromethane: ethyl 
acetate; 9:1 dichloromethane: ethyl acetate + 1% methanol. The percentage of methanol 
was increased gradually to 7% until all SH1 was collected. However, the product of SH1 
was difficult to precipitate by diethyl ether as it was very sticky, therefore column 
chromatography was performed for a second time to remove any impurities that 
prevented the precipitation of SH1. The solvents were evaporated and acetonitrile: diethyl 
ether solution was added and it was cooled (4oC) for 48 hours in order to precipitate SH1. 
The structure of NU:UB 238 was confirmed by its high resolution electrospray (+) mass 
spectrum which showed a clear signal at m/z 640.2594 which corresponded to the 
expected molecular mass of the cation. Also, there was a good correlation between the 
observed data and the theoretical isotope model for [C41H39O4NP]+ Figure 1.72. This 





Figure 1.71: Synthesis of SH1 by reaction of NU:UB 238 with TPP. (a) TPP, DCC, DMAP, 




Figure 1.72: The ESI (+) mass spectrum of SH1 
 
The structure of SH1 was characterized and confirmed by its 1H NMR spectrum (in d6- 
DMSO), which showed, a triplet signal at 9.68 ppm which was assigned to the amino 
proton at position 1 of the anthraquinone. Signals between 1.50-1.80 ppm were assigned 




Another four protons of TPP were found at 3.62 ppm (triplet) and 4.06 ppm (triplet). The 
methylene closest to carbonyl group in the spacer was found at 2.41 ppm (triplet), 
whereas, the methylene group closest to the amino group of the anthraquinone was found 
at 4.06 ppm (singlet). The fifteen aromatic protons of TPP and two of the anthraquinone 
were assigned between 7.72 ppm and 7. 94 ppm. The signals at 7.26 ppm, 7.43 ppm and 
7.65 ppm were assigned to the anthraquinone protons of H-2, H-4 and H-3. The two 
protons for H-5 and H-8 of the anthraquinone were assigned between 8.10-8.21 ppm 















The proton-decoupled 13C NMR spectrum showed signals for all carbon environments. A 
DEPT experiment differentiated the eight methylene CH2 carbons, twenty two methine 
CH carbons and eleven quaternary carbons. Signals between 20.25 ppm and 63.47 ppm 
were assigned to the eight methylene carbons. The two anthraquinone carbonyl groups 
were assigned at 184.00 ppm and 182.81 ppm. Signals at 115.02 ppm, 118.60 ppm, 
126.25 ppm, 126.34 ppm, 134.49 ppm, 134.86 ppm, 135.65 ppm were assigned to the 
seven methine CH carbons of the anthraquinone. Three aromatic methine carbon signals, 
corresponding to the ortho, meta and para carbon atoms of the TPP aromatic group were 
found in their expected positions at 130.13-130.29 ppm (meta), 133.45-133.59 ppm 
(ortho) and 134.90 ppm (para) Figure 1.75 and Figure 1.76 and Figure 1.77. This 






















1.3.3.13 Synthesis of mono-TPP-NU:UB 65 (OM25) 
NU:UB 65 is an aminoanthraquinone derivative that was developed and synthesized at 
the Anticancer Drug Design and Delivery Research Group at Napier University. NU:UB 
65 has similar structural as mitoxantrone but it lacks the amino groups (-NH) in its side 
chains, which play an important role in the biological activity and DNA binding of 
mitoxantrone (Skladanowski and Konopa, 2000). Additionally, the absence of the two 
hydroxy groups (-OH) at positions C-5 and C-8 and poor solubility make NU:UB 65 
inactive and lacking in anticancer activity. Therefore, it was hypothesized that attaching 
TPP to NU:UB 65 could modulate the activity of this compound. Herein, two TPP-NU:UB 
65 drivatives were synthesized; first, the TPP was attached to one side chain of NU:UB 
65. Secondly, TPP groups were attached to both side chains of NU:UB 65 and further 
investigation of the cytotoxicity effect and localization studies were performed. 
Additionally, the synthesis of OM25 and OM26, containing simple aminopentanol side 
chains without and any additional functional groups, was important as the methods 
developed during synthesis when controlling mono- or bis- attachment of TPP, could be 
used in later reactions when attaching TPP to ametantrone and mitoxantrone.  
TPP-NU:UB 65 (OM25) was synthesized by reaction of NU:UB 65 (pre-dissolved in 
dichloromethane) with TPP. TPP and DCC were dissolved in dichloromethane and DMAP 
was added and allowed to react for 10 minutes. The mixture was added to NU:UB 65 and 
allowed to react for 1 hour Figure 1.78. The reaction was carried out in a very dilute 
solution and low equivalents of TPP and DCC (2 x 0.5 eq) were added twice to slow the 
reaction and make sure that TPP had been added on one side arm. The reaction progress 
was monitored by TLC. The reaction mixture was filtered to remove DCU. Solvent 
extraction was carried using dichloromethane and water followed by addition of sodium 
sulphate to remove any water residue in the reaction mixture. The solvents were 
evaporated to a lower volume before purification. OM25 was purified by column 
chromatography using solvent system 19:1 dichloromethane: methanol. The pure 
fractions were collected, filtered and evaporated to dryness. Diethyl ether was added to 
precipitate OM25 which was filtered and collected. The structure of OM25 was confirmed 




755.3590 which corresponded to the expected molecular mass of the cation. Also, there 
was a good correlation between the observed data and the theoretical isotope model for 




Figure 1.78: Reaction of NU:UB 65 with TPP. (a) TPP, DCC (2 x 0.5 eq) and DMAP in dilute solution 
of dichloromethane, 1 h. 
 
1.3.3.14 Synthesis of bis-TPP-NU:UB 65 (OM26)  
OM26 was synthesized by reaction of NU:UB 65 (pre-dissolved in dichloromethane) with 
TPP. TPP and DCC were dissolved in dichloromethane and DMAP was added and 
allowed to react for 10 minutes. The mixture was added to NU:UB 65 and allowed to react 
for 1 hour Figure 1.79. High equivalents of starting compounds and coupling agents (6 
eq) were used in a concentrated solution to make sure that TPP added to both side chains 
of NU:UB 65. The reaction progress was monitored by TLC. The reaction mixture was 
filtered to remove DCU. Solvent extraction was carried out using dichloromethane and 
water followed by addition of sodium sulphate to remove any water residue in the reaction 
mixture. The solvents were evaporated to lower volume before purification. OM26 was 
purified by column chromatography using solvent system 19:1 dichloromethane: 
methanol. The pure fractions were collected, filtered and evaporated to dryness. Diethyl 




OM26 was confirmed by its high resolution electrospray (+) mass spectrum which showed 
a clear signal at m/z 550.2491 at half mass for the doubly charged cation [M-2Br]2+ Figure 
1.80. Furthermore, there was a good correlation between the observed data and the 
theoretical isotope model for [C70H74N2O6P2]2+. 
 
 
Figure 1.79: Reaction of NU:UB 65 with TPP. (a) high equivalent (6 eq) of TPP, DCC and DMAP in 












 Synthesis of mitoxantrone derivatives rhodamine B 
conjugates  
Rhodamine is the oldest, inexpensive and most popular dye used for different purposes 
such as fluorescent markers to study compounds structure under the microscope, laser 
dyes, photosensitizers (Meng et al., 2007) and widely used in fluorescent probes 
(Wolfram et al., 2018). Rhodamine has the ability to penetrate the cell more readily than 
fluoresceins due to the cationic charge of the rhodamine that can penetrate the negative 
plasma membrane potential within the cytoplasm of cells. Upon cell entry, rhodamine 
accumulates inside the mitochondria due to the lipophilic and cationic properties that 
allow it to pass through the high negative potential across mitochondrial inner membrane 
(Mottram et al., 2012). In addition, rhodamine B can be used as a mitochondrial probe for 
determining the ΔΨm of intact drug-resistant and drug-sensitive cells 
(Reungpatthanaphong et al., 2003). Reungpatthanaphong et al., (2003), designed a non-
invasive method to determine and monitor the mitochondrial membrane potential ΔΨm. 
They found that rhodamine B accumulated in the matrix of mitochondria which was 
determined by the decrease of rhodamine B fluorescence in the presence of formazan, 
which acts as a quencher for rhodamine B (Reungpatthanaphong et al., 2003). (Muli et 
al., 2014) designed and synthesised asymmetric zinc phthalocyanine ZnPc-Rho B 
conjugates in which ZnPc-OH chromophores were linked with rhodamine B via a DIC-
activated ester. ZnPc-Rho B were found to be more lipophilic than the unconjugated ZnPc 
precursors and attaching the rhodamine B moiety increased the phototoxicity of the dyes 
and the mitochondrial uptake compared with the unconjugated ZnPc (Muli et al., 2014). 
Based on this demonstrated mitochondrial cellular targeting of rhodamine B, in this 
research programme, rhodamine B conjugates were synthesised in which rhodamine B 
was linked with piperazine-succinate to form tertiary amide bond and lock the rhodamine 
B in the open-ring (fluorescent) form (Nguyen and Francis, 2003). Rhodamine B was also 
amide linked to β-alanine to conjugates that could ring open or ring close, depending 
upon pH (Beija et al., 2009). These novel compounds were synthesised to compare the 
synthesis and purification differences between these conjugates and TPP-conjugates and 




1.3.4.1 Synthesis of Rho-β-ala-OtBu (OM6) and Rho-β-ala-OH (OM7) 
OM6 was synthesized by reaction of rhodamine B with β-ala-OtBu (1.1 eq) in DMF using 
PyBoP (1.5 eq) and DIPEA (4.6 eq) as a coupling conditions with stirring for 2 hours 
Figure 1.81. The reaction progress was monitored by TLC which showed that there was 
still unreacted rhodamine B, therefore additional amounts of β-ala-OtBu (0.55 eq), PyBOP 
(0.75 eq) and DIPEA (2.3 eq) were added and stirring continued for another two hours. 
Solvent extraction was performed with water and chloroform. Sodium sulfate was added 
to remove any water followed by filtration and solvent evaporation. OM6 was purified by 
column chromatography using chloroform at the beginning then, more polar solvent was 
used, 9:1 chloroform: methanol + 1% pyridine. However, there were some impurities, 
therefore some fractions were purified again using the same solvent system. The pure 
fractions were filtered and evaporated to dryness followed by addition of water to solidify 
the product (OM6) and left overnight (4C). The structure of OM6 was confirmed by high 
resolution electrospray (+) mass spectrum which showed a clear signal at m/z 570.3316 
which corresponded to the expected molecular mass of the cation. Furthermore, there 
was good correlation between the observed data and the theoretical isotope model for 
[C35H43N3O4]+. 
Trifluoroacetic acid (TFA) was added and left overnight to remove OtBu group Figure 
1.81. TFA was evaporated and diethyl ether was added and left overnight with cooling 
(4oC) to precipitate the product OM7 which then was filtered and collected. The structure 
of OM7 was confirmed by high resolution electrospray (+) mass spectrum which showed 
a clear signal at m/z 514.2687 which corresponded to the expected molecular mass of 
the cation. Furthermore, there was a good correlation between the observed data and the 






Figure 1.81: synthesis of OM6 and OM7. (a) HN-β-ala-OtBu, PyBop, DIPEA, DMF, 2 h. (b) TFA, 
overnight. 
 
1.3.4.2 Synthesis of Rho-β-ala-EAE-Boc-AQ (4-OH) (OM17) and Rho-β-ala-
EAE-AQ (4-OH) (OM18) 
OM17 was synthesized by the reaction of OM7 (1.1 eq) with pre-dissolved of HO-EAE-
Boc-AQ (4-OH) (OM2) in dichloromethane using DCC (2.4 eq) and DMAP as a coupling 
agent Figure 1.82. The reaction was carried out over ice with stirring. However, OM7 did 
not completely dissolve in dichloromethane therefore a few drops of acetonitrile and 
DIPEA were added. The reaction progress was monitored by TLC, which showed after 
one hour that there was some of OM2 not reacted therefore, additional amounts of OM7 
(0.55 eq) and DCC (1.2 eq) were added. The reaction mixture was filtered to remove DCU 
and extracted using dichloromethane and water. OM17 was purified by column 




then the polarity of solvent was increased using 9:1 dichloromethane: ethyl acetate then 
9:1 dichloromethane: ethyl acetate + 5% methanol. The impurities of fractions were 
monitored by TLC which showed that some fractions were not pure, therefore column 
chromatography was run again using firstly dichloromethane then dichloromethane + 5% 
ethyl acetate to remove all rhodamine impurities and finally, 9:1 dichloromethane: ethyl 
acetate was used to get pure OM17. The pure fractions were filtered and solvents were 
evaporated.  
Trifluoroacetic acid (TFA) was added and left for 30 minutes to remove the Boc group 
Figure 1.82. TFA was evaporated and ethanol was added to lower the boiling point of 
TFA before adding diethyl ether to solidify the product. However, Rho-β-ala-EAE-AQ (4-
OH) OM18 was not precipitated with diethyl ether therefore, hexane was used with few 
drops of 1,4-dioxane and cooled (4OC) overnight. OM18 was collected by centrifugation.  
The structure of OM18 was confirmed by high resolution electrospray (+) mass spectrum 
which showed a clear signal at m/z 822.3857 which corresponded to the expected 
molecular mass of the cation. Furthermore, there was a good correlation between the 





Figure 1.82: Reaction of OM2 with OM7 followed by reaction of OM17 with TFA. (a) OM2, DCC, 




1.3.4.3 Synthesis of Rho-pip-Boc (OM4) and Rho-piperazine TFA (OM4 TFA) 
Rhodamine B was dissolved in 2:1 dichloromethane: DMF and HATU was added as a 
coupling agent with triethylamine and allowed to activate for 10 minutes. Boc-piperazine 
was dissolved in 2:1 dichloromethane: DMF then added to activated rhodamine B. The 
reaction mixture was stirred at room temperature and was left overnight Figure 1.83. The 
reaction progress was monitored by TLC. Solvent extraction was with dichloromethane 
and water followed by addition of sodium sulphate to remove any water. The reaction 
mixture was filtered and solvents were evaporated to a lower volume before purification. 
OM4 was purified by column chromatography using 19:1 dichloromethane: methanol. The 
pure fractions were filtered and solvents were evaporated to dryness. Trifluoroacetic acid 
(TFA) was added and left overnight to remove the Boc group Figure 1.83. TFA was 
evaporated and 1,4-dioxane was added followed by the addition of diethyl ether to 
precipitate the product OM4 TFA which was filtered off and collected. The structure of 
OM4 TFA was confirmed by its high resolution electrospray (+) mass spectrum which 
showed a clear signal at m/z 511.3054 which corresponded to the expected molecular 
mass of the cation [M-TFA]+. Furthermore, there was a good correlation between the 
observed data and the theoretical isotope model for [C32H39N4O2]+. 
 
Figure 1.83: Reaction of Rho B with Boc-piperazine (a) Boc-piperazine, HATU, DIPEA, 




1.3.4.4 Synthesis of Rho-pip-succinate (OM5) 
OM5 was synthesized by reaction of Rho-piperazine-TFA (OM4 TFA) with succinic 
anhydride in DMF using DIPEA as a base Figure 1.84. The reaction progress was 
monitored by TLC. The reaction mixture was extracted using dichloromethane and water. 
However, during the extraction progress it was very difficult to see clear separation, 
therefore a small amount of reaction mixture was extracted every time while carefully 
collecting the organic layer to avoid any water contamination. The solvents were 
evaporated overnight at room temperature to get rid of all DMF. Diethyl ether was added 
to precipitate the product OM5 which was filtered off and collected. 
 
Figure 1.84: Reaction of OM4 with succinic anhydride to give OM5, (a) succinic anhydride, DIPEA, 
DMF, 1 h. 
 
1.3.4.5 Synthesis of Rho-pip-succ-EAE-Boc-AQ(4-OH) (OM15) and Rho-pip-
succ-EAE-AQ(4-OH) (OM16) 
Rho-pip-succinate (OM5) and HO-EAE-Boc-AQ(4-OH) (OM2) were dissolved in 
dichloromethane and cooled over ice with stirring. The coupling agent DCC was dissolved 
in dichloromethane and DMAP was added as a catalytic base which then was added 
dropwise to the cooled mixture and allowed to react for 12 hours Figure 1.85. The 
reaction mixture was monitored by TLC. The reaction mixture was filtered off to remove 
DCU followed by solvent extraction with dichloromethane and water. The solvents were 




chromatography using firstly 9:1 dichloromethane: methanol which was too polar to start 
with because all the mixture ran through the column too quickly. Therefore, the solvent 
was switched to chloroform alone at the beginning and then the polarity of the solvents 
was increased slowly, 9:1 chloroform: ethyl acetate and 9:1 chloroform: methanol. The 
pure fractions were filtered off and solvents were evaporated to dryness. The structure of 
OM15 was confirmed by high resolution electrospray (+) mass spectrum which showed a 
clear signal at m/z 1019.4914 which corresponded to the expected molecular mass of the 
cation. Furthermore, there was a good correlation between the observed data and the 
theoretical isotope model for [C59H67N6O10]+.  
Trifluoroacetic acid (TFA) was added and left for 30 minutes to remove the Boc group 
Figure 1.85. TFA was evaporated and few drops of ethanol was added to lower the boiling 
point of TFA. Once the product was completely dry, diethyl ether was added to precipitate 
the product OM16 which was filtered off and collected. The structure of OM16 was 
confirmed by high resolution electrospray (+) mass spectrum which showed a clear signal 
at m/z 919.4388 which corresponded to the expected molecular mass of the cation [M -
TFA]+. Furthermore, there was good correlation between the observed data and the 





Figure 1.85: Reaction of OM2 with OM5 to give OM15 followed by deprotection of OM15 to give 





 Synthesis of mitoxantrone and ametantrone-linked 
conjugate  
Mitoxantrone is an anticancer drug that was synthesized to reduce the cardiotoxic side 
effects associated with doxorubicin and daunomycin (Parker et al., 2004). Mitoxantrone 
is used mainly in the treatment of prostate and breast cancer, lymphoma, acute leukemia 
and also multiple sclerosis (Rossato et al., 2014). It has been reported that mitoxantrone 
accumulates inside the cell including the nucleus where it functions as a topoisomerase 
II inhibitor (Parker et al., 2004). However, mitoxantrone is also a hydrophobic weak base 
and is trapped in acidic lysosomes and is highly accumulated in the lysosome 
(Zhitomirsky and Assaraf, 2015).  The planar structure and the presence of nitrogen-
containing side chains allow mitoxantrone to intercalate between DNA base pairs and 
bind with the phosphate backbone of DNA (Li et al., 2005). Therefore, taking advantage 
of the unique structural features of mitoxantrone in binding to DNA and to reduce the side 
effects by altering the targeting and localization of mitoxantrone in mitochondria, 
mitochondrial targeted vectors were ester linked with mitoxantrone to increase the 
therapeutic index and reduce side effects. Additionally, the amino groups present in the 
side chains of the mitoxantrone were protected with a Boc group to prevent any side 
reaction that could happen during the attachment of TPP with mitoxantrone. The Boc 
group was then removed by TFA to afford the final product.  
Ametantrone has a similar structure to mitoxantrone but without the two hydroxy groups 
at positions C-5 and C-8. Although mitoxantrone is 100-fold more potent than 
ametantrone due to the absence of the hydroxy groups at these positions (Kapuscinski 
and Darzynkiewicz, 1986). Also, it has been reported that ametantrone has lower efficacy 
on tumour cells of breast cancer, ovarian cancer, melanomas and small cells lung cancer. 
Therefore, further development of ametantrone was stopped (Piccart et al., 1981; 
Rozencweig et al., 1985). Herein, a novel ametantrone-TPP conjugate was developed 
and synthesized to evaluate the effect of attaching a TPP carrier to study the changes in 




1.3.5.1 Synthesis of Mitoxantrone-Boc (OM19) 
Mitoxantrone was dissolved in methanol and was stirred and cooled with addition of 
DIPEA, Boc2O (4 eq) dissolved in methanol added dropwise to the solution and left to 
react for 1 hour Figure 1.86. The reaction progress was monitored by TLC which showed 
there was some unreacted mitoxantrone, therefore a further half equivalent of Boc2O was 
added and allowed to react overnight. The reaction mixture was filtered to remove any 
unreacted Boc2O and was extracted using dichloromethane and water. OM19 was 
purified by column chromatography using dichloromethane alone at the beginning to 
remove any unreacted Boc2O and other impurities, then a more polar solvent system was 
used; 9:1 dichloromethane: methanol. After purification, iodine was used to check if there 
were any invisible impurities that could not be detected by UV or visible light because 
iodine reacts with any hydrocarbon to give a brown color. The TLC of OM19 was left in 
an iodine chamber for 5 minutes and after the plate was removed there was no color 
indicating that the product was free from organic impurities. The pure fractions were 
collected and solvents were evaporated followed by addition of diethyl ether to precipitate 
the product OM19. However, OM19 did not precipitate easily with diethyl ether therefore, 
an empty round bottom flask was weighed and the product was transferred; then the 







Figure 1.86: Reaction of mitoxantrone with Boc2O. (a) Boc2O, DIPEA, methanol, 1 h. 
 
1.3.5.2 Attempted synthesis of Rho-pip-succ-mitoxantrone-Boc (OM20) and 
Rho-pip-succ-mitoxantrone (OM21) 
Mitoxantrone-Boc (OM19) and OM5 (1.1 eq) were dissolved in dichloromethane and 
stirred with cooling. The coupling agent DCC (2.4 eq) was dissolved in dichloromethane 
and DMAP was added and the mixture was cooled and added dropwise to OM19 and 
OM5 and allowed to react for 1 hour Figure 1.87. The reaction progress was monitored 
by TLC which showed that some OM19 did not react with OM5 therefore, a half equivalent 
of the original amount of DCC (1.2 eq) was added and allowed to react overnight. After 
the end of the reaction, the TLC showed that there were two new products. The reaction 
mixture was filtered to remove DCU followed by solvent extraction with dichloromethane 
and water. The solvents were evaporated to a lower volume before purification. OM20 
was purified by column chromatography using dichloromethane alone first followed by 
using more polar solvents, 9:1 dichloromethane: ethyl acetate, 4:1 dichloromethane: ethyl 




product could not be eluted from the column so methanol was used and the product was 
left under methanol to elute from silica. The impure fractions were purified again using 
the same solvents system as previously. The pure fractions were collected, filtered and 
evaporated to dryness. The structure of OM20 was characterized by its high resolution 
electrospray (+) mass spectrum which showed two main signals at m/z 1351.6486 and 
687.3192 which did not correspond to the expected molecular mass of the cation at 
1826.1211, this indicated unsuccessful synthesis of OM20. 
Trifluoroacetic acid (TFA) was added and left for 30 min to remove Boc2O group Figure 
1.88. TFA was evaporated and ether was added to precipitate the product OM21 which 
was filtered and collected. The structure of OM20 was tested by high resolution 
electrospray (+) mass spectrum which showed three main signals at m/z 460.2225, 
919.4388 and 969.1782 which did not correspond to the expected molecular mass of the 






Figure 1.87: Reaction of OM19 with Rho-pip-succinate. (a) Rho-pip-succinate, DCC, DMAP, 














1.3.5.3 Attempted synthesis of TPP-mitoxantrone-Boc (OM23) and bis-TPP-
mitoxantrone-Boc (OM24) 
Mitoxantrone-Boc (OM19) was dissolved in dichloromethane and was stirred with cooling. 
TPP and DCC were dissolved in dichloromethane and DMAP was added and allowed to 
activate for 10 minutes. The mixture was added to OM19 and allowed to react for 1 hour 
Figure 1.89. TPP and DCC were added 3 times with small equivalents in a very dilute 
solution to give the mono-TPP compound (OM23). The equivalents of TPP and DCC were 
increased an additional three times to give the bis-TPP compound (OM24). The reaction 
progress was monitored by TLC. The reaction was extracted with dichloromethane and 
water. The products were purified by column chromatography using dichloromethane first 
then more polar solvents were used, 19:1 dichloromethane: methanol to get OM23 then, 
the solvents system was changed to 9:1 dichloromethane: methanol and 4:1 
dichloromethane: methanol to get OM24. However, there was an unknown compound not 
moving with these solvents, therefore methanol was added and left overnight to get the 
compound from the silica. The pure fractions were collected and solvents were 
evaporated followed by addition of diethyl ether to precipitate OM23 and OM24. The 
structure of OM24 was tested by high resolution electrospray (+) mass spectrum which 
showed the main signal at m/z 580.2807 which did not correspond to the expected 






Figure 1.89: Reaction of OM19 with TPP. (a)  high equivalent of TPP, DCC and DMAP. 
dichloromethane, 1 h.  
 
Therefore, the synthesis of mitoxantrone-linked prodrugs was unsuccessful as unknown 
products were obtained. However, further identification of these products is required to 
identify the reason behind the failure of the synthesis. In addition, new method should be 







1.3.5.4 Synthesis of ametantrone (NK1) 
NK1 was produced by the reaction of leucoquinizarin with a large excess of N-(2-
hydroxyethyl)ethylenediamine. The reaction mixture was heated in dichloromethane over 
a water bath for one hour until the colour of the mixture became greenish blue. The 
intermediate was oxidized with O2 with the addition of few drops of triethylamine and the 
color changed to deep blue over one hour Figure 1.90. The oxidation progress was 
monitored by TLC which shows there were still some unoxidized leuco-products 
therefore, more triethylamine was added and the air oxidation was continued for another 
3.5 hours. NK1 was separated from some impurities by dissolving the reaction mixture in 
ethanol and heating over a boiling water bath (with a water condenser) for 2 hours, 
followed by the cooling. A blue solid was precipitated and then separated from the green 
solvent. NK1 was filtered and more ethanol was added to remove any remaining 
impurities. The TLC was checked and showed that the ethanol residual solvent contained 
more ametantrone and less impurities whereas the solid from partial separation still 
contained the impurities from the ametantrone initial reaction, therefore this method was 
unable to completely separate the NK1 from the impurities and was decided the 
subsequent reaction would be continued without separating ametantrone from the 
impurities.  
 
Figure 1.90: Reaction of leucoquinizarin with N-(2-hydroxyethyl)ethylenediamine. (a) N-(2-






1.3.5.5 Synthesis of Ametantrone-Boc (NK4) 
Ametantrone (NK1) was dissolved in methanol and stirred over ice. Boc2O in cold 
methanol was added dropwise to the solution to let the reaction occur slowly. The solution 
was left over ice and allowed to react for 1 hour Figure 1.91. The reaction progress was 
monitored by TLC. Solvent extraction was carried out using chloroform and water to 
destroy the unreacted Boc2O with water. Sodium sulfate was added to the organic layer 
to remove excess water in the solution by forming sodium sulfate hydrate. The mixture 
was filtered and dried before purification. NK4 was purified by column chromatography 
using chloroform alone at the beginning followed by using more polar solvents, chloroform 
: ethyl acetate (19:1), chloroform: ethyl acetate (19:1) + methanol 2%, chloroform : ethyl 
acetate (9:1) + methanol 2%, chloroform : ethyl acetate (9:1) + methanol 4%, and 










1.3.5.6 Synthesis of TPP-ametantrone-Boc (NK6) and TPP-ametantrone-TFA 
(NK8) 
NK6 was synthesized by dissolving ametantrone-Boc (NK4) in DMF and TPP was 
dissolved in DMF with the coupling agent HATU and 4-methylmorpholine to activate TPP 
carboxylic acid, which were added to NK4 in DMF. The mixture was left to react for 1 hour 
with stirring Figure 1.92. The reaction progress was monitored by TLC which showed that 
NK4 and TPP still in abundance and only a little of NK4 was formed therefore, the reaction 
was continued by heating (water bath 40ºC) without stirring for another 1.5 hours. After 
1.5 hours, the TLC showed that more NK4 was formed and TPP was barely visible 
therefore, it was decided that the reaction was continued for another hour without addition 
of more coupling agents. After twenty hours, TLC showed that NK6 had formed although 
the reaction was not complete. Solvent extraction was performed with chloroform and 
water. The organic layer was collected and dried before purification. NK6 was purified by 
column chromatography using chloroform initially and then more polar solvent chloroform: 
ethyl acetate (19:1), chloroform: ethyl acetate (19:1) + methanol 1%, chloroform: ethyl 
acetate (19:1) + methanol 2% were used. The pure fractions were collected and dried.  
The structure of NK6 was confirmed by high resolution electrospray (+) mass spectrum 
which showed main signal at m/z 651.2971 which corresponded to the expected 
molecular mass of the doubly charged cation. Furthermore, there was a good correlation 
between the observed data and the theoretical isotope model for [C78H88N4O10P2]2+, 





Figure 1.92: Reaction of TPP with NK4. (a) TPP, HATU, 4-methylmorpholine, DMF, room temperature 
for 1 h, 40ºC for 1.5 h, room temperature for 18 h. 
 
Trifluoroacetic acid (TFA) was added and left for 30 minutes to react with TPP-
ametantrone-Boc (NK6) to remove the Boc group Figure 1.93. TFA was evaporated and 
a few drops of ethanol were added to lower the boiling point of TFA. Once the product 
was completely dry, diethyl ether was added to precipitate the product NK8 which was 
filtered off and collected. The structure of NK8 was confirmed by high resolution 
electrospray (+) mass spectrum which showed the main signal at m/z 551.2442 for the 
doubly charged cation and this corresponded to the expected molecular mass of the 



























In conclusion, the synthesis of a series of TPP-conjugated compounds was successful 
and the compounds were characterized by their high resolution electrospray (+) mass 
spectra and 1H NMR and 13C NMR. However, the synthesis of OM23 and OM24 
(mitoxantrone-TPP) was unsuccessful. In vitro assays such as DNA binding, distribution 
coefficient, cytotoxicity (MTT), confocal microscopy imaging and morphology studies 
were then performed for selected compounds as described in the following sections. 
Although, rhodamine B-conjugated compounds were also successfully synthesized, the 
synthesis and purification of these compounds were more complicated due to the 
presence of rhodamine B in compared with the TPP-conjugated compounds which the 
synthesis and purification was easier. In addition, the yield obtained from the reaction of 
TPP with mitoxantrone derivatives was much higher than the yield obtained from the 
reaction of rhodamine B with mitoxantrone derivatives. Therefore, it was decided to focus 
on the TPP conjugate compounds for further evaluations and in vitro assays.  
 
 DNA binding assay  
Development of new chemotherapeutic agents has been a main subject of interest for 
many years (Al-otaibi et al., 2017). Large percentages of these anticancer drugs are 
designed to target the DNA by interacting with DNA directly or by preventing the relaxation 
of DNA, through the inhibition of topoisomerases (Palchaudhuri and Hergenrother, 2007). 
The unique structure of the double helix of DNA, that contains two sugar-phosphate poly-
deoxyribonucleotide strands that bond with each other through a hydrogen bond between 
nucleotide bases, makes the DNA an attractive molecule inside the cell to be targeted to 
inhibit DNA replication, transcription and gene expression. Anticancer drugs interact with 
DNA by two main mechanisms; covalent interaction and non-covalent interactions are 
classified into intercalation and groove binding  (Adhikari and Mahar, 2016). In the 
intercalation process, a planar aromatic molecule binds with DNA by insertion of the 
planar aromatic rings between the DNA base pairs which results in decrease the DNA 
length and DNA helical twist. The stability of the intercalation complex is established by 




electrophilic, cationic and basic functional groups are important factors for the 
genotoxicity of the intercalators (Palchaudhuri and Hergenrother, 2007). Among all these 
properties, anthraquinones, which have aromatic planar structures, are an important class 
of anticancer drug, known to intercalate with DNA between the base pairs of the DNA 
double helix resulting in significant changes in DNA which in turn inhibit the DNA 
replication, inhibition of topoisomerase II and leading to irreversible DNA damage (Al-
otaibi et al., 2017). In addition, mitoxantrone is the leader of the anthraquinone 
compounds that bind with DNA and used in the treatment of breast cancers, ovarian 
cancers and haematological malignancies has a significant cytotoxic activity (Kamal et 
al., 2007).  
However, in vitro experiments can be performed to study the binding of the anticancer 
drugs with DNA. The most popular method to measure the binding affinity of anticancer 
drugs with DNA, is using a fluorometric monitoring of the reaction between the DNA and 
a fluorescent compound that has the ability to bind with DNA and its fluorescence 
emission can increase upon binding with DNA. The most popular fluorescent compound 
that has the ability to bind with DNA is ethidium bromide (EtdBr) (Alonso et al., 2006).  
Therefore, in this research programme, a DNA binding assay was carried out to study the 
binding affinity of the novel compounds with calf thymus DNA (CT DNA) by displacing 
ethidium bromide from the fluorescent DNA-ethidium bromide complex. Ethidium bromide 
(EtdBr) [(3,8-diamino-5-ethyl-6-phenyl phenanthridinium bromide)] Figure 1.95 has the 
ability to intercalate between base pairs in both double stranded DNA and RNA and 
enhances the fluorescence intensity of ligand-DNA and ligand-RNA complexes. 
Therefore, this method was used to study the binding of DNA with EtdBr and other 
compounds that noncompetitively or competitively inhibit the binding between DNA and 
EtdBr (Alonso et al., 2006). When EtdBr binds with DNA, the fluorescence of EtdBr can 
increase by 24-fold. However, when EtdBr is displaced from its intercalated site, its 
fluorescence can decrease by 24-fold and its excitation spectrum will be shifted 






Figure 1.95: Chemical structure of ethidium bromide (EtdBr) 
 
During the addition of active agent, aliquots of compounds were used and the 
concentration of each compound was increased each time until a decrease by 50% in the 
fluorescence intensity (of the ethidium-CT DNA complex) was achieved. QE50 values 
were calculated by plotting the fluorescence intensity against compound concentration 
and were calculated from the mean value (n = 3). The QE50 value is the mean 
concentration of the test compound required to reduce the initial fluorescence of the 
starting DNA-bound ethidium complex by 50%. The apparent binding constant (Kapp) was 
calculated from the equation Kapp=(KEB[EB])/[Drug], where the binding constant for the 
CT DNA-ethidium complex was taken from the literature value for mitoxantrone as 
reported by (Kundu et al., 2011),  therefore, the smaller the QE50 value, the greater 





1.3.6.1 Mitoxantrone  2HCl DNA binding 
 
Figure 1.96: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr (30 
μM) when treated with different concentrations of mitoxantrone in PBS buffer. λex 480 nm; λem 610 
nm (n = 3).  
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  725.98 5.16 140.52 <0.0001 
QE50 4.77 0.15 31.04 <0.0001 
 
The concentration of mitoxantrone 2HCl when the relative fluorescence intensity reached 
50% was 4.77 ± 0.15 μM. Therefore, the binding constant for mitoxantrone was 
6.2×107M-1. 
Mitoxantrone (µM)































1.3.6.2 OM2 [AQ-EAE-OH (4-OH)] TFA DNA binding  
OM2 TFA (µM)
































Figure 1.97: : Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr  
(30 μM) when treated with different concentrations of OM2 TFA in PBS buffer. (n = 3). λex 480 nm; 
λem 610 nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  710.44 2.50 283.34 <0.0001 
QE50 7.37 0.06 105.53 <0.0001 
 
The concentration of OM2 [AQ-EAE-OH (4-OH)] TFA when the relative fluorescence 





1.3.6.3 OM22 [AQ-EAE-TPP(4-OH)] TFA DNA binding 
 
Figure 1.98: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr (30 
μM) when treated with different concentrations of OM22 TFA in PBS buffer. (n = 3) λex 480 nm; λem 
610 nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  719.28 2.86 251.38 <0.0001 
QE50 19.45 0.24 80.19 <0.0001 
 
The concentration of OM22 [AQ-EAE-TPP(4-OH)] TFA when the relative fluorescence 
intensity reached 50% was 19.45 ± 0.2 μM. Therefore, the binding constant for OM22 
TFA was 1.5×107M-1. 
OM22 TFA (µM)


































1.3.6.4 OM30 [AQ-Butyl-TPP(4-OH] DNA binding 
 
Figure 1.99: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr (30 
μM) when treated with different concentrations of OM30 in PBS buffer. (n = 3). λex 480 nm; λem 610 
nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  658.16 16.35 40.23 <0.0001 
QE50 24.83 1.44 17.23 0.05 
 
The concentration of OM30 [AQ-Butyl-TPP(4-OH] when the relative fluorescence 
intensity reached 50% was 24.83 ± 1.4 μM. Therefore, the binding constant for OM30 
was 1.2×107M-1. 
OM30 (µM)
































1.3.6.5 OM31 [AQ-Pentyl-TPP(4-OH)] DNA binding  
 
Figure 1.100: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr 
(30 μM) when treated with different concentrations of OM31 in PBS buffer. (n = 3). λex 480 nm; λem 
610 nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  620.90 7.93 78.28 0.0002 
QE50 17.55 0.59 29.63 0.0011 
 
The concentration of OM31 [AQ-Pentyl-TPP(4-OH)] when the relative fluorescence 
intensity reached 50% was 17.55 ± 0.5 μM. Therefore, the binding constant for OM31 
was 1.7×107M-1. 
OM31 (µM)































1.3.6.6 OM32 [AQ-EOE-TPP(4-OH)] DNA binding  
 
Figure 1.101: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr 
(30 μM) when treated with different concentrations of OM32 in PBS buffer. (n=3). λex 480 nm; λem 610 
nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  632.78 3.15 200.51 <0.0001 
QE50 24.43 0.34 71.57 <0.0001 
 
The concentration of OM32 [AQ-EOE-TPP(4-OH)] when the relative fluorescence 
intensity reached 50% was 24.43 ± 0.3 μM. Therefore, the binding constant for OM32 
was 1.22×107M-1. 
OM32 (µM)































1.3.6.7 SH1 (AQ-Butyl-TPP) DNA binding 
SH1 (µM)
































Figure 1.102: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr 
(30 μM) when treated with different concentrations of SH1 in PBS buffer. (n = 3). to λex 480 nm; λem 
610 nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  692.45 6.60 104.91 <0.0001 
QE50 48.62 1.23 39.33 <0.0001 
 
The concentration of SH1 (AQ-Butyl-TPP) when the relative fluorescence intensity 





1.3.6.8 OM26 (bis-TPP-NU:UB 65) DNA binding  
 
Figure 1.103: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr 
(30 μM) when treated with different concentrations of OM26 in PBS buffer. (n = 3). λex 480 nm; λem 
610 nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  703.62 2.85 246.18 <0.0001 
QE50 32.51 0.34 93.56 <0.0001 
 
The concentration of OM26 (NU:UB 65-bis-TPP) when the relative fluorescence intensity 
reached 50% was 32.51 ± 0.3 μM. Therefore, the binding constant for OM26 was 
0.92×107M-1.  
OM26 (µM)































1.3.6.9 Ametantrone DNA binding  
 
Figure 1.104: Variation of relative fluorescence intensity of CT-DNA (60 μM) with pre-bound EtdBr 
(30 μM) when treated with different concentrations of ametantrone in PBS buffer. (n = 3). λex 480 nm; 
λem 610 nm. 
 
 Coefficient Std. Error t p 
Min  -0.0000 0.0000 (+inf) <0.0001 
Max  706.50 3.29 214.37 <0.0001 
QE50 4.14 0.06 66.89 <0.0001 
 
The concentration of ametantrone when the relative fluorescence intensity reached 50% 
was 4.14 ± 0.06 μM. Therefore, the binding constant for ametantrone was 7.3×107M-1. 
The novel compounds that have been tested in competitive ethidium displacement assay 
are all structurally related to mitoxantrone and to each other, with all having an 
anthraquinone core and amine groups at the C1 position linked with a spacer. The length 
Ametantrone (µM)































and composition of the spacer, which may have amino groups in addition to a hydroxyl 
group, could affect DNA binding constant (Kapp). Also, the number of hydroxyl groups on 
the anthraquinone core structure specially at the C4 and/or C8 position would affect the 
Kapp value. However, with TPP conjugated compounds, the Kapp value might be lower 
when compared with its unconjugated precursor, due to the presence of the bulky TPP 
group adversely binding due to steric factors. These important factors that affect the Kapp 
will be discussed below.  
 
Name Structure QE50 Kapp 
Mitoxantrone 
 
4.77 ± 0.15 μM 6.2×107M-1 
OM2 TFA  
 
7.37 ± 0.06 μM 4.0×107M-1 
OM22 TFA  
 
19.45 ± 0.2 μM 1.5×107M-1 
OM30 
 






17.55 ± 0.5 μM 1.7×107M-1 
OM32 
 


















4.14 ± 0.06 μM 7.3×107M-1 
 
Table 1.1: Summary of QE50 and Kapp values for tested compounds. #ND (not determined) 
 
According to the data obtained from Table 1.1, mitoxantrone has a high DNA binding 
affinity with Kapp 6.2×107M-1 and low QE50 4.77 ± 0.15 μM. This is due to the fact that 
mitoxantrone has two nitrogen-containing side chains that allow electrostatic binding with 
the negatively charged phosphate backbone of DNA and it also has a planar 
anthraquinone ring system that can intercalate between DNA base pairs (Li et al., 2005). 
Furthermore, ametantrone also binds with DNA with high affinity, Kapp 7.3×107M-1, 
although ametantrone has a similar structure to mitoxantrone but with no hydroxyl group 
at  positions 5 and 8. Bailly et al., (1996) reported that in addition of the important role of 
5,8-(OH) groups in intercalation with DNA, there is an additional role in that these groups 
stabilize the drug-DNA complex, hence mitoxantrone dissociates more slowly from DNA 
when compared with ametantrone because there are no hydroxyl groups at positions 5 
and 8 in ametantrone yet both drugs unwind the DNA double helix with equal efficacy 
(Bailly et al., 1996). 
The compound AQ-EAE-OH (4-OH) (OM2) TFA binds to DNA with 1.5-fold less affinity 
than mitoxantrone possibly because the removal of one hydroxyethylaminoalkyl side 
chain as well as the hydroxyl groups at positions 5 and 8 present in mitoxantrone, results 
in decreased intercalation with DNA. However, by attaching triphenylphosphonium (TPP) 
to OM2 TFA to give AQ-EAE-TPP(4-OH) (OM22) TFA, the binding constant Kapp 
decreased by 2.5-fold (1.5×107M-1) this decrease in Kapp may be due to the bulky nature 




decrease in the contact with the DNA backbone phosphate groups or prevents 
intercalation.  
In addition, as predicted , the anthraquinone spacers NU:UB 238 and NU:UB 65 did not 
bind with DNA because they lack the amino group in the side chain and also the hydroxyl 
groups at positions 5 and 8. However, attaching TPP to these compounds, to afford AQ-
Butyl-TPP (SH1) and bis-TPP-NU:UB 65 (OM26), gave compounds which did bind to 
DNA. From the data shown in Table 1.1 OM26 has a higher binding constant (0.9×107M-
1) than SH1 (0.1×107M-1) because OM26 has two TPP groups attached to its two side 
arms. Therefore, this presumably indicates that increasing the number of TPP groups 
increases DNA affinity.  
Table 1.1 showed that the DNA binding constant Kapp for OM22 TFA is almost 15-fold 
greater than the constant Kapp of SH1, which both have TPP attached to the side chain, 
because OM22 TFA has an amino group in the side chain and hydroxyl group at C4 
position of the anthraquinone which is absent in the SH1. So, removing the amino group 
from the side chain and the hydroxyl group from the anthraquinone structure leads to a 
dramatic decrease in the DNA binding affinity.  
However, the binding constant Kapp for the TPP conjugates AQ-Butyl-TPP(4-OH) (OM30), 
AQ-Pentyl-TPP(4-OH) (OM31) and AQ-EOE-TPP(4-OH) (OM32) is nearly equal to the 
binding constant Kapp for OM22 TFA. Although these compounds lack the amino group 
present in the side chain of the TPP conjugate OM22 TFA, they retain the hydroxyl group 
at position C4, clearly showing the importance of the hydroxyl group at position C4 in the 
DNA binding of this series of TPP conjugates.  
Furthermore, when comparing the results for the TPP conjugates SH1 and OM30, which 
differ only in the presence of the hydroxyl group at position C4 in OM30, the binding 
constant Kapp for OM30 was almost 12-fold higher than the binding constant Kapp for SH1. 
This indicated the importance of a hydroxyl group at position C4 of the anthraquinone that 
makes the compounds bind with DNA with high affinity compared with compounds that 




OM30 and OM31 have similar structures. However, in OM31, the pentane spacer 
structure has one additional CH2 compared with the butane spacer in OM30. Thus, the 
Kapp value for OM31 was slightly higher than the Kapp value for OM30. This may suggest 
the compound with a longer spacer binds DNA with higher affinity.   
Interestingly, OM31 and OM32 have similar structure with the same spacer length, but 
with the addition of oxygen atom in the middle of the spacer of OM32. As shown in Table 
1.1. The DNA binding constant Kapp for these two compounds was similar and both 
compounds have similar QE50. This shows clearly that the oxygen atom which was added 
to the spacer has no effect on DNA binding. 
In conclusion, mitoxantrone and ametantrone have high binding constants which 
indicates that these two compounds have high affinity for the base pairs of DNA. These 
results are in agreement with previous studies reported in the literature on binding of 
mitoxantrone and its intercalation into the DNA duplex and where it was reported that the 
electrostatic attraction between the DNA phosphates and cationic charge on mitoxantrone 
and ametantrone might improve the DNA binding affinity (Varadwaj et al., 2010).  The 
results of the DNA binding studies of the novel compounds clearly showed that attaching 
TPP makes the compounds bind with DNA when compared to their unconjugated 
precursors. Also, it was clear that where compounds share the same anthraquinone base 
structure, the DNA binding constant would increase if there were more hydroxyl groups 
attached to the anthraquinone chromophore, regardless of the composition of the side 
chains. Also, the amino group in the side chain plays an important role in the DNA binding 
strength, probably through electrostatic binding with the negatively charged of DNA 
phosphate backbone that sometimes leads to a higher DNA binding value, than the 
compounds that do not have amino group in its spacer (Mcknight et al., 2004).    
 
 Distribution Coefficient 
Distribution coefficient assays were performed in this research programme to determine 
the physicochemical properties (lipophilicity) of the novel compounds. Lipophilicity is an 




(Rutkowska et al., 2013). Lipophilicity is usually expressed by the logarithm of a 
compound’s octanol/buffer distribution coefficient (log D) at specific pH (unionized and 
ionized compound). Distribution coefficients often indicate the logarithmic ratio of the 
concentration of the compounds in two different solvent (immiscible solvents) at 
equilibrium (Stéen et al., 2017). In addition, lipophilicity has a significant role in drug action 
processes that are related with the solubility and permeability of a drug, therefore 
lipophilicity determination during the early stage of drug discovery and development is 
very important and has a crucial role in the further studies of novel drugs (Rudraraju et 
al., 2014).   
Herein, OM2 [HO-EAE-AQ(4-OH)], OM22 [TPP-EAE-AQ(4-OH)], NU:UB 252 [OH-Butyl-
AQ (4-OH)], OM30 [TPP-Butyl-AQ(4-OH)], SH1 (TPP-Butyl-AQ), NU:UB 238 (OH-butyl-
AQ) and OM16 [Rho-pip-succ-EAE-AQ(4-OH)] were studied to determine the distribution 
coefficient (lipophilicity) by using the shake-flask method, using mitoxantrone as  a 
comparator. In this assay, octanol was used as the organic solvent as it has a chemical 
structure similar to that of the hydrophobic fatty molecules present in the cell membrane 
(Rutkowska et al., 2013). In measuring the distribution coefficient, phosphate buffered 
saline (PBS) at pH 7.4 was used as the aqueous phase, allowing for contributions from 
both ionised and un-ionised species, in contrast to the partition coefficient which uses 
water as the aqueous phase (Leo et al., 1971). The distribution coefficient (Log D) assay 
measures whether the compound is hydrophilic or lipophilic, which is important to know 
as it predicts whether the compound will move across the cells phospholipid bilayer and 
can be taken up by the cell. The more lipophilic the compound, the more readily it will 
cross into the cell (Murphy, 2008). 
To obtain log D results, firstly, UV/VIS absorbance calibration curves for tested 
compounds at different concentrations were created in order to quantify the concentration 
of the compound in the organic and aqueous phases. Absorbance measurements were 
recorded using a range of known concentrations of OM2, OM22, NU:UB 252, OM30, SH1, 
NU:UB 238 and OM16 in both PBS buffer pH 7.4 and in octanol. The absorbance at a 




The shake flask octanol-water partition coefficient method was used by dissolving the 
tested compound in PBS (saturated in octanol) and octanol (saturated in PBS) and 
shaken for 24 hours at room temperature allowing the compounds to dissolve and move 
into the desired layer. After 24 hours, the compounds with TPP were almost completely 
partitioned into the octanol layer, whereas some of the compounds without TPP 
distributed between both layers, visually confirming that TPP increases the lipophilicity of 
the compounds in comparison with compounds without TPP.  
To calculate the log D (octanol/PBS), the compound concentrations were determined 
using the absorbance reading from each layer in the Eppendorf tube. A known aliquot 
from each sample was taken from both octanol and PBS layers and diluted to give a 
known final volume in the cuvettes. The absorbance was measured at the wavelength of 
maximum absorbance used to prepare the calibration curves and the linear calibration 
curve graph equation used to calculate the corresponding concentration of each sample. 
Then the log D value was calculated for each compound and a mean log D value for each 
compound was obtained from a minimum of three separate experiments Table 1.2. 
Negative log D values indicate that the compound is hydrophilic whereas positive values 
indicate that the compound is lipophilic. From the results shown in Table 1.2 and Figure 
1.105, OM22 [TPP-EAE-AQ(4-OH)] and SH1 (TPP-Butyl-AQ), which are TPP conjugates, 
have greater log D values, 1.69 ± 0.06 and 2.68 ± 0.04, respectively, in comparison with 
their unconjugated precursors, OM2 [HO-EAE-AQ(4-OH)] (0.69 ± 0.09) and NU:UB 238 
[OH-butyl-AQ] (1.97 ± 0.12), respectively. This indicated that attaching TPP makes the 
compounds more lipophilic when compared with the compounds without TPP which in 
turn should increase the ability of TPP compounds to cross the phospholipid bilayer and 
be taken into the mitochondrial matrix (Bielski et al., 2015).  
On the other hand, OM16 [Rho-pip-succ-EAE-AQ(4-OH)] had a negative value (-0.16 ± 
0.05) this is due to OM16 having rhodamine B-pip-succ attached on its side chain (EAE) 
instead of TPP which makes the compound hydrophilic in comparison with OM22 which 
has the same side chain attached with TPP and it is lipophilic (1.69 ± 0.06). These results 






































































































































Table 1.2: LOG D values for tested compound in PBS buffer 7.4 and saturated octanol 
 
 
Figure 1.105: Relative lipophilicity/ hydrophobicity of OM2, OM22, NU:UB 252, OM30, SH1, NU:UB 
238, OM16 and mitoxantrone.  
 
Therefore, attaching TPP to mitoxantrone derivatives makes them more lipophilic. As 
predicted, which is an important factor to pass easily through lipid bilayers. It has been 
reported that lipophilic cations such as TPP has a unique property of being lipid soluble 
in addition to its net positive charge that they can easily pass through phospholipid 
bilayers into mitochondria (Ketterer et al., 1971; Murphy, 1997). While the hydrophilic 
cations such as Na+ can only cross the biological membrane when it transported by 
ionophores or carrier proteins. In addition, the impermeability of biological membranes to 
hydrophilic cations is due to the fact that moving the ion from aqueous environment to the 
nonpolar interior lipid of membrane required higher activation energy for movement of this 
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which required low activation energy, allowing it to pass through the biological membrane 
(Ketterer et al., 1971; Ross et al., 2005). Therefore, it was extremely important to measure 
the lipophilic properties of the novel compounds synthesised in this research programme 
as a predictor of the ability of these compounds to pass though the biological membrane 
and accumulate inside the mitochondria.  
 
 MTT Assay 
The MTT [(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)] assay is 
generally used as a method to determine the number of viable cells after exposure to 
several drugs at different concentrations (Meerloo et al., 2011). This assay was first 
developed by Mosmann (1983) and was further modified by Denizot and Lang (1986) to 
increase the sensitivity and reliability of the in vitro tumour cells chemosensitivity 
(Mosmann, 1983; Denizot and Lang, 1986) The principle of the MTT assay is that 
succinate dehydrogenase within the mitochondria converts tetrazolium salt (MTT), which 
is water soluble, into water insoluble dark purple formazan crystals Figure 1.106. 
Formazan accumulates in viable cells thereby measuring mitochondrial activity  (Fotakis 
and Timbrell, 2006), by measuring the concentration of formazan using a microplate 
reader, any increase or decrease in viable cell number can be detected.  
Hence, drug toxicity can be measured by MTT assay as a decrease in the number of cells 
indicates cell growth inhibition, therefore, drug potency is usually determined by the 
concentration of the drug required to produce 50% growth inhibition in comparison with 






Figure 1.106: Conversion of MTT to formazan (the basis of the colourimetric method) 
 
In this research programme, the MTT assay was used to determine the cell viability after 
treatment with novel compounds. The assay was carried out in two different cell lines; 
MCF-7 breast carcinoma cell line and HCT-15 colon carcinoma cell line. The advantage 
of using these cell lines is that they are part of the NCI 60 cell line screen, and have been 
well characterized by the Developmental Therapeutics Program in collaboration with 
various investigators who have measured mutation status, protein levels, RNA 
measurements, and enzyme activity levels in 60 human tumour cell lines 
(https://dtp.cancer.gov/default.htm). They measured Mdr1 levels relative to actin RNA by 
RT-PCR RNA [Experiment Id: 20103 Pattern Id: MT1614] and detected that the level for 
HCT-15 was 17-fold higher in HCT-15 than MCF-7. Therefore, these cell lines can be 
used to screen for compounds that have the potential to circumvent P-gp drug resistance. 
Ideally, matched wild type and MDR cell lines would have been used, but MCF-7 and 
HCT-15 were chosen as an initial screen. Thus, comparison of the IC50 values was made 
to determine whether the compounds could potentially circumvent multidrug resistance 
by evading the P-gp pumps after attachment with TPP.   
In vitro cytotoxicity of OM2 [HO-EAE-AQ(4-OH)], OM22 [TPP-EAE-AQ(4-OH)], NU:UB 
238 (OH-butyl-AQ), SH1 (TPP-Butyl-AQ), NU:UB 65 and OM26 (TPP-bis-NU:UB 65) 




[(TPP-Pentyl-AQ(4-OH)] and OM32 [(TPP-EOE-AQ(4-OH)], were measured after 96 
hours incubation by MTT assay. HCT-15 and MCF-7 cells growth curves against different 




Figure 1.107: Survival rate of MCF-7 breast cancer cells treated with OM2, OM22, NU:UB 65 and 




Figure 1.108: Survival rate of HCT-15 colon carcinoma cell lines treated with OM2, OM22, NU:UB 





Figure 1.109: Survival rate of HCT-15 colon carcinoma cell lines treated with Mitoxantrone, OM30, 
OM31 and OM32 for 96 h (n = 8) in comparison with untreated cells. 
 
According to the results presented in Table 1.3, Figure 1.107, Figure 1.108 and Figure 
1.109, the IC50 values of OM2 (3.39 µM in MCF-7 and 3.07 µM in HCT-15) and SH1 (9.69 
µM in MCF-7 and 9.48 µM in HCT-15) suggest that these compounds retained activity in 
both cell lines which indicates that OM2, despite not having a TPP targeting group 
attached, might not be a P-gp substrate and may have the same mechanism of action in 
both cell lines as they both have similar values in MCF-7 and HCT-15, which have a 
higher level of P-gp pumps in comparison with MCF-7. Therefore, this suggests that OM2 
and SH1 might possibly evade the P-gp pumps. Therefore, 48 hours treatment period 
may be too short for the active drug to be completely released. Additionally, OM22 is a 
lipophilic weak base and once entered into acidic lysosomes it may became protonated 
and trapped by the lysosomes and then prevented from reaching its target (Zhitomirsky 







Compounds MCF-7 HCT-15 
Mitoxantrone #ND 0.082 ± 0.02 
OM2  3.39 ± 0.84 3.07 ± 0.96 
OM22  5.78 ± 2.91 8.15 ± 0.80 
OM30 N.D. 21.43 ± 10.11 
OM31 N.D. 23.22 ± 11.97 
OM32 N.D. 36.42 ± 19.28 
NU:UB 238 >100 >100 
SH1 9.69 ± 3.35 9.48 ± 0.32 
NU:UB 256 >100 >100 
OM26 1.8 ± 0.98 7.45 ± 2.80 
Table 1.3: The mean IC50 values for different compounds (µM) in MCF-7 and HCT-16 cell lines, after 
48 h and 96 h incubation. #ND (not determined) 
 
In addition, mitoxantrone has a very low IC50 value (0.082 µM) against HCT15 in 
comparison with all tested compounds; this is likely due to the high binding affinity of 
mitoxantrone with DNA and that it has OH groups at positions C4, C5 and C8, as well as 
amino groups at the side chains which also play an important role in the DNA binging and 
increase the toxicity of the drug. Furthermore, the IC50 value of OM2 [HO-EAE-AQ(4-OH)] 
(3.07 µM) was the lowest amongst the OM series against HCT15 which may be related 
to sharing a similar structure with mitoxantrone having a protonated amine group, an OH 
group at position C4 but lacking the OH groups at positions C5 and C8.   
The data in Table 1.3 illustrates that the more hydroxy groups in the anthraquinone basic 
structure, the more potent and cytotoxic the drug will be, such as in mitoxantrone and 
OM2. Also, having the protonated amine group in the side chain plays a crucial rule in 
DNA binding which in turn can increase the cytotoxicity. This is because the planar 




chain binds with the negatively charged phosphate group of DNA which in turn causes 
DNA condensation and inhibits the DNA replication. Also mitoxantrone inhibits  
topoisomerase II which plays a role in DNA strand repair, which leads to cell death 
(Hajihassan and Rabbani-Chadegani, 2009). In addition, the OH groups at positions C5 
and C8 of the anthraquinone chromophore play a role in the toxicity of the compounds as 
these groups participate in the DNA intercalation – it is known mitoxantrone dissociates 
more slowly from the DNA than ametantrone that lack these groups (Bailly et al., 1996).  
Furthermore, Hong et al., (2017), synthesized drugs targeted to mitochondria using TPP-
conjugated superoxide dismutase mimetic carboxypropyl (Mito-CP) and TPP-conjugated 
ubiquinone (Mito-Q). They studied the cytotoxicity of these compounds by MTT assay 
and they found that Mito-CP decreased the viability of all cell lines at concentrations 
ranging from 0.01-10 µM within 48 hours and the IC50 values were calculated at 0.84 µM 
for RPMI-7951, 0.30 µM for A375 and 0.28 µM for SK-MEL28 cells. However, the same 
concentrations for CP were used and no significant decrease in cell growth was observed. 
The same results were obtained with Mito-Q, which effectively decreased the growth of 
all cell lines with no decrease in cells growth for CoQ10. Hong et al., (2017) further 
investigated the toxicity of TPP to indicate whether the toxicity of TPP conjugates was 
from TPP itself or from the conjugates. They revealed that TPP alone caused very little 
decrease in cell viability even at higher dose (Hong et al., 2017). 
Han et al., (2014) linked a TPP carrier with doxorubicin to deliver the drug to mitochondria. 
the cytotoxicity of TPP-doxorubicin was studied by MTT assay using MDA-MB-435/WT 
and MDA-MB-435/DOX cell lines with incubation times 24, 48, and 72 hours. They found 
that TPP alone did not show any significant toxicity in both cell lines. The results revealed 
that the free doxorubicin has a better cytotoxicity than TPP-doxorubicin after 24 hours in 
MDA-MB-435/WT cells. However, the cytotoxicity of TPP-doxorubicin increased with the 
time and reached the cytotoxicity of free doxorubicin after 48 hours and exceeded it after 
72 hours. The reason behind increasing the cytotoxicity of TPP-doxorubicin with time is 
the differences in mechanism of action of TPP-doxorubicin and free doxorubicin and/or 
the intracellular escaping of TPP conjugates to reach the target site (Han et al., 2014). 




compounds such as OM22, OM30, OM31 and OM32 as they required more time to reach 
the target site and produce cytotoxicity at the targeted site.  
In conclusion, according to the results obtained from MTT assay in this project and along 
with the results from the literature, it clearly shows that attaching a TPP carrier to 
anticancer drugs, significantly increases the cytotoxicity even after a long period of time. 
Also, the free NU:UB 252 and NU:UB 238 showed no cytotoxicity and they were inactive 
and upon attaching the TPP carrier, these compounds showed significant increase in 
toxicity. Notably, two compounds retained activity in both the sensitive MCF7 cell line and 
resistant HCT15 cell line. TPP-conjugate SH1 was equipotent in each of these cell lines, 
which suggests it may be able to circumvent multidrug resistance. In addition, when 
comparing the obtained results from DNA binding assay and MTT assay, it seems that 
the stronger DNA binding affinity a compound shows, the more cytotoxic potency a 
compound will show, as it appeared that there is a direct correlation between DNA binding 
and cytotoxicity. This illustrates that there is a good connection between drug-DNA 
binding affinity and the drug inhibition of cancer cell growth.  
    
 Cellular uptake and localization 
The main problem with most chemotherapy treatments is limited by lack of tumour cell 
specific selectivity, systemic toxicity and drug resistance. Several methods and strategies 
have been developed to increase the selectivity of anticancer drugs and reduce side 
effects and avoid drug resistance. Now-a-days, a most notable and interesting method to 
increase the efficiency of anticancer drug is by specific delivery of anticancer drug to 
mitochondria. Mitochondria are vital organelles in eukaryotic cells known as a 
powerhouse by playing a central role in energy generating processes (adenosine 
triphosphate, ATP) via oxidative phosphorylation. Mitochondria also have crucial roles in 
other complex processes such as metabolism, apoptosis and intracellular signaling (Via 
et al., 2014). Therefore, as the mitochondria play an essential role in cell death, 
mitochondrial targeting could be a promising strategy for cancer therapy (Biswas et al., 




higher than in that of normal cells. Thus, lipophilic cations that have a delocalized positive 
charge pass through the hydrophobic barrier of plasma and mitochondrial membranes 
and accumulate in the mitochondrial matrix in response to the negative charge inside the 
mitochondria (Modica-Napolitano and Aprille, 2001). Mitochondrial membrane potential  
can uptake the cationic compounds to give concentration 100-1000 higher than in the 
cytoplasm (Murphy, 1997). Therefore, specific targeting of anticancer drug to 
mitochondria using lipophilic cations such as triphenylphosphonium (TPP), could drive 
the uptake of the anticancer drug by mitochondria and increase the accumulation inside 
the mitochondria which in turn reduce side effects, avoid drug resistance and increase 
drug efficiency. 
Diffusion of anticancer drugs across the lysosomal membrane and mitochondrial 
membrane depends on the physicochemical properties (lipophilicity) of these drugs. As 
shown in (section 1.3.6.10), attaching TPP to the novel compounds makes the 
compounds lipophilic as they have positive Log D value. It is well known from the literature 
that the main localization site of mitoxantrone is inside the nucleus (Panousis and Phillips, 
1994), while Smith et al., (1992) indicated the subcellular distribution of mitoxantrone in 
nucleus and cytoplasm (Smith et al., 1992). Additionally, Shaul et al., (2013) showed that 
anthracycline based derivatives are localized in lysosomes (Shaul et al., 2013). 
Therefore, it was hypothesized that attaching the TPP could alter the subcellular 
localization of anticancer drugs such as mitoxantrone and doxorubicin from lysosome or 
nucleus to mitochondria. Furthermore,  it has been reported that  attaching TPP to an 
anticancer drug, increases the accumulation of this drug inside the mitochondria (Smith 
et al., 2003; Theodossiou et al., 2013; Bielski et al., 2015).  Han et al., (2014) altered the 
localization of doxorubicin by attaching TPP to its side chain from lysosome to the 
mitochondria due to the cationic and lipophilic properties of TPP that take the compound 
to the mitochondria (Han et al., 2014). This supports the concept that mitoxantrone 
derivatives that have been synthesized in this project, which have anthracycline-based 
structures, can be targeted to mitochondria by attaching TPP.  
Therefore, confocal imaging was performed in this project to analyse the cellular uptake, 




binding assays. Three cell lines were used; (live) prostate cancer cells (PC-3), (live) colon 
carcinoma cells (HCT-15) and (live) colon carcinoma cells (HCT-116) in the presence of 
MitoTracker green FM (fluorescent mitochondrial) and LysoTracker green DND26 for the 
mitochondria and lysosomes, respectively. However, the focus was on HCT-116 due to 
the growth rate and the shape of the cells under the microscope was better than HCT-15 
and PC-3. 
MitoTracker green was used in this test because it is good and suitable for live cells 
(Invitrogen Ltd.) and to distinguish the green colour from the red colour of tested 
compounds. To stain mitochondria, the cells were incubated with MitoTracker green FM 
probes, which then passively diffuse across the plasma membrane and accumulate in 
active mitochondria (according to Invitrogen Ltd.). LysoTracker green DND26 was used 
to stained lysosomes due to its ability to penetrate the cell membrane and it contains 
fluorophore which is attached to a weak base that helps in staining acidic compartments 
(lysosomes) in live cells. 
Taking the advantage of anthraquinone natural fluorescence, the subcellular localization 
of mitoxantrone derivatives was studied and determined. Herein, cell lines were treated 
with a co-stain solution tested compounds and MitoTracker Green FM (50 nM) and the 
solution was applied to the cell culture medium and incubated as 37oC for 15 minutes 
prior to imaging. Also, cell culture medium was treated with LysoTracker Green DND 26 
(60 nm) and tested compound solution and incubated at 37oC for 30 minutes. Figure 
1.110 shows the cellular uptake of SH1 (TPP-Butyl-AQ) after 90 minutes of live cell 
imaging. The results confirmed that SH1 was detected in mitochondria, but not in the 
lysosome and nucleus. SH1 showed a clear staining in HCT-116 cells (panel A) and a 
clear yellow dot indicating the localization of SH1 in mitochondria (panel C ii). Panel C is 
the merged image for panel A (SH1) and panel B (MitoTracker Green FM or LysoTracker 
green DND26). The yellow dots (panel C ii) confirming the colocalization of SH1 with 
mitochondria. The cellular uptake of SH1 was due to its cationic and lipophilic properties 
(Log D: 2.68 ± 0.04). To indicate that SH1 staining was specific to mitochondria, HCT-
116 cells were stained with an alternative marker for lysosomes (LysoTracker green 




the nucleus. The co-localization of SH1 with MitoTracker Green FM, instead of 
LysoTracker Green DND26, suggested that SH1 displayed a better selectivity for 
mitochondria as compared to lysosomes in HCT-116 live cells, this is consistent with  
mitochondria in cancer cells that have a high membrane potential (ΔΨm) compared with 
plasma membrane and mitochondria in healthy cells, which in turn increases the 
mitochondrial  penetration of cationic drugs (SH1), consequently increasing the 
accumulation of cationic drug inside mitochondria (Constance and Lim, 2012). This result 
aligns with literature reporting that attaching TPP to anticancer drugs make it more 
lipophilic and increase the cationic properties of the anticancer drug, which allow it to 
accumulate in mitochondria.  
 
 
Figure 1.110: Localisation of SH1 in HCT-116 cells. SH1 (2 µM) localised to the mitochondria within 
90 min as measured by live cell imaging. (i) SH1 stained with LysoTracker Green DND26, (A) SH1, 
(B) LysoTracker and (C) merged image. (ii) SH1 stained with MitoTracker Green FM, (A) SH1, (B) 





In addtion, the co-localization study was also performed for OM22 [TPP-EAE-AQ(4-OH)] 
compound, which has a structure related to SH1 with addition of an amino group in its 
side chain and a hydroxyl group at position C4 in the anthaquinone base structure. The 
cellular uptake of OM22 showed that OM22 co-localized with lysosomes observed after 
90 minutes of live cell imagaing as shown in Figure 1.111 (i). OM22 showed a clear 
staining of HCT-116 cells (panel A) and a clear yellow dot indicating the localization of 
OM22 in lysosomes (C i), Panel C is the merged image for panel A (OM22) and panel B 
(MitoTracker Green FM or LysoTracker green DND26). The yellow dots (panel C i) 
confirmed the colocalization of OM22 with lysosome and not with mitochondria. However, 
the lipophilicity of OM22 (Log D: 1.69 ± 0.06) and the cationic properties should allow the 
compound to penetrate the mitochondrial membrane and accumulate inside the 
mitochondria, but OM22 is a lipophilic amine drug. The localization of lipophilic amine 
drugs in the lysosome known as lysosomal sequestration or lysosomal trapping in which 
the weak base (OM22) will sequester or trap inside the acidic lysosomes (Ndolo et al., 
2012). It is well known from the literature that lipophilic weak amine base drugs diffuse 
through cell membranes at physiological pH via passive diffusion, once it is inside the 
lysosomes, they become protonated, therefore sequestered in lysosomes in their cationic 
state (Zhitomirsky and Assaraf, 2015). This is likely the reason behind the localization of 
OM22 in the lysosome. However, to demonstrate that OM22 staining was specific for 
lysosomes, HCT-116 cells were stained with an alternative marker for mitochondria 
(MitoTracker Green FM). Figure 1.111 (ii), shows a lack of co-localization of OM22 with 
mitochondria and nucleus after 90 minutes of live cell imaging. Therefore, the localization 
of OM22 with LysoTracher Green DND26, not with MitoTracker Green FM, suggested 
that OM22 was trapped in acidic lysosomes which prevented it from reaching to its 
targeting site of mitochondria. This result is consistent with literature reporting that the 







Figure 1.111: Localisation of OM22 in the HCT-116 cells. OM22 (2 µM) localised to the lysosome 
within 90 min as measured by live cell imaging. (i) OM22 stained with LysoTracker Green DND26, 
(A) OM22, (B) LysoTracker and (C) merged image. (ii) OM22 stained with MitoTracker Green FM, 
(A) OM22, (B) MitoTracker and (C) merged image. Images were captured as 63 x magnification. 
 
To further investigate the effect of anticancer drug structure on the localization inside the 
cells, OM30 [(TPP-Butyl-AQ(4-OH)], OM31 [(TPP-Pentyl-AQ(4-OH)]  and OM32 [(TPP-
EOE-AQ(4-OH)] were synthesised. These compounds are structurally related  to SH1 
and OM22; OM30 has an extra hydroxyl group at the C4 position in the anthraquinone 
base structure and no amino group in the side chain, OM31 has a longer side chain 
compared with SH1, OM22 and OM30 and no amino group in the side chain and OM32 
has a similar structure to OM22 and OM30 with the addition of oxygen atom at the side 
chain. These compounds showed a promising results in the DNA binding assay and MTT 
assay. The cellular uptake of these compounds was studied using the HCT-116 cells and 
the localisation was observed after 90 minutes by live cell imaging.  Figure 1.112 shows 
a clear staining of these compounds to HCT-116 (panel A) and a clear yellow dot 




merged image for panel A and panel B (MitoTracker Green FM), confirming the 
colocalization of these compounds in the mitochondria. To further investigate the 
localization of these compounds with lysosomes, HCT-116 cells were stained with an 
alternative marker for lysosomes (LysoTracker green DND26), we found that these 
compounds lacked the localization with lysosomes and nucleus after 90 minutes of live 
cell imaging (image not shown). This indicated that changing the structure of the targeted 
compounds for example, by replacing the amino group in the side chain of OM22 with an 
oxygen atom in OM32, altered the basic properties of OM22 and changed localization of 
this compound from lysosome to mitochondria by successfully escaping the acidic 
lysosome and co-localized in the mitochondria.  
Furthermore, the effect of the structure on the localisation of anticancer drugs was further 
studied for mitoxantrone and ametantrone, which are clinically approved anticancer drugs 
and they are structurally related to each other. Figure 1.113 shows the cellular uptake of 
mitoxantrone which is clearly co-localized with lysosomes Figure 1.113 C, this is due to 
the two amino groups present at the side chains of mitoxantrone. These amino groups 
make the compunds weak bases, and suggesting that mitoxantone was trapped in the 
acidic lysosomes (same as OM22) (Ndolo et al., 2012). However, for ametantrone which 
has no hydroxyl groups at position C5 and C8 of the anthraquinone base structure 
compared with mitoxantrone, as shown in the confocal imaging, Figure 1.114, showed 
that ametantrone was co-localized in the nucleus of the cells not in the lysosomes or 
mitochondria. These results, indicated that even small alterations in the structrure of the 
molecule could effect its localization inside the cells. Also it was necessary to evaluate 
several features including lipophilicity, to better understand which aspect of the molecule 






Figure 1.112: Localization of OM30 (2 µM), OM31 (2 µM) and OM32 (2 µM) with mitochondria in 
HCT-116 cells within 90 min as measured by live cell imaging. (A) OM30, OM31 and OM32, (B) 





Figure 1.113: Structure and localization of mitoxantrone (1 µM) with lysosome in HCT-116 cells 
within 90 min of live cell imaging. (A) mitoxantrone, (B) LysoTracker and (C) merged images. 
Images were captured as 63 x magnification.  
 
 
Figure 1.114: Structure and localization of ametantrone with nucleus in stained HCT-116 cell line 
with MitoTracker Green FM within 90 min of live cell imaging. (A) ametantrone, (B) MitoTracker 




All in all, from the above images obtained from live cell imaging it clearly indicates the 
role of triphenylphosphonium (TPP) in the co-localisation of anticancer drugs in the 
mitochondria as it will increase the lipophilic and cationic properties of these drugs, which 
in turn increases the accumulation of the anticancer drug inside the mitochondria, which 
could avoid drug resistance, reduce side effects and increase drug activity. However, in 
addition to the role of TPP in the localizaion of anticancer drugs inside the mitochondria, 
it was clearly observed that changing the structure, even in the presence of the lipophilic 
and cationic vector (TPP), may alter the localization of compounds from the mitochondria 
to the lysosomes as seen in TPP conjugate drug OM22. Therefore, these results 
demonstrated that even small structural changes and differences  between members of 
the this anthraquinone family, studied by confocal live cell imaging, have a significant 
effect on their subcellular distribution and co-localization inside the cells.  
 
 Morphological evaluation 
Cell death is an essential part and occur frequently in complex organism (multicellular 
organism) to maintain tissue homeostasis and killing of infected cells by immune system 
(Ziegler and Groscurth, 2004). Different expressions have been formulated to describe 
cell death such as necrosis and apoptosis. Necrosis describes the sudden or premature 
form of cell death and characterized by comparatively slow disintegration (by autolysis) 
of the cell and often applies to describe cell death in vivo. On the other hand, apoptosis 
describes the morphology and the mechanism of cell active processes in which specific 
signaling pathways are active to kill the cell and regulating its disposal (Majno and Joris, 
1995). In addition, cells dying by apoptosis usually show similar manner of morphological 
changes regardless of which agent is used to induce apoptosis (programmed cell death). 
However, in vitro, a cell line can show a full apoptosis when treated with one initiator and 
can show only a few morphological changes when treated with another initiator 
suggesting that cell death is initiated by different cell death mechanisms or by a part of 
the apoptotic pathway only (Hacker, 2000).  




and in vitro but Kerr et al., (1972) were the first who coined the term of apoptosis by 
describing a specific morphological part of cell death and this description remains a 
morphological descripion (Doonan and Cotter, 2008) and found wide acceptance 
(Hacker, 2000). The beginning of the apoptosis is characterised by shrinkage of the cells, 
contraction of the nucleus and condensation of nuclear chromatin. As cells shrink they 
detach and lose contact with surrouding cells (Saraste and Pulkki, 2000) or extracellular 
matrix, then the cells become more rounded in morphology (Doonan and Cotter, 2008). 
This is followed by formation of irreversible blebs at the cell surface (plasma membrane); 
this process called plasma membrane blebbing (Elmore, 2007) is due to the separation 
of the cell from the cytoskeleton (Doonan and Cotter, 2008). After blebbing, the cell 
dissociates into apoptotic bodies which consist of cytoplasm with tightly packed cell 
organelles or any other part of cellular materials. Finally, apoptotic bodies are taken up 
by macrophages or other cells and degraded by lysosomal pathways (Hacker, 2000) 
Figure 1.115.  
 
 




Therfore, in this experiment, a more in-depth evaluation using a  bright field microscope 
has been carried out to determine the effect of SH1 (TPP-Butyl-AQ) and OM22 [TPP-
EAE-AQ(4-OH)] on the morphological characteristics of HCT-116 colon cancer cells as 
an indication that these conjugates were inducing apoptosis. Apoptotic cells were 
characterised by suggesting that the cells get smaller in size, round shape, shrinkage and 
floating in the medium solution (Hacker, 2000), as HCT-116 cells when metabolically 
active should adhere to the flask surface.  
Different concentrations of OM22 and SH1 at different time points with HCT-116 cells 
were tested (1 µM, 5 µM, 10 µM; 2, 4, 6, 24 hours) and compared with untreated control 
cells, DMSO treated cells (vehicle control) and mitoxantrone (1 µM; positive control). 
Figure 1.116-1.119 shows the effect of SH1 on HCT-116 after treating with different 
concentrations and period of time. At 10 µM, SH1 exhibited prominent growth inhibition 
of HCT-116 and cells were shrunken and floating indicating that the cells were dead at all 
tested time points compared to untreated cells and other concentrations. However, SH1 
has a lower and slower effect on the cell morphology at concentrations of 1 µM and 5 µM 
compared with 10 µM. After 2 hours, SH1 at 1 µM and 5 µM had no effect on the HCT-
116 cells Figure 1.116-1.117, whereas the effect at 1 µM and 5 µM was noticed after 4 
hours and 6 hours, when there was some cell shrinkage and changes in the cell 
morphology Figure 1.116-1.119. After 24 hours, most of the cells were shrunken and 
floating indicating the cell death at all concentrations but with less effect compared with 
the 10 µM concentration Figure 1.119. This is in line with results from the MTT assay 
which showed that SH1 is a cytotoxic compound and induced toxicity at IC50 values of 
9.69 µM in MCF-7 cell line and 9.48 µM in HCT-15 cell line. Although there was no 
significant change in the cell morphology noticed at all time points of culture in the 
untreated HCT-116 cells and in the presence of DMSO. There were significant changes 
observed after 24 hours of culture in the presence of SH1 at all concentrations with 
different apoptotic ratio for each concentration, lower apoptosis at 1 µM and higher 
apoptosis at 10 µM. In addition, there were no significant changes in cell morphology in 
the presence of mitoxantrone at all concentrations, this was most likely due to the 24 
hours incubation time not being long enough for mitoxantrone to induce toxicity as it was 




was also confirmed by Bellosillo et al., (1998)  when they studied the effect of 
mitoxantrone on B-CLL cells, they found that mitoxantrone induced decrease in cells 
viability after 48 hours when treating the B-CLL cells with mitoxantrone (0.5 µg/ml) 
(Bellosillo et al., 1998). 
 
Figure 1.116: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 
morphology after 2 h post-treatment with SH1 at 10 µM with no changes at other concentrations 
and control cells. 
 
Figure 1.117: Cytotoxic effects of SH1 on HCT-116 cells.  Bright field microscopy changes in cell 
morphology after 4 h post-treatment with SH1 at 5 µM and 10 µM with no changes at other 





Figure 1.118: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 
morphology after 6 h post-treatment with SH1 at 1 µM, 5 µM and 10 µM with no changes in control 
cells. 
 
Figure 1.119: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 
morphology after 24 h post-treatment with SH1 at 1 µM, 5 µM and 10 µM with no changes in 
control cells. 
 
Figure 1.120-1.123 show the morphological changes of HCT-116 induced by OM22 at 




shrinkage at a concentration of 5 µM after 4, 6 and 24 hours of incubation compared with 
SH1 in which there was less growth inhibition and apoptosis at this concentration and 
period of time Figure 1.121-1.23. This was due to OM22 having a lower IC50 (5.78 µM in 
MCF-7 cell line and 8.15 µM in HCT-15) than SH1, suggesting that OM22 is more toxic 
and changes the cell morphology at lower concentrations than SH1. However, at high 
concentration 10 µM, OM22 induced apoptosis and growth inhibition for duration 2 - 24 
hours Figure 1.120-1.123. At 1 µM, there were no significant morphological changes at 
2, 4 and 6 hours with less morphological changes at 24 hours compared with cells treated 
with 5 µM and 10 µM. In addition, there were no morphological changes noticed after 24 
hours of culture in the untreated cells or in the presence of DMSO or in the presence of 
mitoxantrone, but there were significant changes observed after 24 hours of cell culture 
treated with OM22 at all concentrations. 
 
 
Figure 1.120: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 






Figure 1.121: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 
morphology after 4 h post-treatment with OM22 at 5 µM and 10 µM with no changes at other 
concentrations and control cells. 
 
Figure 1.122: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 






Figure 1.123: Cytotoxic effects of SH1 on HCT-116 cells. Bright field microscopy changes in cell 
morphology after 24 h post-treatment with OM22 at 1 µM, 5 µM and 10 µM with no changes in control 
cells. 
 
In conclusion, cell morphological changes characteristic of apoptosis such as round 
shape of the cell, cell shrinkage, nucleus condensation, plasma membrane blebbing and 
formation of apoptotic bodies (Hacker, 2000) were confirmed under bright field 
microscopy. According to Doonan and Cotter (2008), using bright field microscopy to 
determine the morphological features remains the best and easiest way and these special 
morphological changes form the basis of a widely used technique for the definition of cell 
apoptosis (Doonan and Cotter, 2008). Thus, the morphological changes induced by SH1 
and OM22 indicated that these novel compounds induced cell apoptosis. The percentage 
of apoptotic cells treated with SH1 and OM22 increased with time at all tested 
concentrations in contrast with untreated cells, DMSO treated cells and cells treated with 
mitoxantrone which there were no morphological changes observed in cell culture at all 






 Conclusion  
Many anticancer drugs experience limitations from high side effects on normal cells, poor 
selectivity to target cells and resistance of cancer cells which leads to a decrease in the 
accumulations of the anticancer drugs inside the targeted cells. Therefore, a series of 
novel prodrugs and experimental mitoxantrone-related anthraquinone derivatives were 
synthesized and ester-linked with TPP or rhodamine B. The prodrugs were designed in 
order to evade P-glycoprotein (P-gp) efflux pumps and thus potentially circumvent 
multidrug resistance. The TPP and rhodamine B conjugate compounds were successfully 
synthesized in this research programme and the structures of these novel compounds 
were confirmed by high resolution electrospray (+) mass spectrometry, 1H NMR and 13C 
NMR spectroscopy. However, the synthesis of mitoxantrone conjugates was 
unsuccessful and compounds of unconfirmed structure were obtained from the reactions 
of TPP or rhodamine B with mitoxantrone. During in vitro assays, the distribution 
coefficient assay revealed that attaching TPP to the target compounds increased the 
lipophilic properties of these compounds which meant that they will be easily taken up by 
the cells. In addition to the lipophilic characteristic, the cationic charge also plays a 
significant role in the localisation of TPP conjugates inside the mitochondria as shown by 
confocal microscopy. The results from the cellular uptake also indicated that even small 
structural changes could alter the localisation of the targeting compound as in OM22 
[TPP-EAE-AQ(4-OH)] which has a secondary amine in its side chain and make it weakly 
basic and localised in the lysosome. From DNA binding studies, the results showed that 
the novel TPP conjugated compounds bind with DNA with high affinity compared with 
unconjugated compounds. The DNA binding for TPP conjugates were also compared 
with mitoxantrone, which is known to bind with DNA with high affinity, in order to determine 
the factors that could affect the drug-DNA binding affinity. In general, the more hydroxy 
groups in the anthraquinone chromophore, the greater the DNA binding affinity a 
compound possesses. Also, the presence of the amino groups in the side chains has a 
crucial effect on the DNA binding affinity. These results are in line with the results obtained 
from the MTT assay and the morphology study, which showed that attaching TPP makes 
the compound more cytotoxic in comparison with unconjugated compounds in tested cells 




cytotoxic potency they will possess. Additionally, The TPP conjugated compounds 
showed effective morphological changes such as cell shrinkage, floating and change in 
cell size indicating that these compounds effectively induced apoptosis in HCT-116 colon 
cancer cells. Therefore, this shows the great potential of the novel compounds that have 
been synthesised in this research project as promising mitochondrial targeting agents in 













































1.4 Experimental  
 
 Analytical methods 
 
1.4.1.1 Instruments  
UV-visible absorbance spectra were obtained on a Beckman Coulter DU800 
spectrophotometer and fluorescence experiments were obtained on a Perkin Elmer LS55 
spectrophotometer. 
1.4.1.2 Thin layer chromatography (TLC) 
Thin layer chromatography was carried out on Kieselgel 60 F254 pre-coated aluminium 
plates (Merck). Most compounds synthesised absorbed in the visible region, additional 
visualisation where required was by UV light (254 and 365 nm). Solvent systems used for 
TLC were A) chloroform: methanol 4:1; B) chloroform: methanol 9:1; and C) butanol: 
glacial acetic acid: water 4:5:1. 
1.4.1.3 Column chromatography  
Kieselgel 60 (0.063-0.0200 mm, Merck) silica gel was used in column chromatography. 
1.4.1.4 Mass spectrometry  
High and low resolution (nano) electrospray mass spectra were recorded on a 
Thermofisher LTQ Orbitrap XL and Waters ZQ4000 instruments (EPSRC National Mass 
Spectrometry Facility, Swansea). 
1.4.1.5 High performance liquid chromatography (HPLC) 
Reverse-phase HPLC was performed on Phenomenex Synergi POLAR column [4 µM (30 
mm x 4.6 mm), flow rate 2 mL/min] using mobile phase 100% ACN + 0.1% TFA (A) and 




1.4.1.6 Proton and carbon nuclear magnetic resonance (1H and 13C NMR) 
1H and 13C NMR spectra were recorded on either a Bruker AC300 NMR spectrometer at 
25oC at 300.1 MHz and 75.5 MHz, the samples were dissolved either in deuterated DMSO 
or deuterated chloroform and transferred to standard NMR testing tubes with a solution 
height range between 5 and 5.5cm. 
 General method A: For dichloromethane or chloroform 
/ water solvent extraction 
The reaction mixture was partitioned between chloroform and water (1:1, 200 mL, total 
volume), the chloroform layer was washed with water (3x100 mL), dried (anhydrous 
sodium sulfate), filtered and evaporated to dryness. 
 
 Synthesis of the mitoxantrone derivative-TPP 
conjugates 
 
1.4.3.1 Synthesis of 1-hydroxy-4-((2-((2-
hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione (HO-EAE-
AQ(4-OH) (OM1) 
Leucoquinizarin (1 g, 4.13 mmol) was dissolved in CH2Cl2 (50 mL) and N-(2-
hydroxyethyl)ethylenediamine (1.3 mL, 12.5 mmol) was added and heated at 400OC for 
1 h. The product was then oxidized by aeration with the addition of triethylamine (Et3N, 
0.5 mL). The product OM1 (Rf 0.43) was then isolated by CH2Cl2/water solvent extraction 
[general method A] and the organic extracts were left overnight to dry. The crude product 
was then used for further reaction without further purification. 
TLC of the crude mixture (chloroform: methanol, 4:1): Rf 0.43 (purple) OM1, 0.88 (orange) 




1.4.3.2 Synthesis of tert-butyl (2-((4-hydroxy-9,10-dioxo-9,10-
dihydroanthracen-1-yl)amino)ethyl)(2-hydroxyethyl)carbamate (HO-
EAE-Boc-AQ (4-OH) (OM2) 
Crude OM1 (2 g, 6.15 mmol) was suspended in methanol (50 mL) and cooled over ice 
(0oC). Di-tert-butyl dicarbonate (Boc2O) (2.6 g, 12 mmol) was dissolved in methanol and 
was added to OM1 dropwise with stirring and allowed to react over ice for 60 min. The 
product OM2 was extracted into chloroform using chloroform/water solvent extraction 
[general method A]. The product was filtered and applied to a silica gel chromatography 
column initially using neat chloroform and then the polarity of the solvent was increased 
by using chloroform: ethyl acetate + 6% methanol. Fractions containing OM2 were filtered 
and evaporated to dryness in vacuo.  
TLC of OM2 (chloroform: methanol, 4:1) Rf 0.7 (purple) (OM2). 
ESMS (+) m/z: 427.1864 (100%) [M+H]+, 449.1681 (37%) [M+Na]+, 875.3477 (51%) 
[2M+Na]+.   
 




4-Carboxybutyl)triphenylphosphonium bromide (TPP) (0.24 g, 0.54 mmol), DCC (0.24 g, 
1.18 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 (10 mL) and allowed to react 
for 15 min then added to OM2 (0.21 g, 0.49 mmol) in CH2Cl2 (5 mL) and left over ice with 
stirring for 1 h. After 1 h, additional half amounts of TPP and DCC were added and allowed 
to react for another 1 h. The product was washed with water and filtered. OM22-Boc was 
applied to a silica gel chromatography column using neat CH2Cl2 initially and then more 
polar solvents CH2Cl2: ethyl acetate and then CH2Cl2: ethyl acetate + 2% methanol were 
used. OM22-Boc was filtered and evaporated to dryness in vacuo. Ethyl acetate was 
added then cooled for 30 min. The product was isolated by filtration and evaporation to 




TLC of OM22 BOC (dichloromethane: methanol, 9:1) Rf 0.4 (purple) (OM22 BOC). 
HRMS (ESI) (+) m/z: 771.3177 (100%) [M]+. Calculated for [C46H48N2O7P]+ 771.3177; 
Found 771.3177. 
 
1.4.3.4 Synthesis of (5-(2-((2-((4-hydroxy-9,10-dioxo-9,10-dihydroanthracen-
1-yl)amino)ethyl)ammonio)ethoxy)-5-
oxopentyl)triphenylphosphonium TPP-EAE-AQ(4-OH) (OM22) 
Trifluoroacetic acid (TFA) (1 mL) was added for 30 min. The solvent was evaporated and 
addition of diethyl ether (20 mL) gave a precipitate of OM22, which was filtered off and 
dried. Yield 47%, 0.24 g.   
TLC of OM22 (dichloromethane: methanol, 9:1) Rf 0.32 (purple) (OM22). 
HRMS (ESI) (+) m/z: 671.2658 (100%) [M-TFA]+. Calculated for [C41H40N2O5P]+ 
671.2669; Found 671.2658. 
1H NMR (DMSO-d6, 300 MHZ):  (ppm) 1.51-1.81 (m, 4H, CH2CH2CH2CH2P), 2.45 (t, 2H, 
CH2-C=O, J 12 Hz), 3.19-3.32 (m, 4H, CH2-NH- CH2), 3.64 (t, 2H, CH2-P, J 21 Hz) 3.82 
(m, 2H, AQ-NH-CH2), 4.27 (t, 2H, CH2O, J 12 Hz), 7.39 (d, 1H, AQ-H2, J 15 Hz), 7.61 (d, 
1H, AQ-H3, J 15 Hz), 7.73-7.99 (m, 17H, HAR of AQ and TPP), 8.23-8.28 (m, 2H, AQ-H5 
and H8), 9.03 (s, 2H, NH2,), 10.20 (t, 1H, AQ-NH, J 12 Hz), 13.54 (s, 1H, AQ-OH). 
13C NMR (DMSO-d6, 75.5 MHZ):  (ppm) 21.10 (-ve, CH2), 21.16 (-ve, CH2), 25.03 (-ve, 
CH2-P), 32.19 (-ve, CH2), 38.40 (-ve, CH2-NH), 45.73 (-ve, CH2-NH2), 46.06 (-ve, NH2-
CH2), 59.41 (-ve, CH2-O), 108.46 (ab, q, CAR-AQ), 113.13 (ab, q, CAR-AQ), 117.87 and 
119.00 (d, ab, CAR-TPP), 125.21 (+ve, CAR-AQ), 126.09 (+ve, CAR-AQ), 126.35 (+ve, CAR-AQ), 
128.63 (+ve, CAR-AQ), 130.14 and 130.31 (+ve, CAR-TPP meta), 131.90 (ab, q, CAR-AQ), 
133.28 (+ve, CAR-AQ), 133.47 and 133.61 (+ve, CAR-TPP ortho), 134.52 (+ve, CAR-AQ), 
134.88 (+ve, CAR-AQ and CAR-TPP para), 146.61 (ab, q, CAR-AQ), 156.12 (ab, q, CAR), 172.30 




1.4.3.5 Synthesis of 1-hydroxy-4-((4-hydroxybutyl)amino)anthracene-9,10-
dione (OH-Butyl-AQ (4-OH) (NU:UB 252) 
Leucoquinizarin (1 g, 4.13 mmol) was dissolved in CH2Cl2 (50 mL) and 4-amino-1-butanol 
(1.901 mL, 20.65 mmol) was added and heated at 40oC for 1 h. The product was then 
oxidized by aeration with the addition of triethylamine (Et3N, 0.5 mL). The product was 
then isolated by CH2Cl2/water solvent extraction [general method A] and the organic 
extracts were evaporated. The product was purified by using silica gel chromatography 
column initially using neat chloroform then chloroform: ethyl acetate was used. The 
solvent was evaporated and addition of diethyl ether (20 mL) gave a precipitate of NU:UB 
252, which was filtered off and dried. Yield 22%, 0.28 g 
TLC of the crude mixture (chloroform: methanol, 9:1): Rf 0.51 (purple) NU:UB 252, 0.42 
(blue) 1,4-bis substituted compound, 0.8 (orange)  oxidized form of leucoquinizarin.  
1H NMR  (DMSO-d6, 300MHz): (ppm) 1.50-1.73 (m, 4H, NHCH2CH2CH2CH2OH), 3.35 
(m, 2H, AQ-NH-CH2), 3.48 (t, 2H, CH2OH, J 6 Hz), 4.51 (s, 1H, OH), 7.21 (d,1H, AQ-H2, 
J 9 Hz), 7.35 (d, 1H, AQ-H3, J 9 Hz), 7.74-7.90 (m, 2H, AQ-H6 and H7), 8.13 (m, 2H, AQ-
H5 and H8),  10.16 (s,1H, AQ-NH), 13.57 (s, 1H, AQ-OH).  
13C NMR (DMSO-d6, 75.5 MHZ):  (ppm) 25.67 (-ve, CH2), 29.86 (-ve, CH2), 41.92 (-ve, 
CH2-NH), 60.32 (-ve, CH2-O), 106.99 (ab, q, CAR-AQ), 112.66 (ab, q, CAR-AQ), 125.22 (+ve, 
CAR-AQ), 125.78 (+ve, CAR-AQ), 126.15 (+ve, CAR-AQ), 128.60 (+ve, CAR-AQ), 131.74 (ab, q, 
CAR-AQ), 132.67 (+ve, CAR-AQ), 134.44 (+ve, CAR-AQ), 134.61 (ab, q, CAR-AQ), 147.18 (ab, q, 
CAR-AQ), 156.04 (ab, q, CAR-AQ), 180.45 (ab, q, C=O), 186.47 (ab, q, C=O).  
 
1.4.3.6 Synthesis of (5-(4-((4-hydroxy-9,10-dioxo-9,10-dihydroanthracen-1-
yl)amino)butoxy)-5-oxopentyl)triphenylphosphonium (TPP-Butyl-
AQ(4-OH) (OM30) 
(4-Carboxybutyl)triphenylphosphonium bromide (TPP) (0.42 g, 0.94 mmol), DCC (0.46 g, 
2.23 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 (10 mL) and allowed to react 




left over ice with stirring for 1 h. After 1 h, additional half amounts of TPP and DCC were 
added and allowed to react for another 1 h. The product OM30 was extracted using 
chloroform/water solvent extraction [general method A]. The product was filtered and 
applied to a silica gel chromatography column using neat chloroform initially and then 9:1 
chloroform: ethyl acetate and chloroform: ethyl acetate + 3% methanol were used. The 
solvent was evaporated and addition of diethyl ether (20 mL) gave a precipitate of OM30, 
which was filtered off and dried. Yield 42%, 0.26 g. 
TLC of OM30 (chloroform: methanol, 9:1) Rf 0.4 (purple) (OM30).  
HRMS (ESI) (+) m/z: 656.2546 (100%) [M-Br]+. Calculated for [C41H39NO5P]+ 656.2560; 
Found 656.2546. 
1H NMR (DMSO-d6, 300MHz):  (ppm) 1.50 – 1.80 (m, 8H, NHCH2CH2CH2CH2O and 
OCOCH2CH2CH2CH2P), 2.41 (t, 2H, CH2-C=O, J 6 Hz), 3.42 (m, 2H, AQ-NH-CH2), 3.62 
(t, 2H, CH2P, J 12 Hz), 4.05 (m, 2H, CH2O), 7.33 (d,1H, AQ-H2, J 9 Hz), 7.48 (d,1H, AQ-
H3, J 9 Hz), 7.71 – 7.95 (m, 17H, HAR of AQ and TPP), 8.17 – 8.25 (m, 2H, AQ-H5 and 
H8); 10.25 (s,1H, AQ-NH), 13.63 (s, 1H, AQ-OH).  
13C NMR (DMSO-d6, 75.5 MHZ):  (ppm) 20.25 (-ve, CH2), 21.11 (-ve, CH2), 21.17 (-ve, 
CH2), 25.03 and 25.26 (-ve, CH2-P), 25.54-25.67 (-ve, CH2CH2-P), 32.41 (-ve, CH2), 41.60 
(-ve, CH2-NH), 63.45 (-ve, CH2-O), 107.20 (ab, q, CAR_AQ), 112.79 (ab, q, CAR0-AQ), 117.87 
and 119.01 (d, ab, CAR-TPP), 125.46 (+ve, CAR-AQ), 125.96 (+ve, CAR-AQ), 126.25 (+ve, CAR-
AQ), 128.83 (+ve, CAR-AQ), 130.13 and 130.29 (+ve, CAR-TPP meta), 131.85 (ab, q, CAR-AQ), 
132.94 (+ve, CAR-AQ), 133.46 and 133.59 (+ve, CAR-TPP ortho), 134.67 (+ve, CAR-AQ), 
134.86 (ab, q, CAR-AQ)  134.89 (+ve, CAR-TPP para), 147.27 (ab, q, CAR-AQ), 156.12 (ab, q, 
CAR-AQ), 172.49 (ab, q, C=O), 180.74 (ab, q, C=O), 186.66 (ab, q, C=O).  
 
1.4.3.7 Synthesis of 1-hydroxy-4-((5-hydroxypentyl)amino)anthracene-9,10-
dione (HO-pentyl-AQ(4-OH) (OM28) 
Leucoquinizarin (1 g, 4.13 mmol) was dissolved in CH2Cl2 (50 mL) and 5-amino-1-




oxidized by aeration with the addition of triethylamine (Et3N, 0.5 mL). The product was 
isolated by CH2Cl2/water solvent extraction [general method A] and the organic extracts 
were evaporated. The product was purified by using silica gel chromatography column 
using neat chloroform initially then, chloroform + 2% ethyl acetate was used. The solvents 
were evaporated in vacuo to dryness and addition of diethyl ether (20 mL) gave a 
precipitate of the AQ-aminopentanol compound (OM28), which was filtered off and dried. 
Yield 21%, 0.28 g. 
TLC of the crude mixture (chloroform: methanol, 9:1): Rf 0.51 (purple) OM28, 0.5 (blue) 
bis-subsituted compound, 0.83 (orange)  oxidized form of leucoquinizarin. 






4-Carboxybutyl)triphenylphosphonium bromide (TPP) (0.4 g, 0.9 mmol), DCC (0.45 g, 
2.18 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 (10 mL) and allowed to react 
for 15 min then added to OM28 (0.2 g, 0.61 mmol, 1 eq) in CH2Cl2 (5 mL) and left over 
ice with stirring for 1 h. The product OM31 was extracted using chloroform/water solvent 
extraction [general method A]. The product was filtered and applied to a silica gel 
chromatography column using neat chloroform initially and then the polarity of the 
solvents was increased as follows; chloroform + 3% ethyl acetate, 9:1 chloroform: ethyl 
acetate, 4:1 chloroform: ethyl acetate, 4:1 chloroform: ethyl acetate + 5% methanol and 
9:1 chloroform: methanol. The solvents were evaporated in vacuo to dryness and addition 
of diethyl ether (20 mL) gave a precipitate of OM30, which was filtered off and dried. Yield 
39%, 0.16 g.  





HRMS (ESI) (+) m/z: 670.2698 (100%) cation (+). Calculated for [C42H41NO5P]+ 670.2717; 
Found 670.2698. 
1H NMR (DMSO, 300MHz):  (ppm) 1.35-1.49 (m, 2H, NH-CH2CH2CH2CH2CH2-O), 1.5-
1.81 (m, 8H, NH-CH2CH2CH2CH2CH2-O and CH2CH2CH2-P) 2.39 (t, 2H, CH2-C=O, J 9 
Hz), 3.42 (q, 2H, AQ-NH-CH2), 3.61 (t, 2H, CH2-P, J 15 Hz), 4.01 (t, 2H, CH2-O, J 6 Hz), 
7.36 (d,1H, AQ-H2, J 9 Hz), 7.51 (d,1H, AQ-H3, J 9 Hz), 7.71-7.95 (m, 17H, HAR of AQ 
and TPP), 8.24 (m, 2H, AQ-H5 and H8), 10.3 (s,1H, AQ-NH), 13.67 (s, 1H, AQ-OH).  
13C NMR (DMSO-d6, 75.5 MHZ):  (ppm) 20.22 (-ve, CH2), 21.08 (-ve, CH2), 22.80 (-ve, 
CH2), 25.00 (-ve, CH2-P), 27.72 (-ve, CH2), 32.40 (-ve, CH2), 38.67 (-ve, CH2), 41.85 (-
ve, CH2-NH), 63.57 (-ve, CH2-O), 107.19 (ab, q, CAR-AQ), 113.78 (ab, q, CAR-AQ), 117.86 
and 119.0 (d, ab, CAR-TPP), 125.58 (+ve, CAR-AQ), 126.01 (+ve, CAR-AQ), 126.27 (+ve, CAR-
AQ), 128.95 (+ve, CAR-AQ), 130.13 and 130.29 (+ve, CAR-TPP meta), 131.97 (ab, q, CAR-AQ), 
132.94 (+ve, CAR-AQ), 133.45 and 133.59 (+ve, CAR-TPP ortho), 134.73 (+ve, CAR-AQ), 
134.82 (ab, q, CAR-AQ)  134.90 (+ve, CAR-TPP para), 147.39 (ab, q, CAR-AQ), 156.24 (ab, q, 
CAR-AQ), 172.47 (ab, q, C=O), 180.72 (ab, q, C=O).   
 
1.4.3.9 Synthesis of 1-hydroxy-4-((2-(2-
hydroxyethoxy)ethyl)amino)anthracene-9,10-dione (HO-EOE-AQ(4-
OH) (OM29) 
Leucoquinizarin (1 g, 4.13 mmol) was dissolved in CH2Cl2 (50 mL) and 2-(2-
aminoethoxy)ethanol (2.16g, 20.57 mmol) was added and heated at 40oC for 1 h. The 
product was then oxidized by aeration with the addition of triethylamine (Et3N, 0.5 mL). 
The product was then isolated by CH2Cl2/water solvent extraction [general method A] and 
the organic extracts were evaporated in vacuo to a low volume. The product was purified 
by using silica gel chromatography column using neat chloroform at the beginning then 
chloroform + 4% methanol followed by chloroform + 6% methanol. Yield 39%, 0.52 g. 
TLC of the crude mixture (chloroform: methanol, 9:1): Rf 0.58 (purple) OM29, 0.51 (blue) 




HRMS (ESI) (+) m/z: 328.1181 (100%) [M+H]+. Calculated for [C18H17O5NH]+ 328.1179; 
Found 328.1181. 
 
1.4.3.10 Synthesis of (5-(2-(2-((4-hydroxy-9,10-dioxo-9,10-dihydroanthracen-1-
yl)amino)ethoxy)ethoxy)-5-oxopentyl)triphenylphosphonium (TPP-
EOE-AQ(4-OH) (OM32) 
(4-Carboxybutyl)triphenylphosphonium bromide (TPP) (0.4 g, 0.9 mmol), DCC (0.37 g, 
1.79 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 (10 mL) and allowed to react 
for 15 min then added to OM29 (0.25 g, 0.76 mmol, 1 eq) in CH2Cl2 (5 mL) and left over 
ice with stirring for 1 h. After 1 h, additional half amounts of TPP and DCC were added 
and allowed to react for another 1 h. The product OM32 was extracted using 
chloroform/water solvent extraction [general method A]. The product was filtered and 
solvents were evaporated in vacuo to lower volume and applied to a silica gel 
chromatography column using neat chloroform initially and then the polarity of the 
solvents were increased as follows ; chloroform + 3% ethyl acetate, 9:1 chloroform: ethyl 
acetate, 4:1 chloroform: ethyl acetate, 4:1 chloroform: ethyl acetate + 5% methanol and 
9:1 chloroform: methanol. The solvents were evaporated in vacuo to dryness and addition 
of diethyl ether (20 mL) gave a precipitate of OM32, which was filtered off and dried. Yield 
47%, 0.24 g.  
TLC of OM32 (chloroform: methanol, 9:1) RF 0.12 (purple) OM32, 0.28 (red) unknown 
compound.  
HRMS (ESI) (+) m/z: 672.2501 (100%) cation (+). Calculated for [C41H39NO6P]+ 672.2510; 
Found 672.2501. 
1H NMR (DMSO-d6, 300 MHZ):  (ppm) 1.47-1.79 (m, 4H, CH2CH2CH2CH2P), 2.41 (m, 
2H, CH2-C=O), 3.34 (m, 2H, AQ-NH- CH2), 3.5-3.73 (m, 6H, NHCH2CH2-O-CH2CH2O and 
CH2-P) 4.12-4.18 (m, 2H, NHCH2CH2-O-CH2CH2O), 7.37 (d, 1H, AQ-H2, J 15 Hz), 7.55 
(d, 1H, AQ-H3, J 15) Hz, 7.71-7.95 (m, 17H, HAR of AQ and TPP), 8.20-8.27 (m, 2H, AQ-




13C NMR (DMSO-d6, 75.5 MHZ):  (ppm) 20.28 (-ve, CH2), 21.09 (-ve, CH2), 32.26 (-ve, 
CH2-P), 41.92 (-ve, NHCH2), 59.74 (-ve, CH2), 62.99 (-ve, CH2O), 68.12 (-ve, OCH2), 
68.88 (-ve, CH2O), 107.36 (ab, q, CAR-AQ), 112.82 (ab, q, CAR-AQ), 117.82 and 117.89 (d, 
ab, CAR-TPP), 118.96 and 119.03 (d, ab, CAR-TPP), 125.81 (+ve, CAR-AQ), 126.02 (+ve, CAR-
AQ), 126.25 (+ve, CAR_AQ), 128.71 (+ve, CAR-AQ), 130.12 and 130.28 (+ve, CAR-TPP meta), 
131.90 (ab, q, CAR-AQ), 133.00 (+ve, CAR-AQ), 133.48 and 133.56 (+ve, CAR-TPP ortho), 
133.61 (+ve, CAR-AQ), 134.70 (ab, q, CAR-AQ), 134.90 (+ve, CAR-TPP para), 147.34 (ab, q, 
CAR-AQ), 156.17 (ab, q, CAR-AQ), 172.46 (ab, q, C=O), 180.81 (ab, q, C=O), 186.78 (ab, q, 
C=O).  
 
1.4.3.11 Synthesis of 1-((4-hydroxybutyl)amino)anthracene-9,10-dione (OH-
butyl-AQ) (NU:UB 238) 
1-Chloroanthraquinone (40 mmol) was suspended in DMSO (15 mL) and 4-amino-1-
butanol (5.0 g, 56 mmol) was added and the mixture was heated for 30 min over a boiling 
water bath. The solution was cooled and added to a large excess of water (500 mL). The 
red precipitated solid was filtered off, dried and used for subsequent reactions without 
further purification.  
TLC of the crude mixture (dichloromethane: methanol, 9:1): Rf 0.1 (red) NU:UB 238, 0.9 
(yellow) 1-chloroanthraquinone. 
HRMS (ESI) (+) m/z: 296.1284 (100%) [M+H]+. Calculated for [C18H17O3NH]+ 296.1281; 
Found 296.1284. 
 
1.4.3.12 Synthesis of (5-(4-((9,10-dioxo-9,10-dihydroanthracen-1-
yl)amino)butoxy)-5-oxopentyl)triphenylphosphonium (TPP-Butyl-AQ) 
(SH1) 
(4-Carboxybutyl)triphenylphosphonium bromide (TPP) (0.49 g, 1.10 mmol), DCC (0.49 g, 
2.37 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 (10 mL) and allowed to react 




0.84 mmol) in CH2Cl2 (5 mL) and stirred for 1 h. The product SH1 was extracted using 
chloroform/water solvent extraction [general method A]. The product was filtered and 
applied to a silica gel chromatography column using neat CH2Cl2 initially and then CH2Cl2: 
ethyl acetate and then CH2Cl2: ethyl acetate + 2% - 7% methanol. SH1 was filtered and 
evaporated to dryness in vacuo. The compound was sticky, so second column 
chromatography was performed. The crude product was filtered and evaporated to 
dryness under vacuo and acetonitrile: diethyl ether solution was added to solidify SH1. 
Yield 46%, 0.11 g.  
TLC of SH1 (chloroform: methanol, 9:1) Rf 0.34 (red) (SH1). 
HRMS (ESI) (+) m/z: 640.2594 (100%) [M]+. Calculated for [C41H39NO4P]+ 640.2611; 
Found 640.2594. 
1H NMR (DMSO-d6, 300MHz):  (ppm) 1.50 – 1.80 (m, 8H, NHCH2CH2CH2CH2O and 
OCOCH2CH2CH2CH2P), 2.41 (t, 2H, CH2-C=O, J 15 Hz), 3.36 (m, 2H, AQ-NH-CH2), 3.62 
(t, 2H, CH2P, J 30 Hz), 4.06 (s, 2H, CH2O), 7.26 (d,1H, AQ-H2, J 18 Hz), 7.43 (d,1H, AQ-
H4, J 15 Hz), 7.65 (d, 1H, AQ-H3, J 15 Hz), 7.72 – 7.94 (m, 17H, HAR of AQ and TPP), 
8.10 – 8.21 (m, 2H, AQ-H5 and H8); 9.68 (t, 1H, AQ-NH, J 9 Hz).  
13C NMR (DMSO-d6, 75.5 MHZ):  (ppm) 20.25 (-ve, CH2), 21.11 (-ve, CH2), 21.16 (-ve, 
CH2), 25.02 and 25.09 (-ve, CH2-P), 25.54-25.67 (-ve, CH2CH2-P), 32.41 (-ve, CH2), 41.69 
(-ve, CH2-NH), 63.47 (-ve, CH2-O), 111.89 (ab, q, CAR-AQ), 115.02 (+ve, CAR-AQ), 117.87 
and 119.00 (d, ab, CAR-TPP), 126.25 (+ve, CAR-AQ), 126.34 (+ve, CAR-aq), 130.13 and 130.29 
(+ve, CAR-TPP meta), 132.30 (ab, q, CAR-AQ), 133.45 and 133.59 (+ve, CAR-TPP ortho), 
133.89 (ab, q, CAR-AQ), 134.28 (ab, q, CAR-AQ)  134.49 (+ve, CAR-AQ), 134.86 (+ve, CAR-AQ), 
134.90 (+ve, CAR-TPP para), 135.65 (+ve, CAR-AQ), 151.28 (ab, CAR-AQ), 172.49 (ab, q, 





1.4.3.13 Synthesis of (5-((5-((4-((5-hydroxypentyl)amino)-9,10-dioxo-9,10-
dihydroanthracen-1-yl)amino)pentyl)oxy)-5-
oxopentyl)triphenylphosphonium TPP-NU:UB 65 (OM25) 
NU:UB 65 (0.1 g, 0.24 mmol) was dissolved in CH2Cl2. TPP (0.05 g, 0.121 mmol), DCC 
(0.025 g, 0.121 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 and allowed to 
react for 10 min then was added to NU:UB 65 in CH2Cl2 and allowed to react at rt for 1 h. 
The reaction was filtered and was extracted using CH2Cl2/ water solvent extraction 
[general method A]. OM25 was purified by column chromatography using CH2Cl2: 
methanol (19:1). The solvents were evaporated and diethyl ether was added to solidify 
OM25, which was filtered and dried. Yield 33%, 0.06 g.  
TLC for OM25 (dichloromethane: methanol, 9:1) Rf 0.35 (purple) (OM25). 
HRMS (ESI) (+) m/z: 755.3590 (100%) cation (+). Calculated for [C47H52N2O5P]+ 
755.3608; Found 755.3590. 
 
1.4.3.14 Synthesis of (((((9,10-dioxo-9,10-dihydroanthracene-1,4-
diyl)bis(azanediyl))bis(pentane-5,1-diyl))bis(oxy))bis(5-oxopentane-
5,1-diyl))bis(triphenylphosphonium) bis-TPP-NU:UB 65 (OM26) 
NU:UB 65 (0.1 g, 0.24 mmol) was dissolved in CH2Cl2. TPP (0.64 g, 1.46 mmol), DCC 
(0.3 g, 1.46 mmol) and DMAP (5-10 mg) were dissolved in CH2Cl2 and allowed to react 
for 10 min then added to NU:UB 65 in CH2Cl2 and allowed to react at rt for 1 h. The 
reaction was filtered to remove DCU and was extracted using CH2Cl2/ water solvent 
extraction [general method A]. Ethyl acetate was added to remove DCU and it was filtered 
and dried. OM26 was applied to a silica gel chromatography column using CH2Cl2: 
methanol (19:1). The solvents were evaporated and diethyl ether was added and cooled 
overnight to solidify OM26, which was filtered and dried. Yield 69%, 0.18 g.  
TLC for OM26 (dichloromethane: methanol, 9:1) Rf 0.17 (purple) (OM26). 
HRMS (ESI) (+) m/z: 550.2491 (100%) [cation]2+. Calculated for [C70H74N2O6P2]2+ 




 Synthesis of mitoxantrone derivatives rhodamine B 
conjugates 
 
1.4.4.1 Synthesis of tert-butyl 3-(3',6'-bis(diethylamino)-3-
oxospiro[isoindoline-1,9'-xanthen]-2-yl)propanoate (Rho-β-ala-OtBu) 
(OM6) 
Rhodamine B (0.6 g, 1.25 mmol), PyBOP (0.98 g, 1.87 mmol) were dissolved in DMF (5 
mL) and DIPEA (0.99 mL, 5.76 mmol) was added and allowed to react for 15 min. The 
mixture was added to HN-β-ala-OtBu.HCl (0.25 g, 1.37 mmol) pre-dissolved in DMF (5 
mL) and DIPEA (0.25mL) and was left at rt with stirring to react for 2 h. Additional amount 
of HN-β-ala-OtBu (0.25 g, 1.37 mmol) and PyBop (0.98 g, 1.87 mmol) were Rho B and 
allowed to react for another 2 h. The product was separated from DMF using chloroform/ 
water solvent extraction [general method A]. OM6 was purified by using silica gel 
chromatography column using neat chloroform initially then chloroform: methanol + 1% 
pyridine was used. OM6 was filtered and evaporated to dryness in vacuo. Water was 
added (100 mL) and precipitated OM6 was filtered and dried. Yield 44%, 0.52 g.  
TLC of OM13 (dichloromethane: methanol, 9:1 + 1% pyridine) Rf 0.73 (pink) OM6, 0.43 
(pink) rhodamine B. 
HRMS (ESI) (+) m/z: 570.3316 (100%) [M]+. Calculated for [C35H44N3O4]+ 570.3326; 
Found 570.3316. 
 
1.4.4.2 Synthesis of N-(9-(2-((2-carboxyethyl)carbamoyl)phenyl)-6-
(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium (Rho-β-
ala-OH) (OM7)  
Trifluoroacetic acid (TFA) (1 mL) was added and left overnight. The solvent was 
evaporated and addition of diethyl ether (20 mL) gave a precipitate of OM7, which was 
filtered off and dried. Yield 97%, 0.14 g. 




HRMS (ESI) (+) m/z: 514.2687 (100%) [M]+. Calculated for [C31H36N3O4]+ 514.2700; 
Found 514.2687. 
 
1.4.4.3 Synthesis of N-(9-(2-((3-(2-((tert-butoxycarbonyl)(2-((4-hydroxy-9,10-
dioxo-9,10-dihydroanthracen-1-yl)amino)ethyl)amino)ethoxy)-3-
oxopropyl)carbamoyl)phenyl)-6-(diethylamino)-3H-xanthen-3-
ylidene)-N-ethylethanaminium Rho-β-ala-EAE-Boc-AQ(4-OH) (OM17) 
Rho-β-ala-OH (OM7) (0.12 g, 0.413 mmol) was dissolved in CH2Cl2 with few drops of 
acetonitrile and DIPEA. DCC (0.126 g, 0.901 mmol) and DMAP (5-10 mg) were dissolved 
in CH2Cl2 (10 mL) and were added to pre-dissolved OM7 and allowed to react for 15 min 
then added to OM2 (0.16 g, 0.37 mmol) in CH2Cl2 (5 mL) and was left over ice with stirring 
for 1 h. After 1 h, additional amounts of OM7 (0.12 g, 0.413 mmol) and DCC (0.126 g, 
0.901 mmol) were added and allowed to react overnight. The product was filtered and 
was extracted using CH2Cl2/ water solvent extraction [general method A]. OM17 was 
applied to a silica gel chromatography column using neat CH2Cl2 initially then a more 
polar solvent CH2Cl2: ethyl acetate was used and 5 mL of methanol was added at the end 
to elute all the product from the column. Column chromatography was repeated using 
neat CH2Cl2 at the beginning and the solvent system was changed by adding 5% ethyl 
acetate to CH2Cl2 to remove all rhodamine B impurity from the product. OM17 was filtered 
and evaporated to dryness in vacuo. 
TLC for OM17 (chloroform: ethylacetate: methanol, 40:9:1) Rf 0.87 (purple) OM17, 0.59 
(purple) AQ-SP.  









Trifluoroacetic acid (TFA) (1 mL) was added for 30 min. TFA was evaporated and 1, 4-
dioxane (0.5 mL) and hexane was used to solidify OM18, which was centrifuged and 
dried. Yield 17%, 0.051 g  
TLC for OM18 (dichloromethane: methanol, 9:1 +2 drops of acetic acid) Rf 0.68 (purple) 
(OM18). 
HRMS (ESI) (+) m/z: 822.3857 (100%) [M-TFA]+. Calculated for [C49H52N5O7]+ 822.3861; 
Found 822.3857. 
 
1.4.4.5 Synthesis of N-(9-(3-(4-(tert-butoxycarbonyl)piperazine-1-
carbonyl)phenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-
ethylethanaminium (Rho-pip-Boc) (OM4)  
Rhodamine B (1 g, 2.08 mmol) and HATU (1.19 g, 3.13 mmol) were dissolved in 
CH2Cl2/DMF (1:2).Triethylamine (1.45 mL, 8.35 mmol) was added and allowed to react 
for 10 min. Boc-piperazine in CH2Cl2/DMF (1:2) was added to the mixture and allowed to 
react at rt with stirring overnight. The reaction was extracted using CH2Cl2/ water solvent 
extraction [general method A]. The product OM4 was purified by column chromatography 
using 19:1 CH2Cl2: methanol. Rho-pip-Boc was filtered and evaporated to dryness in 
vacuo.  




1.4.4.6 Synthesis of N-(6-(diethylamino)-9-(3-(piperazine-1-carbonyl)phenyl)-
3H-xanthen-3-ylidene)-N-ethylethanaminium (Rho-piperazine TFA) 
(OM4 TFA) 
TFA (1 mL) was added for 30 min. TFA was evaporated and 1, 4-dioxane (0.5 mL) was 
added. Diethyl ether was used to precipitate the product, which was filtered and dried. 
Yield 79%, 0.84 g. 
TLC for OM4 TFA (dichloromethane: methanol, 9:1) Rf 0.105 (pink) (OM4 TFA). 
HRMS (ESI) (+) m/z: 511.3054 (100%) [M-TFA]+. Calculated for [C32H39N4O2]+ 
511.3068; Found 511.3054. 
 
1.4.4.7 Synthesis of 4-(4-(3-(6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-
yl)benzoyl)piperazin-1-yl)-4-oxobutanoate (Rho-pip-succinate) (OM5) 
Succinic anhydride (0.192 g, 1.92 mmol) was dissolved in DMF (5 mL) and DIPEA (0.334 
mL, 1.92 mmol) was added and allowed to react for 10 min then was added to OM4 TFA 
(0.6 g, 0.96 mmol) in DMF and allowed to react at rt with stirring for 1 h. The reaction was 
extracted using CH2Cl2/water solvent extraction [general method A]. The solvents were 
evaporated and diethyl ether was added to solidify the product, which was filtered and 
dried. Yield 77%, 0.55 g.  
TLC for OM5 (butanol: acetic acid: water, 4:5:1) Rf 0.608 (pink) (OM5).  
 





OM2 (0.12 g, 0.28 mmol) was dissolved in CH2Cl2, cooled and stirred. OM5 (0.16 g, 0.25 




allowed to react for 10 min then added dropwise to OM2 in CH2Cl2 and allowed to react 
for 12 h.  The reaction was filtered and extracted using CH2Cl2/water solvent extraction 
[general method A]. OM15 was applied to a silica gel chromatography column using neat 
chloroform initially then more polar solvents chloroform: ethyl acetate then chloroform: 
methanol were used. Column chromatography was repeated a further three times to 
obtain the product in a homogenous form on TLC. 
TLC for OM15 (dichloromethane: methanol, 9:1) Rf 0.35 (purple) OM15, 0.1 (pink) 
rhodamine B.  
HRMS (ESI) (+) m/z: 1019.4914 (100%) [M]+. Calculated for [C59H67N6O10]+ 1019.4913; 
Found 1019.4914. 
 
1.4.4.9 Synthesis of 2-((4-(4-(3-(6-(diethylamino)-3-(diethyliminio)-3H-
xanthen-9-yl)benzoyl)piperazin-1-yl)-4-oxobutanoyl)oxy)-N-(2-((4-
hydroxy-9,10-dioxo-9,10-dihydroanthracen-1-yl)amino)ethyl)ethan-1-
aminium (Rho-pip-succ-EAE-AQ(4-OH) (OM16) 
TFA (1 mL) was added for 20 min then it was evaporated to dryness under vacuum.  
Ethanol was added then diethyl ether was added to precipitate OM16, which was filtered 
and dried. Yield 91%, 0.21 g  
TLC for OM16 (chloroform: methanol, 4:1) Rf 0.38 (purple) (OM16). 
HRMS (ESI) (+) m/z: 919.4388 (86%) [M-TFA]+. Calculated for [C54H59N6O8]+ 919.4389; 







 Synthesis of mitoxantrone and ametantrone-linked 
prodrugs 
 
1.4.5.1 Synthesis of di-tert-butyl (((5,8-dihydroxy-9,10-dioxo-9,10-
dihydroanthracene-1,4-diyl)bis(azanediyl))bis(ethane-2,1-diyl))bis((2-
hydroxyethyl)carbamate) (Mitoxantrone-Boc) (OM19) 
Mitoxantrone (0.03 g, 0.058 mmol) was dissolved in methanol (10 mL) and cooled down 
with stirring. Boc2O (0.05 g, 0.23 mmol) was dissolved in methanol and DIPEA (0.025 ml, 
0.14 mmol) was added then the mixture was added to activated mitoxantrone dropwise 
and allowed to react for 1 h. A further half amount of Boc2O was added. The reaction was 
filtered and extracted using CH2Cl2/ water solvent extraction [general method A]. OM19 
was applied to a silica gel chromatography column using neat CH2Cl2 at the beginning 
then the polarity of the solvent system was increased by using CH2Cl2: methanol. OM19 
was filtered and evaporated to dryness under vacuum. The crude product was then used 
for further reaction without precipitation. 
TLC for OM19 (dichloromethane: methanol, 9:1) Rf 0.47 (blue) (OM19). 
HRMS (ESI) (+) m/z: 645.3128 (100%) [cation]2+. Calculated for [C32H42N4O10H]+ 
643.2974; Found 645.3130.  
 
1.4.5.2 Attempted synthesis of Rho-pip-succ-mitoxantrone-Boc (OM20) 
OM19 (0.12 g, 0.18 mmol) was dissolved in CH2Cl2 and it was cooled in ice with stirring. 
OM5 (0.125 g, 0.204 mmol), DCC (0.092 g, 0.186 mmol) and DMAP (5-10 mg) were 
dissolved in CH2Cl2 and allowed to react for 10 min then added dropwise to Mitoxantrone-
Boc in dichloromethane and allowed to react for 1 h. The reaction was filtered and 
extracted using CH2Cl2/water solvent extraction [general method A]. OM20 was applied 
to a silica gel chromatography column using neat CH2Cl2 initially then more polar solvents 




methanol were used. Column chromatography was performed twice to obtain a product 
homogenous on TLC.  
TLC for OM20 (dichloromethane: methanol, 9:1) Rf 0.40 (purple) 1 arm product, 0.14 
(purple) 2 arm product, 0.03 (pink) rhodamine B. 
HRMS (ESI) (+) m/z: 1351.6486 (100%) [M+H]+. Calculated for [C104H126N12O18]+, not 
match with Theoretical Isotope Model 1832.9417 and Observed Data 1826.1211. 
 





TFA (1 mL) was added for 30 min then it was evaporated to dryness. Diethyl ether was 
added to precipitate OM21, which was filtered and dried. Yield 20%, 0.06 g  
TLC for OM21 (dichloromethane: methanol, 9:1) Rf 0.44 (purple) (OM21) 
HRMS (ESI) (+) m/z: 576.2742 (100%) [M+H]2+. Calculated for [C94H110N12O14]+, the data 
did not match with the Theoretical Isotope Model 1632.8369 and the Observed Data 
1684.2618. 
 
1.4.5.4 Attempted synthesis of TPP-mitoxantrone-Boc (one arm) (OM23) and 
TPP-mitoxantrone (two arm) (OM24) 
OM19 (0.06 g, 0.093 mmol) was dissolved in CH2Cl2 and cooled in ice with stirring. TPP 
(0.02 g, 0.046 mmol), DCC (0.03 g, 0.186 mmol) and DMAP (5-10 mg) were dissolved in 
CH2Cl2 and allowed to react for 10 min then added dropwise to OM19 in CH2Cl2 and 
allowed to react for 1 h. The reaction was filtered and extracted using CH2Cl2/water 
solvent extraction [general method A]. OM23 and OM24 were purified by column 




CH2Cl2: methanol (19:1), CH2Cl2: methanol (9:1) and CH2Cl2: methanol (4:1) were used 
to get one arm and two arms products respectively. The solvents were evaporated and 
diethyl ether was added to precipitate OM23 and OM24, which were filtered and dried. 
Yield 67%, 0.06 g and 23%, 0.03 g.  
TLC for OM23 and OM24 (chloroform: methanol, 4:1) Rf 0.29 (blue) (OM!) one arm 
product, 0.58 (blue) (OM!) 2 arm product.  
HRMS (ESI) (+) m/z: 667.2919 (22%) [cation]2+. Calculated for [C78H88N4O12P2]+ 
667.2932; Found 667.2919.  
 
1.4.5.5 Synthesis of ametantrone (NK1) 
Leucoquinizarin (1 g, 4.13 mmol, 1 eq) was dissolved in CH2Cl2 (50 mL) and N-(2-
hydroxyethyl)ethylenediamine (8.59 g, 82.60 mmol, 20 eq ) was added and heated at 
50oC for 1 h. The product was then oxidized by aeration with the addition of triethylamine 
(Et3N, 1 mL) for 4.5 h and the solution colour became blue. The solid was precipitated 
and filtered under vacuum. The solid was washed with CH2Cl2 (20 mL) and dried (rotary 
evaporation). The sticky blue solid was precipitated using diethyl ether (5 mL) and was 
filtered and evaporated to dryness in vacuo. Yield: 71%, 1.2 g. 
TLC of the anthraquinone crude product (butanol : acetic acid : water, 4:5:1): Rf 0.08 
[blue, ametantrone (NK1)], 0.29 (purple, single armed anthraquinone derivative), 0.56 
(pink). 
1.4.5.6 Synthesis of di-tert-butyl (((9,10-dioxo-9,10-dihydroanthracene-1,4-
diyl)bis(azanediyl))bis(ethane-2,1-diyl))bis((2-
hydroxyethyl)carbamate) (ametantrone-Boc) (NK4) 
NK1 (0.7 g, 2.03 mmol, 1 eq) was dissolved in methanol (20 mL) and cooled over ice 
(0oC). Boc2O (1.77 g, 8.12 mmol, 4 eq) was dissolved in methanol (30 mL) and was added 
to NK1 dropwise and allowed to react over ice for 60 min. The product NK4 was extracted 
using chloroform/water solvent extraction [general method A]. The product was filtered 




neat chloroform at the beginning and then the polarity of the solvent was increased by 
using chloroform : ethyl acetate (19:1), chloroform: ethyl acetate (19:1) + methanol 2%, 
chloroform : ethyl acetate (9:1) + methanol 2%, chloroform : ethyl acetate (9:1) + methanol 
4%, and chloroform : ethyl acetate (9:1) + methanol 6%. NK4 was filtered and evaporated 
to dryness in vacuo. Addition of diethyl ether (20 mL) gave a precipitate of NK4, which 
was filtered off and dried. Yield: 68%, 0.86 g. 
 TLC of NK3 and NK4 (chloroform: methanol, 9:1): Rf 0.54 (purple) OM2, 0.57 (blue) NK4. 
 





4-Carboxybutyl)triphenylphosphonium bromide (TPP) (0.45 g, 1.02 mmol, 6 eq) and 
HATU (0.46 g, 1.19 mmol, 7 eq) were dissolved in DMF (2.25 mL), and added with 4-
methylmorpholine (242 µL, 2.21 mmol) and allowed to react for 30 min then added to pre-
dissolved NK4 (0.1 g, 0.17 mmol, 1 eq) in DMF (2.75 mL) The mixture was stirred using 
magnetic stirrer for 1 h, heated over water bath at 40ºC (without stirring) for 1.5 h, and left 
to react overnight at rt. The product NK6 was extracted using chloroform/water solvent 
extraction [general method A].  NK6 was applied to a silica gel chromatography column 
using neat chloroform initially and then more polar solvent chloroform: ethyl acetate 
(19:1), chloroform: ethyl acetate (19:1) + methanol 1%, chloroform: ethyl acetate (19:1) + 
methanol 2% were used. NK6 was filtered and evaporated to dryness in vacuo. Addition 
of diethyl ether (3 mL) gave a precipitate of NK6, which was filtered and evaporated to 
dryness in vacuo. Yield: 50%, 0.10 g.  
TLC of NK6 (chloroform: methanol, 9:1): Rf 0.53 (blue) (NK6). 
HRMS (ESI) (+) m/z: 651.2971 (100%) [M-Br2]+. Calculated for [C78H88N4O10P2]+ 









Boc-Ametantrone-bis-TPP (0.07 g) was dissolved in TFA (1 mL) for 30 min. Ethanol (0.3 
mL) was added and the solvent was evaporated, to give (NK8) which was precipitated 
with diethyl ether (2 mL). Yield: 71%, 0.05 g. 
TLC of NK8 (butanol: acetic acid: water, 4:5:1): Rf 0.03 (blue) (NK8). 
HRMS (ESI) (+) m/z: 551.2442 (100%) [M-(TFA)2]+. Calculated for [C68H72N4O6P2]+ 
551.2458; Found 551.2442. 
 
 DNA binding assay  
 
1.4.6.1 Materials 
PBS buffer was made by dissolving one phosphate tablet (Sigma) in 200 mL of distilled 
water to obtain 0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium 
chloride, pH 7.4 at 25oC. Ethidium bromide 10 mg/mL (300 µM) of stock solution in 
deionized water was prepared and protected from light and kept at 4oC, which was further 
diluted to 30 µM (final concentration). One centimeter portion (approximately) of Calf 
Thymus DNA (Sigma) was dissolved slowly in 5 mL of PBS buffer at 4oC for 24 h. 
Undissolved Calf Thymus DNA residue was filtered off and the concentration of Calf 
Thymus DNA stock solution was determined by using Beckman DU800 UV/Vis 
spectrophotometer at 260 nm using a molar extinction coefficient of 6600 M-1cm-1. Drug 
test solutions were prepared and by making a stock solution of 1 mg/mL or 10 mg/mL in 
DMSO, then further diluted to give a final concentration in the cuvette of 1~10 μM as 





1.4.6.2 DNA quantification  
DNA stock solution (100~300 μL) was transferred into the cuvette and diluted with PBS 
buffer to give a final volume of 3 mL. 3 mL of PBS was added to a cuvette and was used 
as a blank. The analytical wavelength for the spectrophotometer was set at 260 nm. 
According to the linearity range of the Beer-Lambert Law, the ideal absorbance should 
fall between 0.5 and 0.7. The experiments were performed in triplicate. The mean value 
was then used to determine the concentration of this DNA stock solution using the 
equation below: 
Absorbance (A) = Concentration (C) × Cell length (L) × Molar extinction coefficient (Σ) 
(The units are: mol/L for C, cm for L, mol-1dm3cm-1 for Σ) 
the concentration of the original DNA stock solution were determined by using equation 
C1 V1 = C2 V2.  
 
1.4.6.3 Method 
Excitation and emission wavelengths were set at 480 nm and 550-750 nm, respectively 
to measure the fluorescence intensity. Solutions (3 mL ) were added to the fluorescence 
cuvette in the following order: 1) DNA (final conc. 60 M), 2) ethidium bromide (final conc. 
30 M) 3) buffer to complete the volume to 3 mL. The fluorescence intensity of this mixture 
was recorded after it came to equilibrium. Drugs solutions in DMSO (stock solution) were 
further diluted to give a final concentration in cuvette 1~10 μM as required, then the 
solution was mixed well and allowed to reach equilibrium for 5 min each time. Aliquots of 
drug solution were added into the cuvette until the fluorescence intensity reach below half 
the fluorescence intensity of the original DNA-drug free solution. The apparent DNA 
binding constant Kapp were calculated from the plot of relative fluorescence intensity 
against DNA binding ligand concentration, using the equation: KEB[EB]=Kapp[DNA 
binding ligand] where (KEB=1.0×107M-1, EB ethidium bromide concentration and DNA 
binding ligand is the concentration that caused a 50% decrease of the relative 
fluorescence intensity of DNA-bound ethidium bromide. The DNA binding QE50 values for 




      Distribution Coefficient Assay 
 
1.4.7.1 Materials 
Beckman DU800 spectrophotometer; octanol; PBS buffer (Sigma-Aldrich Phosphate 
buffered saline. One tablet dissolved in 200 mL of deionized water yields 0.01 M 
phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4, at 
25 °C.); 3 mL quartz cuvette; test compounds: [HO-EAE-AQ (4-OH)] OM2 TFA, [TPP-
EAE-AQ(4-OH)] OM22, [(OH-Butyl-AQ (4-OH)] NU:UB 252, [(TPP-Butyl-AQ(4-OH)] 
OM30, (OH-butyl-AQ) NU:UB 238, (TPP-Butyl-AQ) SH1 and [(Rho-pip-succ-EAE-AQ(4-
OH)] OM16. 
 
1.4.7.2 Calibration curve methods 
PBS buffer solution was made by dissolving a PBS tablet in (100 mL) of deionized water 
and was used in the measurement of standard calibration curve. Saturating buffer was 
made by using PBS buffer (100 mL) and octanol (100 mL) and shaken for 24 h on vortex. 
Each phase layer of phosphate and octanol were separated using a separating funnel. 
1mg/mL of stock solution samples (OM2 TFA, OM22, NU:UB 252, OM30, NU:UB 238, 
SH1 and OM16) in dimethyl sulfoxide (DMSO) was taken and diluted with PBS (octanol 
saturated) or octanol (PBS saturated) in cuvettes to give a series of different 
concentrations of the test compounds. Scan speed was set as 1200 nm/min and 
wavelength range was set as 400 to 700 nm and the maximum absorbance was plotted 
into a regression graph to obtain the y = mx + c equation. The experiments were 
performed in triplicate. 
 
1.4.7.3 Distribution coefficient  
Compounds (OM2 TFA, OM22, NU:UB 252. OM30, NU:UB 238, SH1 and OM16) 1 mg 
were dissolved in 900 µL of octanol (PBS saturated) and 900 µL of PBS 7.4 (octanol 




compound.  The tubes were shaken for 24 h at rt. For the experiment, for example; 50 µL 
of OM2 TFA in PBS and 400 µL of OM22 were taken out and transferred into cuvette and 
diluted with PBS to give a final volume of 800 µL. 100 µL of OM2 TFA in octanol and 200 
µL of OM22 in octanol were taken out and transferred into cuvette and diluted with octanol 
to give a final volume of 3000 µL. The absorbance in both layers was measured. Finally, 
the concentrations of samples in each phase were determined from standard curves 
made by plotting absorbance against concentration. Log D values were calculated from 
the calibration curves equation by dividing the concentration in the octanol by the 
concentration in PBS phase.  
 
      MTT assay 
 
1.4.8.1 Materials 
HCT-15 (Human colon carcinoma cells, MCF-7 (human breast cancer cells), RPMI 1640 
medium containing phenol red (sigma), 10% foetal bovine serum, FBS, 1% L-glutamine, 
1% penicillin and streptomycin, sodium chloride (NaCl), 0.5% trypsin, PBS buffer, 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT), test compounds: OM2 
[HO-EAE-AQ(4-OH)], OM22 [TPP-EAE-AQ(4-OH)], NU:UB 238 (OH-butyl-AQ), SH1 
(TPP-Butyl-AQ), NU:UB 65 and OM26 (TPP-bis-NU:UB 65), mitoxantrone, OM30 [TPP-
Butyl-AQ(4-OH)], OM31 [(TPP-Pentyl-AQ(4-OH)] and OM32 [(TPP-EOE-AQ(4-OH)]. 
 
1.4.8.2 Cell culture method 
HCT-15 and MCF-7 cells line were used for cytotoxicity assay. The cells were grown in 
RPMI media replenished with 10% foetal bovine serum, FBS, 1% L-glutamine, 1% 
penicillin and streptomycin in T-75 tissue culture flasks at 37oC in 5% CO2 in air. The 
media was removed and cells were washed with NaCl (10 mL; 2x) and the flask was 
gently shaken without disturbing the layer of the cells to wash off any remaining foetal 




After 5 min, the cells were removed from the incubator and observed under the 
microscope if the cells were detached. Then 8 mL of fresh RPMI 1640 media was added 
to the flask (to de-activate the action of trypsin) and wash all the cells to the bottom and 
the mixture was centrifuged (2 min, 2000 rpm). The supernatant was poured off and the 
cell pellet was re-suspended in RPMI 1640 media according to passage split (1/2, 1/4, 
1/8, 1/10) in mLs and 1 mL of this was transferred to a fresh flask. Cell count and MTT 
assay were performed using the reminder of the cells. 
 
1.4.8.3 MTT assay method 
HCT-15 and MCF-7 cells were seeded in 96 well plates at a cell density 5 x 104 cells/well 
for 24 h at 370C. Each cell line was plated on separate plates. Row A1-A3 contained 
RPMI media only (blank); row B1-B3 contained media and cells (positive control); row 
C1-C3 contained media and cells (negative control); row D-H contained cells and media, 
which treated with test compounds. After 24 h of incubation, all media was removed and 
replaced with test compounds (50 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM and 100 µM) in 
triplicate and incubated for 48 h. after 48 h, all medium was removed from wells C1-C3 
and replaced with Triton X (0.5%, 70 µL) to kill the cells. The medium from the rest of the 
well was removed and replaced with fresh media RPMI (70 µL). C1-C3 were then also 
replaced with fresh media RPMI (70 µL). MTT solution (5mg/mL) was prepared by adding 
10 mg MTT to 2 mL PBS. 50 µL of MTT solution was then added to each well and 
incubated 4 h at 37oC. after 4 h, all medium was removed and replaced with DMSO (150 
µL) and mixed vigorously and left in dark place for 30 min at 37oC. the absorbance was 
measured at 550 nm with a microplate reader and the IC50 was recorded for each test 







    Confocal microscopy  
 
1.4.9.1 Materials 
HCT-15 (Human colon carcinoma cells, HCT-116 (Human colon carcinoma) and PC3 
(prostate cancer cells); RPMI 1640 medium containing phenol red; sterile NaCl; 35 mm 
glass bottomed micro well dish (Ibidi/Thistle Scientific); compounds: [HO-EAE-AQ(4-OH)] 
OM2 TFA, [TPP-EAE-AQ(4-OH)] OM22, OM30 [TPP-Butyl-AQ(4-OH)], OM31 [(TPP-
Pentyl-AQ(4-OH)], OM32 [(TPP-EOE-AQ(4-OH)], (TPP-Butyl-AQ) SH1, ametantrone, 
mitoxantrone. LysoTracker Green DND 26 probe and MitoTracker Green FM probe. Live 
cell imaging was performed using Zeiss LSM800 confocal laser scanning microscope with 
HCX PL APO lambda blue (63.0 x 1.4 oil objective). Lasers used were: diode (405nm), 
Argon (458 nm, 488 nm and 514 nm), HeNe (543 nm), HeNe (543 nm), HeNe (594 nm) 
and HeNe (633 nm).  
 
1.4.9.2 Method  
Stock solutions of tested compounds (1 mg/mL) were prepared in DMSO. PC-3 cells (1.5 
x 105), HCT-15 (2.5 x 105) and HCT-116 (2 x 105) were seeded in 35 mm glass bottomed 
micro well dish and incubated for 24 h. Cells were washed with PBS x3. For the 
LysoTracker Green DND 26, a solution of dye (60 nM) was added to the cell culture 
medium and incubated at 37oC for 20 m. After 20 min the medium was removed and the 
cells were washed with sterile NaCl. Then tested compound solution was applied to cell 
culture medium and were imaged live using a Zeiss LSM800 confocal laser scanning 
microscope. For MitoTracker Green FM, a solution of dye (50 nM) was added to the cell 
culture medium and incubated at 37oC for 20 min. After 20 min the medium was removed 
and the cells were washed with sterile NaCl. Then tested compound solution was applied 
to cell culture medium and were imaged live using a Zeiss LSM800 confocal laser 
scanning microscope. Lens used was a 63.0 x 1.4 oil-immersion objective. Image analysis 




 Morphology studies   
 
1.4.10.1 Materials  
HCT-116 (Human colon carcinoma), RPMI 1640 medium containing phenol red; sterile 
NaCl; 35 mm glass bottom micro 6-well dish; compounds: [TPP-EAE-AQ(4-OH)] OM22 
and (TPP-Butyl-AQ) SH1 (1 mg/mL) and mitoxantrone (1 mg/mL) were prepared in 




HCT-116 cells (2 x 105) were seeded in a 6 well plate and incubated for 24 h. Cells were 
washed with NaCl x3. Cells were left untreated (negative control) or cultured with DMSO 
(0.1% vehicle control), mitoxantrone (1 µM positive control), OM22 (1 µM, 5 µM, 10 µM), 
SH1 (1 µM, 5 µM, 10 µM). Morphological characteristics of HCT-116 cells were tested 
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2 Chapter 2 
 
 
2.1 Aim  
The main aim of this aspect of the research programme was to synthesise a novel prodrug 
designed to exploit the proteolytic activity of legumain, which is an asparaginyl 
endopeptidase (AEP) that is overexpressed in the tumour microenvironment in order to 
simultaneously deliver a therapeutic agent and to detect the activity of this protease 
(therefore to act as a theranostic).  The specificity of legumain for asparagine residues at 
the C-terminus in the P1 position of substrates was taken advantage of in the design of 
the prodrug. The main goal of this prodrug is to improve the therapeutic index by reducing 
toxicity on healthy cells, eventually enhancing the therapy for cancer patients. The 
activation of the prodrug was to be determined by fluorescence spectroscopy. 
Additionally, this theranostic prodrug may offer a smart tool in early detection of tumours 















 Tumour Microenvironment  
The tumour microenvironment is rich in proteolytic activity and it is acidic and hypoxic and 
there is wide spectrum of proteases that include the cysteine endopeptidase legumain. 
The acidic character of the tumour microenvironment is due to the higher glycolytic rate 
of tumor cells. Also, the tumour microenvironment is a favorable environment for protease 
targeted alteration of prodrugs, which is from inactive compounds to potent cytotoxic 
agents. Additionally, the cellular microenvironment has a role in tumourigenesis which 
has become a major area of research (Arroyo-crespo et al., 2018). It is also possible to 
design a drug delivery system that has the ability to accumulate within the tumour 
microenvironment by exploiting the acidic pH and the presence of proteases such as 
legumain. The tumour microenvironment plays an interesting role in the activation of 
targeted prodrug due to the overexpression of key proteases and then reduce the toxicity 
on the cells lacking expression of the target enzyme, therefore, encouraging safety on 
healthy cells and efficiency of tumour destruction. In summary, the activation of a prodrug 
in the tumour microenvironment, promises to reduce active drug access to normal tissues, 
improve availability to tumour cells, and consequently, significantly reduce toxicity to 
normal tissues (Wu et al., 2006).  
 
 Proteases 
Proteases are hydrolase enzymes that are expressed intracellularly and extracellularly. 
These enzymes play an important and essential role in many biological and pathological 
processes by proteolysis, which is an irreversible regulatory mechanism and can 
selectively cleave specific substrates (López-Otín and Hunter, 2010). Furthermore, 
proteases play effective roles in DNA replication, cell proliferation, angiogenesis, blood 
coagulation, immunity, and necrosis. Therefore, decontrolled alterations in proteolytic 




associated with cancer development, especially invasion and metastasis because of the 
ability of proteases to degrade extracellular matrices and proteins. As a result, proteases 
play a significant role in drug development because many therapies have been designed 
to target and inhibit proteases that are deregulated, particularly for tumour suppression 
(Choi et al., 2012). One of the most important peptidases is legumain, belonging to the 
C13 family of cysteine proteases (Løvsletten et al., 2014).  
 
 Legumain  
Legumain or asparaginyl endopeptidase (AEP) was initially recognized in leguminous 
seeds as a cysteine protease with specific activity for asparagine residues in the P1 
position of peptide substrates. Also, legumain plays a significant role in 
endosomal/lysosomal degradation system (Zhou et al., 2017). Chen and his colleagues 
first described legumain in human and other mammalians in 1997 (Chen et al., 1997). 
Mammalian legumain is clearly homologous with non-mammalian legumain. The human 
legumain gene encodes a preproprotein of 433 amino acids (Haugen et al., 2013). Human 
legumain is a lysosomal cysteine protease which is a member of the clan CD protease 
family and it is over expressed in kidney, placenta, liver, spleen, and testis (Smith et al., 
2012). Legumain is synthesized as an inactive pro-enzyme which reaches full proteolytic 
activity after a complex series of maturation steps (Haugen et al., 2013). In order to deliver 
the inactive AEP to the acidic compartment, the C-terminal and N-terminal of the AEP 
must be removed. AEP can be activated through the removal of C-terminal propeptides  
because the C-terminal acts as an auto-inhibitory area that covers the catalytic site, 
therefore, the removal of the C-terminal propeptide is crucial for the activation of AEP 
(Shirahama-Noda et al., 2003).  
Legumain is normally present intracellularly in endosome/lysosome systems and is 
related with intracellular protein degradation. Moreover, legumain is present 
extracellularly in the tumour microenvironment, related with matrix and cell surfaces and 
it plays an important role in the degradation of the extracellular matrix (ECM) and thus, 




The overexpressed and up-regulation of legumain in tumour cells combined with 
recognition of unique substrate, makes legumain a potential candidate enzymatic target 
for prodrug activation and tumour destructive therapy (Haugen et al., 2015). The invasive 
and metastatic properties of tumour cells are often associated with the cell surface 
proteases and overexpression of legumain. Legumain activates also the gelatinase A 
zymogen (pro-MMP 2), which is an important mediator of ECM degradation (Guo et al., 
2013), therefore, the overexpression of legumain is considerable with high invasion and 
metastasis and directly correlated with the degree of malignancy (Zhou et al., 2017). The 
overexpression in colon cancer may play a role in encouraging tumour progression and 
may display more aggressive characteristics (Ohno et al., 2013). However, in normal 
tissues, legumain is mainly localized in the endo-lysosomal system where its protease 
domain is activated due to acidic environment. Additionally, legumain translocates to the 
nucleus and cytosol and it is related to pathological conditions including cancer (Ammirati 
and Fogacci, 2017).  
Therefore, legumain may exemplify a target for inhibition of progression and metastasis 
because of its regulation related with tumour growth.  
 
 Protease activated probes 
One of the numerous aims for the design of protease-activated probes is in vivo molecular 
imaging. The probe is usually optically inhibited in its quenched state and fluorescence is 
released upon cleavage of the fluorophore (donor) from its acceptor (quencher) by the 
specific action of the targeted protease on a peptide linker, which acts as a substrate of 
the protease (Chang et al., 2005). This method is used to detect the expression and 
activity of proteases for imaging purposes (Edgington et al., 2011) 
Some fluorescent substrate probes can be designed with specific peptide sequences with 
fluorophores whose spectral properties change when cleaved by an active protease. An 
example of a fluorogenic substrate consisting of a peptide sequence sensitive to 
legumain, attached at the C terminus, is the fluorophore aminomethylcoumarin (AMC) 




organic fluorophores in a variety of different studies. Kircher el al., (2004) and Wolf and 
Friedl (2005) used fluorophores narrowly to auto-quench fluorescence and upon cleavage 
of the fluorophores by enzymatic action of the labeled substrate, fluorescence occurred 
(Kircher et al., 2004; Wolf and Friedl, 2005). Others have employed FRET (fluorescence 
resonance energy transfer) where, the donor and acceptor (paired fluorophores) are 
linked together by a substrate targeted to a specific protease to monitor protease activity 
(Stockholm et al., 2005). Other methodologies involving the use of fluorescent emitters 
linked to a non-fluorescent absorber have been established and used in imaging (Pham 
et al., 2004). Despite advantages and promising results of these methods, there are 
disadvantages, including the demand for specific pairing between donor and acceptor 
molecules with respect to wavelength, rapid photobleaching under regular imaging 
circumstances and use of organic fluorophores which are sensitive to the physical 
environment (Chang et al., 2005).  
 
 Fluorescence resonance energy transfer (FRET) 
Fluorescence is a process by which the molecule in the singlet electronic ground state 
(S0) absorbs a photon of appropriate energy. This makes the electrons travel to the higher 
energy orbitals and then quickly back to the first singlet excited state (S1). The decay of 
the excitation state can go via different pathways such as: photon emission 
(fluorescence), in a nonradiative (NR) fashion (quenching of the fluorophore excited state 
by bond rotation, vibration, molecular collision and photoinduced electron transfer [PET]), 
forbidden intersystem crossing to the triplet excited state and relaxation by photon 
emission (phosphorescence) or NR (Lavis and Raines, 2008b).  
In addition, there is another interesting pathway for decay of the excited state which is 
FRET (fluorescence resonance energy transfer), which takes its name from the scientist 
Forster, who first described the mechanism of this process (Forster, 1948). FRET is the 
energy transferred nonradiatively from an excited state donor, which is usually a 
fluorophore, to a proximal ground state acceptor by long-range dipole-dipole interaction 




superposition of donor emission and acceptor absorption spectra, (2) the relative-
direction of the donor absorption and acceptor transitions moments (3) the reflective index 
(Jares-Erijman and Jovin, 2003). Additionally, FRET is distance-dependent less than 10 
nm between the acceptor and donor that are bound to the ends of the substrates (Kim 
and Kim, 2012).  
 
Figure 2.1: Representation of the FRET concept. 
 
 Rhodamine B 
Rhodamine is the analogue of fluorescein and eosin dyes, which are members of the 
xanthene family (Beija et al., 2009). This fluorophore is widely used as a dye in 
microscopy and in modern research such as in biological, biochemical and medicinal 
research due to its unique photophysical properties and structural change response to 
pH between opened ring (fluorescent) and closed ring (non-fluorescent). In addition, 
rhodamine is often utilized in biological functions because it is an inexpensive, robust 
molecule, with a high extinction coefficient and it is valuable for protein and peptide 
labelling to visualize inside cells (Birtalan et al., 2011). Another important property of 
rhodamine is that there are different forms of rhodamine B depending on the pH and 
solvent polarity these forms are: cationic, zwitterionic and lactone. Additionally, in acidic 




rhodamine B will be dissociated to give two forms, zwitterion and lactone forms, which 
are the main forms in non-polar organic solvents. However, both the cationic and 
zwitterionic forms are fluorescent, but there is a minor reduction in the extinction 
coefficient for the zwitterion compared to the cationic form, with identical change in both 
absorbance and fluorescence emission (Beija et al., 2009). Furthermore, the lactone form 
is colourless and non-fluorescent (absorbs in the UV region) when compared with the 
cationic and zwitterion form (Karpiuk et al., 1994) Figure 2.2. 
 
 
Figure 2.2:Chemical structures of three forms of rhodamine B. cationic and zwitterionic forms are 
fluorescent whereas the lactone form is nonfluorescent. 
 
Rhodamine derivatives that have two nitrogen atoms substituted with two alkyl groups, 
can have variation (dependent) in both quantum yield and fluorescence lifetime with 
temperature, while rhodamine derivatives that are either have no substituent or have only 
one alkyl substituent at each nitrogen atom are not subject to activation and quantum 
yield is independent of temperature (Ferreira and Costa, 2006).  
Moreover, for rhodamine to be used as a fluorescent probe, it requires some modifications 
such as, the modification of the 2 carboxylic acid group of rhodamines, modification of 3 
and 6 positions of the amino group of xanthene and modification on positions 4’ and 5’ of 
the caboxyphenyl ring. This modification occurs by the reaction of the 2 carboxylic acid 
group of rhodamine with primary amines to give secondary amides. Notably, that 
secondary amides are normally found in their non-fluorescent, ring-closed, spirolactam 




sensitivity of rhodamine B to pH can be altered and become low when linked to a tertiary 
amide and locked in the ring-open form as in Rho-Pro-OH Figure 2.3. The fluorescence 
emission for Rho-Pro-OH remains constant over the measured pH range, whereas 
fluorescence emission increases with increasing pH for FAM-Pro-OH. These results 
indicate the stability of rhodamine under different pH conditions.  
 
 
Figure 2.3: Fluorescence emission of (a) Rho-Pro-OH (10µM) and (b) FAM-Pro-OH in phosphate-
citrate buffer, pH 3-8. 
 
The modification on the amino group usually occurs using an acyl chloride or with a 
carboxylic acid using a carbodiimide as a coupling agent. It was noticed that the 
modification of the amino groups increases the nucleophilicity of the phenolic oxygen and 
leads to lactone formation (these rhodamine derivatives are non-fluorescent).  
A study by Reungpatthanaphong et al., (2003) showed that rhodamine B was well 
targeted specifically to the mitochondria. Reungpatthanaphong et al., 2003 studied the 
advantage of using rhodamine B as a probe to assist the mitochondria membrane 
potential (ΔΨm) in drug-resistant and drug-sensitive cells. They used this study to 
determine the spontaneous changes in mitochondria function. They found that the 
accumulation of rhodamine B inside the cell depended on the ΔΨm as a rhodamine is a 
lipophilic cation therefore, they suggest that rhodamine B is an appropriate probe for 




by Xie et al., (2013) used rhodamine B as a carrier group for the prodrug paclitaxel. As a 
result, the conjugation of rhodamine B with paclitaxel provided the chance to control the 
intracellular delivery of the prodrug and the possibility of realizing higher therapeutic 
efficacy by activating mitochondria related apoptosis. Xie et al., (2013) showed that the 
conjugation of rhodamine B with another prodrug 4FDT by a biodegradable linker, would 
decrease the cytotoxicity of the active drug and increase intracellular delivery to 
mitochondria and improve the conversion of the prodrug inside the mitochondria by 
specific proteases (Xie et al., 2013). 
Additionally, Longmire et al., 2008 studied the fluorescence of 4 rhodamine core based 
fluorescent dyes in vivo and in vitro in a mouse model of metastatic ovarian cancer Figure 
2.4. They conjugated the 4 rhodamine core with galactosamine serum albumin (GmSA) 
(clinically D-galactose receptor targeting reagent). They found that carboxyrhodamine 6G 
(CaRG) and carboxytetramethylrhodamine (TAMRA) are superior probes for in vivo 
optical imaging due to that at low pH, CaRG produce a high fluorescence intensity and 
increased in fluorescence intensity of fluorophore-targeting protein. However, at low pH, 
TAMRA produce a high fluorescence intensity and continuous fluorescence after 
internalization and the most notable advantage of using TAMRA is the maximum in vivo 






Figure 2.4: The structures of the four rhodamine core fluorophores 
 
      Protease activated prodrugs 
A prodrug is a chemically modified form of the pharmacologically active agent, rendering 
it inactive, that requires one or more enzymatic and chemical transformation in vivo to 
release the active drug. The aims of a prodrug are to improve water solubility, 
bioavailability, chemical stability and improve drug targeting and avoid unwanted and 
unspecific effects. Sometimes, a prodrug may contain two pharmacologically active 
agents that are coupled together and each drug acts as a promoiety for the other (Rautio 
et al., 2008). Once a prodrug has been activated by its specific target it will recover its 
activity.  
The overexpression of specific proteases such as legumain can be utilized for prodrug-
targeting resulting in the release of the active drug (Stern et al., 2009). The active form of 
drug is usually bonded to a biodegradable linker (peptide sequence, which is a substrate 
for the targeting protease) to control the translation of the prodrug into the active drug. It 




increases the availability of active drug at the site of action and decreases the cytotoxicity 
of the active drug (Xie et al., 2013). 
Legumain is active only at low pH (4-6) and it is inactive at physiological neutral pH, 
therefore, it can specifically catalyze prodrug activation in acidic tumour cells and in the 
acidic tumour microenvironment. Liu et al., (2011) and Wu et al., (2006) designed 
legumain-activated prodrugs by covalently linking a cell-impermeable succinyl blocked 
substrate peptide to the aminoglycoside of doxorubicin. This prodrug is inactive and 
nontoxic until activated by legumain in the acidic tumour microenvironment. The result in 
vivo showed markedly reduced toxicity and enhanced efficacy in compared with 
doxorubicin alone. Additionally, the pharmacokinetic indication supports the tumour 
microenvironment-activated prodrug approach (Wu et al., 2006; Liu et al., 2012).  
Following the discovery of overexpression of legumain in the tumour microenvironment 
and in tumour tissues when compared with normal tissue (Liu et al., 2003) and the 
discovery of its high cleavage specificity (Haugen et al., 2015), it was important to focus 
on the design of legumain substrates. Løvsletten and colleagues (2014), synthesized a 
legumain-cleavable prodrug by conjugating N-Boc-Ala-Ala-Asn-Val-OH with deacetyl 
colchicine to produce Suc-Ala-Ala-Asn-Val-colchicine Figure 2.5. They used different cell 
lines with different expressions and activities of legumain to study the specificity, efficacy 
and toxicity of the microtubule inhibitor colchicine and the legumain-cleavable colchicine 
prodrug. They found that the prodrug was more toxic to the colorectal cancer HCT116 
cells (expressing both the active legumain and prolegumain) than SW620 cells (only 
expressing the prolegumain). Also, the toxicity of the prodrug was higher in monoclonal 
legumain over-expressing HEK293 cells when compare with native HEK293 cells. This 
indicated the specificity of legumain to cleave the C-terminal of asparagine and the 
relationship between the activity of legumain in the cells and the toxicity of the prodrug 





Figure 2.5: Structure of Suc-Ala-Ala-Asn-Val-colchicine 
 
Chen and colleagues (2015), designed and synthesized a novel doxorubicin (Dox) 
prodrug, N-benzyloxycarbonyl-Ala-Ala-Asn-Doxorubicin (CBZ-AAN-Dox) by linking the 
tripeptide Ala-Ala-Asn with amino acylation of doxorubicin Figure 2.6. They reported that 
CBZ-AAN-Dox was specific for targeting tumor cells with reduced toxicity to normal cells 
and induced apoptosis on tumor cells upon the cleavage by legumain and released 
doxorubicin under hypoxic conditions. In addition, the IC50 of the prodrug in human 
cervical carcinoma cell line (SiHa) was much higher compared with doxorubicin alone 
(Chen et al., 2015).  
 




Furthermore, Mathur (2017) designed and synthesized the first legumain-based 
theranostic prodrug (diagnostic and therapeutic) ALS5 targeted to the overexpression of 
legumain in cancer cells. In ALS5, a Rho-Pro-Ala-Asn tripeptide was conjugated with a 
cytotoxic agent Propyl-Pip-Propyl-AQ(4-OH) (ALS1) via an amide bond Figure 2.7. The 
release of cytotoxic agent and rhodamine-based fluorophore tripeptide was studied in 
vitro upon the addition of recombinant human legumain, which showed an increase in 
relative fluorescence intensity with the time, which demonstrates that the prodrug ALS5 
was cleaved by legumain resulting in the release of fluorescent rhodamine B-tripeptide.   
Mathur et al., (2017) studied the cytotoxicity of prodrug AL5 and its legumain cleaved 
fragment ALS1 using MTT assay in PC-3 cell line. The IC50 value for prodrug ALS5 was 
41.15 ± 0.09 µM, and it is less potent than ALS1 which was 1.21 ± 0.12 µM (Mathur et 
al., 2017).  
 
Figure 2.7: Structure of ALS5 
 
Therefore, in this research programme, the dual properties of a diagnostic and therapeutic 
(theranostic) were designed to improve this concept of legumain-activated prodrug. The 
theranostic system was designed through the use of NU:UB 51 (an available experimental 
toxic drug with in vivo activity; a therapeutic), which also acts as a quencher (FRET-based 
pair) and by synthesis of tripeptide (Pro-Ala-Asn), which acts as a legumain substrate 
together with labelling with rhodamine B  (fluorophore) which acts as a donor and plays 
a role in the activation process as a reporter molecule (with future potential in the 




      NU:UB 51 (Gly-APA-AQ) 
NU:UB 51 is a bis-hydroxylated propyl-spaced glycine conjugate Figure 2.8. NU:UB 51 
belonging to the wide range of NU:UB compounds of spacer-linked anthraquinone-amino 
acid conjugates. These compounds were developed and synthesized within the 
Anticancer Drug Design and Delivery Research Group at Napier Edinburgh University as 
rationally designed topoisomerase inhibitors (Mincher, 1999). The majority of NU:UB 
compounds are amino substituted at the 1-position of the anthraquinone. The leader of 
these compounds showed a broad-spectrum activity in vitro at low micromolar 
concentrations and have also been shown to inhibit DNA topoisomerases I and II 
(Mincher et al., 1999; Pettersson, 2004).  
 
Figure 2.8: Chemical structure of NU:UB 51 
 
NU:UB 51 can act as an acceptor in the FRET process and as an active agent after the 
asparagine cleavage of the prodrug by legumain to give both rhodamine B and NU:UB 
51. After cleavage, the active agent NU:UB 51 (Mincher, 1999; Turnbull, 2003) will be 
released and it has the ability to inhibit both topoisomerase I and topoisomerase II. 
Topoisomerase I cut a single strand of double-stranded DNA to allow relaxation of the 
DNA for replication of the DNA and the single strand break is then religated, therefore 
restoring the DNA double strands (Teicher, 2008). While topoisomerase II cuts both 
strands of DNA (Zhang et al., 2001). Once NU:UB 51 is released, it inhibits topoisomerase 
IIα and II β mediated decatenation and relaxation of DNA and it inhibits topoisomerase I 




However, tumour cells have developed resistance to classical inhibitors of 
topoisomerase, therefore, the need to develop new inhibitors, such as NU:UB 51, which 
shows reduced resistance of tumour cells to this drug (Mincher, 1999; Turnbull, 2003). 
This novel anthraquinone shows notably different behaviour to other anthraquinones such 
as, mitoxantrone and doxorubicin. NU:UB 51 produces a tumour volume reduction and 
significant growth delay in a colon tumour model, whereas mitoxantrone and doxorubicin 
produce a simple growth delay with no reduction in tumour volume as shown in Figure 
2.9 (Mincher, 1999). 
 
 
Figure 2.9: Comparison of NU:UB 51, doxorubicin and mitoxantrone in vivo chemosensitivity 



























2.3 Results and discussion 
This chapter describes the design and synthesis of a novel theranostic prodrug Rho-Pro-
Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) Figure 2.10 by solution phase peptide 
synthesis and solid phase peptide synthesis. The following sections in this chapter 
describes the rational design, synthetic strategy, synthesis, purification and 
characterization of OM50 and its legumain-mediated cleavage products: Rho-Pro-Ala-
Asn-OH and Gly-APA-AQ(4,8-di-OH) (NU:UB 51). In vitro evaluation of the prodrug is 
then presented together with studies of incubation of OM50 with recombinant human 
legumain (rh-legumain), a fluorescence study and demonstration of the sub-cellular 
localization of the intact prodrug and NU:UB 51 using confocal microscopy.  
 
 Rational design  
The prodrug Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) (proposed theranostic) 
was designed and synthesized to exploit the proteolytic activity of legumain. The 
legumain-targeted prodrug OM50 employs a three component design which are a 
cytotoxic topoisomerase inhibitor (NU:UB 51) as the active agent and quencher, a 
tripeptide Pro-Ala-Asn (substrate sequence) and rhodamine B (fluorophore) Figure 2.10. 
Theranostics is a technology that combines therapeutic modalities with diagnostic 
imaging which in  turn can increase drug delivery kinetics, drug efficacy and local 
response (Bhuniya et al., 2014). Therefore, this technology allow to monitor the release 
of drug at the targeted site to study drug release kinetics, drug delivery and response 
location (Kim et al., 2014). Therefore, this technique was employed in the design of OM50 
in which rhodamine B was used to label the N-terminus of Pro-Ala-Asn (legumain 






Figure 2.10: General structure of Rhodamine labeled prodrug OM50 (a theranostic) 
 
In the design of theranostic prodrug Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50), 
the quencher aminoanthraquinone NU:UB 51 [Gly-APA-AQ(4,8-di-OH)] was selected as 
it is non-fluorescent and used as aqumcher, thus remove any fluorescence that may 
appear from the fluorophore rhodamine B. Also, it has the ability to quench a wide range 
of fluorophores due to the fact that aminoanthraquinone has a wide absorption region 
(λmax 550-700nm) (May et al., 2005). Kodama and colleagues (2006), designed a 
fluorescent probe consisting of a fluorophore (fluorescein; donor) and anthraquinone as 
a quencher. They found that the oligoDNA probes quenched the excitation of the 
fluorophore efficiently and the emission of the fluorophore (λmax 520nm) interfered with 
the absorption spectrum of  anthraquinone (λmax 520nm) (Kodama et al., 2006). Therefore, 
NU:UB 51 should quench the fluorescence generated by rhodamine B and can work as 
an energy acceptor.  
In addition, the selection of the amino acid residues at the N- and C- terminal is a key 
step toward the synthesis of OM50. Therefore, Asparagine (Asn) was used at position 
P1, due to the fact that asparagine is important for recognition and cleavage by legumain 




P3 to maintain constant fluorescence once cleaved by legumain because proline has a 
secondary amine, therefore the conjugation of proline with rhodamine B should lock the 
rhodamine B in a ring open form by linking it through a tertiary amide bond (Beija et al., 
2009; Choe et al., 2006). Therefore, to make the prodrug OM50 recognized and cleaved 
by legumain, it was critical to introduce asparagine (Asn) at position P1 to be recognized 
by legumain. Alanine (Ala) and Proline (Pro) were decided to be in positions P2 and P3 
respectively for the maximum fluorescence.  
Furthermore, Wu et al., (2006), used the amino acids Ala-Asn at positions P2 and P1 
respectively in their prodrug LEG-3 (N-succinyl-h-alanyl- L-alanyl-L-asparaginyl-L-leucyl-
doxorubicin), same as the positions of the amino acids P2 and P1 in the prodrug OM50. 
They revealed that the prodrug LEG-3 was cleaved by overexpressed legumain at the 
tumour site resulting in the release of Leu-doxorubicin (Wu et al., 2006). Stern et al., 
(2009) synthesized another prodrug targeted to the overexpression of legumain by linking 
the chemotherapeutic agent etoposide to legumain substrate CBZ-Ala-Ala-Asn-
ethylenediamine-etoposide. In their prodrug, the amino acids at positions P2 and P1 was 
Asn and Ala, which they also found that this prodrug was recognized and cleaved by 
legumain (Stern et al., 2009). These results from the literature encouraged us to e 
synthesized our prodrug Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) with the 
same amino acids sequences. Therefore, we hypothesized that the prodrug OM50 will be 
a substrate for legumain and has the prospect to exploit the proteolytic activity of 
overexpression of legumain at the tumour site.  
 
  Synthetic strategy 
 
2.3.2.1  NU:UB 51 quencher  
The first step is the synthesis of the anthraquinone spacer compound is the synthesis of 
APA-AQ (4,8-di-OH) NU:UB 59, which is an aminoanthraquinone derivative and prepared 
to use as rhodamine B fluorescence quencher. This compound will be prepared via 




and purification by column chromatography should afford the free base of NU:UB 59 
Figure 2.11. The next step was the synthesis of NU:UB 51, which acts as a cytotoxic 
agent and a quencher for rhodamine B fluorescence. The reaction of NU:UB 59 with Boc-
Gly-OH followed by removal of Boc2O group and purification, to afford the spacer-linked 
anthraquinone NU:UB 51.   
 
 
Figure 2.11: Schematic presentation of NU:UB 51 synthesis. 
 
 Peptide coupling  
The next step was the peptide sequence synthesis by both solution and solid phase 
peptide synthesis. Using commercially available, suitably protected amino acid 
derivatives and established peptide coupling and deprotection methods (Montalbetti and 
Falque, 2005). The legumain peptide substrate was built onto the free amino group of 
NU:UB 59 to give NH-Pro-Ala-Asn~Gly-SP-AQ. In the solution phase peptide method, 
the amino acids were completely protected except the reacting end of the amino acids. 
In order to react multiple amino acids to get the desired length of the peptide, the α-amino 
protecting group should be removed and then reacted with the next C-activated, N-
protected amino terminus. This process was continued until the desired length of the 
peptide is achieved. Finally, to afford the final peptide sequence, all protecting groups 






Figure 2.12: Solution phase peptide synthesis schematic representation 
 
In solid phase peptide synthesis (SPPS), the first amino acid in the peptide chain is added 
to a resin followed by continuous addition of other protected α-amino acid residues. Fmoc-
SPPS was used instead of Boc-SPPS because Fmoc is commercially available and 
release fluorene when deprotected which is an important indicator for the successful 
reaction (Sheppard, 2003; Behrendt et al., 2016). In addition, the removal of Boc2O group 
with TFA could cleave any other side chain protecting group or loss of the peptide from 
the resin (Behrendt et al., 2016).  
Herein, the side chain of Asparagine (Asn) was protected with triphenylmethyl (Trt) to 
avoid any possiple side reaction under chemical conditions used in the peptide coupling 




removed once this terminus ready for the final reaction. The carboxyl group of the amino 
acids was activated by using PyBOP, PyClock, HOBt and DIPEA. The removal of the 
Fmoc protecting group was performed by using 20% piperidine (v/v) in DMF (Carpino, 
1987). However, SPPS gives a low percentage yield compared with solution phase 
peptide synthesis, but SPPS method has been estimated to be fifty times easier than the 
solution phase peptide synthesis when preparing the same synthetic peptide (Kent, 2008) 









2.3.3.1 Fluorophore coupling  
Rhodamine B was chosen over other fluorophore dye due to its great photostability, has 
high quantum yield, has long excited wavelength and been used widely in the biological 
system study (Yang et al., 2002). Rhodamine B is inexpensive dye, widely used to label 
peptides and proteins, microscopy and cell imaging. Also, the structural changes of 
rhodamine Between open ring (fluorescent) and closed ring (non-fluorescent) according 
to the pH change and high extinction coefficient (Birtalan et al., 2011). These properties 
give rhodamine B priority to be used in this research over other fluorescent dye  
The final step in the solution phase peptide synthesis was attaching rhodamine B 
fluorophore to the free amino group of the tripeptide legumain substrate. Then, the trityl 
protecting group was removed from the side chain of asparagine (deprotection) to afford 
the target fluorescently labeled prodrug Figure 2.12. The ability of legumain to cleave at 
the C-terminal side of asparagine resulting in release of both fluorescence and the toxic 
drug. 
Additionally, in SPPS, rhodamine B was reacted with the free amino group of the resin 
bound tripeptide. Rho-Pro-Ala-Asn(Trt) was cleaved from the resin using 0.5% TFA in 
dichloromethanethen then, the C-terminus of (Asn) was reacted with the free amino group 
of NU:UB 51, to afford the final prodrug OM50 Figure 2.13. 
 
 Synthesis of legumain targeted theranostic prodrug 
Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50)  
Two different synthetic strategies were adopted towards the synthesis of the target 
prodrug OM50 Figure 2.14, in order to investigate which method would give the greater 
yield of final product and also take in consideration any potential solubility and purification 
problems that might be encountered. These two methods were; (1) solution phase peptide 
synthesis in which the linear peptide synthesis was carried out on the free amino group 
of NU:UB 51 using suitably protected amino acids and standard peptide coupling 




approach, Rho-Pro-Ala-Asn-(Trt) was synthesized on resin using standard phase peptide 
synthesis methods. The Rhodamine labeled tripeptide was cleaved from resin and 




Figure 2.14: Chemical structure of the target compound Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) 
(OM50) 
 
2.3.4.1 Synthesis of anthraquinone spacer compound APA-   AQ(4,8-di-OH) 
(NU:UB 59) 
The first step in the synthesis of the legumain substrate prodrug (OM50) involved 
preparation of APA-AQ (4,8-di-OH) (NU:UB 59) which is an aminoanthraquinone 
derivative, designed to serve as the quencher and starting point in the building of the 
legumain synthetic peptide sequence and the rhodamine B fluorophore.  
Leuco-5-hydroxyquinizarin was dissolved in dichloromethane and 1,3-diaminopropane 
was added and heated for 1.5 hours Figure 2.15. The reaction was monitored by TLC, 
which showed that a new purple spot had formed after adding a small spot of triethylamine 
with one drop of the reaction mixture to oxidize the product indicating that the reaction 
was complete. After that, the entire reaction mixture was oxidized using triethlyamine and 
aeration. The product was then isolated by chloroform and water solvent extraction to 




the product APA-AQ (4,8-di-OH) (NU:UB 59). NU:UB 59 was dried at room temperature 
and collected. 
 
Figure 2.15: Reaction of leuco-5-hydroxyquinizarin (1) with 1,3-diaminopropane. (a) 1,3-
diaminopropane, dichloromethane, 40ºC, triethylamine, O2, 1.5 h. 
 
2.3.4.2 Synthesis of Boc-Gly-APA-AQ(4,8-di-OH) (NU:UB 51-Boc) 
The synthesis of bis-hydroxylated propyl spaced glycine conjugate Gly-APA-AQ(4,8-di-
OH) NU:UB 51 is a key step in the design of the theranostic system because NU:UB 51 
can act both as a toxic drug to inhibit both topoisomerase I and II and act as the potential 
quencher (acceptor) of rhodamine  B (donor) fluorescence in the final target fluorogenic 
prodrug.   
Boc-Gly-OH was coupled to the anthraquinone spacer compound NU:UB 59  using 
PyBOP in DMF with DIPEA Figure 2.16. The reaction was monitored by TLC which 
showed the conversion of NU:UB 59 to NU:UB 51-Boc Once most of NU:UB 59 was 
converted to NU:UB 51-Boc the product was partially purified by solvent extraction, using 
sodium bicarbonate in one of the washes to remove any acidic impurities. The product 
was then purified by silica gel column chromatography and dichloromethane solvent was 
used initially. Then the solvent was changed to the more polar solvent dichloromethane: 
ethyl acetate (4:1) + 2% methanol to accelerate the elusion. Finally, the polarity of the 
solvent was increased through increasing the percentage of methanol to 6% to elute the 





Figure 2.16: Reaction of NU:UB 59 with Boc-Gly-OH. (a) Boc-Gly-OH, PyBOP, DIPEA, DMF, 1.5 h. 
 
2.3.4.3 Synthesis of Gly-APA-AQ(4,8-di-OH) (NU:UB 51) 
The removal of the Boc group was carried out by adding trifuoroacetic acid (TFA) at room 
temperature for 30 minutes and it was evaporated under vacuum and some ethanol was 
added to lower the boiling point of TFA Figure 2.17. Finally, diethyl ether was added to 
precipitate the product NU:UB 51 and it was filtered and collected. The purity of the 
product was confirmed by TLC after deprotection of NU:UB 51 by TFA and it was shown 







Figure 2.17: Reaction of NU:UB 51-Boc with TFA. (a) TFA, 30 min, room temperature 
 
 
 Synthesis of prodrug OM50, Rho-Pro-Ala-Asn-Gly- 
APA-AQ(4,8-di-OH), by solution phase peptide 
synthesis 
 
2.3.5.1 Synthesis of Fmoc-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM43) 
The synthesis of Fmoc-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM43) was an important step 




legumain is exclusively located at the C-terminus of this amino acid (Bajjuri et al., 2011). 
The incorporation of asparagine in peptide synthesis requires the use of N-terminal and 
side chain protection to avoid complications during peptide coupling reactions. 
Fmoc-Asn(Trt)-OH and coupling agents (PyBOP and HOBt)  were dissolved in DMF to 
activate Fmoc-Asn(Trt)-OH then DIPEA was added and  allowed to react for 15 minutes 
at room temperature. The activation takes place when PyBOP attaches to the carboxyl 
group of the asparagine, which is then replaced by the HOBt group. The asparagine was 
activated and it was added to NU:UB 51 pre-dissolved in DMF and allowed to react at 
room temperature for 1.5 hours Figure 2.18. The TLC was eluted using chloroform: 
methanol (4:1) to detect the end of reaction and formation of OM43. According to the TLC 
and in comparison with NU:UB 51 , a new spot had formed and moved higher than NU:UB 
51, this indicates the formation of OM43. The compound was partially purified by solvent 
extraction.  
Chloroform was used initially for silica gel column chromatography and later the solvent 
was changed to more polar solvent chloroform: methanol (4:1) and 5% methanol. The 
target compound was obtained after chromatography and the TLC was carried out on 






Figure 2.18: Reaction of NU:UB 51 with Fmoc-Asn(Trt)-OH. (a) Fmoc-Asn(Trt)-OH, PyBOP, HOBt, 
DIPEA, DMF, 1.5 h. 
 
In this reaction, the (Trt) group, was used to protect the alpha-amino group of asparagine. 
The trityl group (Trt), is very important because it prevented the dehydration of the primary 
amine to a nitrile group in the side chain of asparagine. Therefore, the trityl group was left 
attached to the asparaginyl residue, until no further reactions that could cause 
dehydration of this group. The trityl group is relatively stable when exposed to a range of 
deprotecting reagents, for this reason, Trt was preferred over other protecting groups 




loss of the primary amide in the side chain would result in a non-productive insertion into 
the active site S1 pocket of legumain and no further recognition would occur. 
Finally, the structure of the target compound OM43 was confirmed by high resolution 
electrospray (+) mass spectrum which clearly showed a signal at m/ z 948.3609 which 
corresponded to the expected molecular mass of the 947.3530 [M+H]+. Also, there was 
a good correlation between the observed data and the theoretical isotope model for 
C57H49N5O9 [M+H]+ Figure 2.19. Therefore, this result confirms the successful addition 
of Fmoc-Asn(Trt)-OH to NU:UB 51 and it was now possible to remove the Fmoc group 









2.3.5.2 Synthesis of H-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM44) 
The Fmoc group was removed from OM43 by dissolving it in piperidine (20% in DMF) 
and allowing it to react for 15 minutes Figure 2.20. Piperidine was chosen over other 
reagents because it takes few minutes at room temperature to remove the Fmoc group 
and piperidine has no effect on the trityl (Trt) group. In addition, the Fmoc group is very 
stable to acidic reagents, but under specific basic conditions, Fmoc group is cleaved 
easily (Fields, 1994).  
The reaction was monitored by TLC in chloroform: methanol (4:1) solvent system which 
shown that new spot has been formed indicating that Fmoc group has been removed 
from OM43 and OM44 [H-Asn(Trt)-Gly-APA-AQ(4,8-di-OH)] has been formed. The DMF 
was removed using chloroform/water extraction.  
 





OM44 was purified by silica gel chromatography column after the Fmoc group had been 
removed by using in the beginning chloroform to ensure that the more mobile Fmoc-
piperidine side product (pale yellow color) of the reaction was completely removed. After 
all the yellow color had been removed, the solvent system was changed to 4:1 chloroform: 
ethyl acetate and 10% methanol, since OM44 was more mobile in this ratio of mixed 
solvent. Finally, the TLC was checked for different fractions in 4:1 chlorofom: methanol 
system. 
As a result, the deprotection of asparagine would afford the free amino group and it is 
ready to be coupled with the next amino acid residue, alanine which would occupy the P2 
position of the substrate. 
 
2.3.5.3 Synthesis of Fmoc-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM45) 
The next step was the addition of the Fmoc-Ala-OH to the deprotected alpha amino group 
of the asparagine residue to complete the tripeptide sequence. Fmoc-Ala-OH was 
coupled to OM44 using PyBOP and HOBt in DMF with DIPEA Figure 2.21. The TLC was 
checked and after confirmation of a new spot, and most of OM44 converted to OM45 
[Fmoc-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH], the product was partially purified by solvent 
extraction. At this stage, silica gel chromatography column was not applied because the 
product was considered to be pure enough for further reaction. Therefore, the product 







Figure 2.21: Reaction of OM44 with Fmoc-Ala-OH. (a) Fmoc-Ala-OH, PyBOP, HOBt, DIPEA, DMF, 
1.5 h. 
 
2.3.5.4 Synthesis of H-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM46) 
The Fmoc group was removed from OM45 to give OM46 [H-Ala-Asn(Trt)-Gly-APA-
AQ(4,8-di-OH) ] and the TLC was checked in comparison with protected OM45 and it 
showed that the Fmoc group had been removed successfully. The product was partially 
purified by solvent extraction. The volume of solvents was reduced before purifying by 
silica gel column chromatography. Initially, chloroform was used to ensure that all the side 
product (Fmoc-piperidine) of the reaction was fully removed. Then, the solvent was turned 




this ratio. The fractions were checked by TLC using chloroform: methanol (4:1) solvent 
system. The product was then evaporated, and there was some DMF that was not 
evaporated by the rotary evaporator and did not mix with diethyl ether (two layers formed), 
therefore, some ethanol was added because it is able to mix with DMF and ether as well. 
Finally, the product was left in the fridge (4oC) to obtain a solid, which was filtered to afford 






Figure 2.22: Reaction of OM45 with piperidine (20% in DMF). (a) piperidine (20% in DMF), 15 min, 
room temperature. 
 
2.3.5.5 Synthesis of Fmoc-Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM47) 
Fmoc-Pro-OH was added to complete the tetrapeptide sequence and to occupy the 
position P3 of the protease substrate. In this step, PyClock was used as a coupling agent 
instead of PyBOP because PyClock has been reported to be faster than ByBOP in 




Fmoc-Pro-OH was coupled with OM46 pre-dissolved in DMF using PyClock in DMF with 





Figure 2.23: Reaction of OM46 with Fmoc-Pro-OH. (a) Fmoc-Pro-OH, PyClock, DIPEA, DMF, 1.5 h. 
 
2.3.5.6 Synthesis of H-Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM48) 
The Fmoc group was removed from OM47 using 20% piperidine in DMF Figure 2.24. 
TLC test was used to check the deprotection of OM47 by using 4:1 chloroform: methanol 




product was purified by silica gel column chromatography using dichloromethane at the 
beginning to ensure that all Fmoc-piperidine was completely removed and then, the 
solvent was turned to dichloromethane: ethyl acetate and 10% methanol until OM48 [H-
Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH)] has been removed from the column and the 
product was completely pure.  
Finally, the product was evaporated and diethyl ether was added to precipitate the product 
OM48. The product was then ready for the final step in the synthesis of the target 
compound which was the addition of rhodamine B. 
 
Figure 2.24: Reaction of OM47 with piperidine (20% in DMF). (a) piperidine (20% in DMF), 15 min, 
room temperature. 
 
2.3.5.7 Synthesis of Rho-Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM49) 
The final step in the synthesis of theranostic system was the addition of rhodamine B to 




target fluorogenic probe designed for activation by legumain (after removal of the Trt 
group). It is hypothesized that the fluorescence of rhodamine B will be quenched by the 
amino anthraquinone NU:UB 51. The preparation involved the activation of the 
fluorophore of the carboxylic acid group and reaction with N-terminal of proline.  
Rhodamine B was coupled to OM48 using PyClock in DMF with DIPEA Figure 2.25. The 
reaction was shown to be complete by using TLC, which showed a new purple product 
spot with pink spot (activated rhodamine B) close to the purple spot had formed in 4:1 
chloroform: methanol. The compound was partially purified using chloroform/water 
solvent extraction. Evaporation was performed before purified by silica gel column 
chromatography. The solvent was used in the purification was chloroform: ethyl acetate 
(4:1) and 5% methanol to ensure all rhodamine B had been removed. However, there 
was still some rhodamine B with the final product, indicating that the final product was not 
completely pure therefore, the silica gel column chromatography was performed again to 
remove all rhodamine B by using the same solvent.  
After the second run of column chromatography, most of the rhodamine B had been 
removed and the percentage of methanol was increased to 15% to make the product 
move faster and elute the product from the column. However, the percentage of methanol 
was increased again to 30% because the product was precipitating from solution in ethyl 
acetate, therefore, the silica was removed from the column and 100% methanol was 
added and left for 15 minutes. Filtration was performed to remove the product from the 
silica and the TLC was checked in 4:1 chloroform: methanol to ensure that the product 
was pure, but there was some rhodamine B. Therefore, the product was purified for the 
third time by using 9:1 chloroform: methanol solvent system. The purification was 







Figure 2.25: Reaction of OM48 with rhodamine B. (a) rhodamine B, PyClock, DIPEA, DMF, 1.5 h. 
 
2.3.5.8 Removal of the trityl (Trt) group 
After the product had been purified, the trityl (Trt) group was removed by exposing the 
product to TFA for longer time (more than 3 hours) in contrast to the removal of the Boc 
group which takes only few minutes (Isidro-Llobet et al., 2009). The end of the reaction 
was monitored by TLC using 4:1 chloroform: methanol solvent system and it was shown 
that a new lower spot was formed, this indicated that the reaction was complete and the 
trityl group had been removed successfully Figure 2.26. The product was purified by 
column chromatography using 9:1 choloroform: methanol solvent system and it was 




ether was added to aid in solidification. Filtration was performed on the resulting 
suspension and the solid was dried to afford OM50 [Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-
di-OH)] as a purple solid Figure 2.26.  
 
Figure 2.26: Reaction of OM49 with TFA. (a) TFA, ~ 3 h, room temperature. 
 
Finally, the structure of the target compound OM50 was confirmed by the high resolution 
electrospray (+) mass spectrum which clearly showed a signal at m/ z 1076.4855 which 




was a good correlation between the observed data and the theoretical isotope model for 




Figure 2.27: The mass spectrum for OM50 
 
 Synthesis of the target compound Rho-Pro-Ala-Asn-
Gly-APA-AQ(4,8-di-OH) (OM50) by solid phase peptide 
synthesis 
The fluorescent tripeptide sequence Rho-Pro-Ala-Asn(Trt)-OH was synthesized by solid 
phase peptide synthesis in addition to the solution phase peptide synthesis to compare 
the results from this process with the results from solution phase in order to determine  
the best synthesis method for the target compound OM50. Solid phase peptide synthesis 
is the process by which peptide synthesis can be carried out on solid support (Merrifield, 
1963). The main advantages of this process over other processes are all reagents can 




intermediates do not have to be isolated. By contrast, in solution phase peptide synthesis, 
all synthetic intermediates require isolation. The Fmoc-amino acids was used due to it is 
high quality Fmoc-building block, commercially available with minimum cost and the 
deprotection conditions is suitable with modified peptide in contrast with Boc2O protection 
which lack the differentiation in cleavage of Boc2O group and any other side chain 
protecting group (Behrendt et al., 2016).  In addition, the deprotection of Fmoc result in 
releases of fluorene which is a UV absorption properties, indicating the successful 
synthetic reaction (Sheppard, 2003). Fmoc-Pro-Ala-Asn(Trt)-OH was synthesized by five 
steps: (1) resin swelling (2) peptide coupling (3) color test to detect the presence or 
absence of free primary amino group (4) deprotection (removal of Fmoc group) (5) 
cleavage of Novasyn TGT. 
 
2.3.6.1 Resin swelling 
Fmoc-Asn(Trt)-Novasyn TGT resin was transferred to the SPPS vessel and 10ml 
dichloromethane was added and was shaken for 1 hour to maximize its surface for 
peptide coupling. Dichloromethane was drained off and the resin was washed 2 times by 
DMF. 
 
2.3.6.2 Deprotection of amino acid  
The Fmoc protecting group of the growing resin must be removed before the next amino 
acid can be attached. This process was achieved by adding 20% piperidine in DMF to the 
SPPS vessels and shaken for 10 mins (3 times). The reagents were drained off and the 
resin was washed by DMF for 3 times. This process was repeated after each coupling.  
 
2.3.6.3 Colour test 
This test was used to indicate the addition of new amino acid and after the removal of 




the presence of free amino group whereas, clear beads indicate that the amino group is 
protected by Fmoc group. 
HZ22 was added to a small number of resin beads and left for 15 minutes at room 
temperature and the beads were then washed with dichloromethane and filtered. After 
the beads were filtered, if red beads were observed there is a free amino group (after 




Figure 2.28: The mechanism of colour test 
 
2.3.6.4 Peptide coupling 
At this stage, an amide bond is formed between the free carboxylic acid group of the 
Fmoc-protected amino acid and the free amino terminus of the growing peptide on the 
resin. By using suitable coupling agents, under basic conditions, an active ester will be 
generated during the coupling reaction Figure 2.29. 
Fmoc-Ala was added to the SPPS vessel to couple with NH-Asn(Trt)-resin using PyClock 
and HOBt in DMF with DIPEA two times and shaken each time for 40 minutes. The 
reagents were drained and the resin was washed with DMF three times. The color test 
was performed to confirm the completion of peptide coupling which showed clear beads. 
Finally, the Fmoc group was removed by adding 20% piperidine in DMF to the resin, 
drained and repeated 2 times and the resin was washed with DMF 3 times. The color test 




After the removal of Fmoc group, the resin was ready for next coupling step which was 
the addition of Fmoc-Pro-OH. Fmoc-Pro-OH and coupling agents in DMF with DIPEA was 
added to the SPPS vessel and shaken for 40 minutes. Same amount of the amino acid 
and coupling reagents were added again to the vessel and shaken for another 40 minutes 
to ensure that the amino terminus of the resin was completely reacted with the Fmoc-Pro-
OH. The reagents were drained and the resin was washed with DMF (x3). At the end of 
the reaction, the color test was performed and it showed clear beads indicating that there 
was no free amino group. Finally, Fmoc group has been removed and another colour test 
was performed and it showed red resin beads, indicating that Fmoc group has been 
removed successfully and the compound is ready for the addition of rhodamine B. 
The free amino terminus of proline was ready to react with rhodamine B. Rhodamine B 
was coupled with tripeptide-resin using PyClock in DMF with DIPEA. The color of the 
resin was not completely pink, therefore, rhodamine B and coupling reagents were added 
again to get deep pink resin beads. The coupling reagents were drained and the resin 





Figure 2.29: The five steps of the solid phase peptide synthesis. 
 
2.3.6.5 Rho-Pro-Ala-Asn(TRT)-resin cleavage 
After tripeptide coupling, the Rho-Pro-Ala-Asn(Trt)-OH was removed from the resin for 
the conjugation with Gly-APA-AQ (NU:UB 51). Novasyn TGT is very sensitive to acid and 
hence the resin was cleaved by adding 0.5% of trifuloroacetic acid in 100 ml 
dichloromethane to the resin in small portions. However, triethylamine (base) was added 
with the same quantity of the TFA to neutralize the product and avoid the removal of Trityl 




The filtrates containing Rho-Pro-Ala-Asn(TRT)-OH were dried using a rotary evaporator 
and diethyl ether was added to aid in solidification along with a little 1,4-dioxane (to 
prevent two layers forming). Then, diethyl ether was added again and the product was 
left in the fridge to get more solid. During the filtration, more ether was added because 
the product was very sticky. The product was collected after filtration and drying Figure 
2.30. 
 
Figure 2.30: The chemical structure of the Rho-Pro-Ala-Asn(TRT)-OH 
 
Finally, the structure of the target compound Rho-Pro-Ala-Asn(Trt)-OH was confirmed by 
the high resolution electrospray (+) mass spectrum which clearly showed a signal at m/ z 
967.4752 which corresponded to the expected molecular mass of the 967.4753 Da cation 
(+). Also, there was a good correlation between the observed data and the theoretical 
isotope model for C59H63N6O7 cation (+) Figure 2.31. Therefore, this result confirmed the 
successful addition of rhodamine B to the tripeptide and it was ready to react with Gly-






Figure 2.31: Mass spectrum for Rho-Pro-Ala-Asn(Trt)-OH 
 
2.3.6.6 Reaction of Rho-Pro-Ala-Asn(Trt)-OH with Gly-APA-AQ(4,8-di-OH) 
[NU:UB 51] to give OM49 
Rho-Pro-Ala-Asn(Trt)-OH was reacted with NU:UB 51 [Gly-APA-AQ(4,8-di-OH)] using 
HATU as a coupling agent with DIPEA. The product was then isolated from DMF using 
chloroform/water extraction. The reaction was monitored by TLC which showed purple 
spot with some close running rhodamine B derived impurities. Silica gel column 
chromatography was performed to purify OM49 and remove rhodamine with several 
attempts and using different solvents system. Firstly, 4:1 chloroform: ethyl acetate + 5% 
methanol solvent system was used. TLC was achieved for different fractions which 
showed that OM49 was not completely pure and there was some rhodamine B. Secondly, 
9:1 chloroform: methanol was used and the result was better and there was less 
rhodamine B but OM49 was still contaminated by fluorescence. Finally, the product was 
subjected to column chromatography for a third purification using 4:1 chloroform: ethyl 




purification, there was less rhodamine B derived fluorescence but the product was still 
fluorescent and not completely quenched.  
After the attempted purification, the trityl group (Trt) was removed by adding trifluoroacetic 
acid (TFA) to OM49 and it was left overnight. The TLC showed that Trt had been removed 
successfully from OM49. Finally, the product was purified by repeated column 
chromatography using 9:1 chloroform: methanol solvent system. However, OM50 was 
still contaminated by background fluorescence after several purification attempts and the 
reason for this fluorescence is still unknown.  
Finally, the structure of the target compound OM50 from the solid phase peptide was 
confirmed by the high-resolution electrospray (+) mass spectrum which clearly showed a 
signal at m/ z 1076.4868 which corresponded to the expected molecular mass of 
1076.4876 Da for cation (+). Also, there was a good correlation between the observed 
data and the theoretical isotope model for C59H66N9O11 cation (+) Figure 2.32. Therefore, 
this result confirms the successful synthesis of OM50 by solid phase. However, the 
presence of the major peak in the spectrum at m/z 810.4183 confirmed that the product 
was not pure and as yet the structure of the rhodamine derived fluorescent impurities not 
known as shown in Figure 2.32. 
 





 FRET and legumain studies 
After the structure and purity of OM50 was confirmed by mass spectrometry, the following 
experiment was carried out to detect that Gly-APA-AQ(4,8-di-OH) (NU:UB 51) was 
quenching the rhodamine B fluorophore. FRET is a distance dependent -transfer of 
energy from a rhodamine B (the donor), which is in an excited state, to an acceptor 
molecule NU:UB 51 by nonradiative dipol-dipole interaction (Taya et al., 2018). Legumain 
assay buffer (50 mM MES hydrate, 250 mM NACl, pH 5.0) was used in all absorbance 
and emission assays and ensured that all absorbance and emission assays were carried 
out at the same pH (pH 5) because this process could be pH sensitive. 
 
2.3.7.1 UV-Visible absorption assays 
2.3.7.2 Rhodamine B-Pro-Ala-Asn-OH and NU:UB 51 
The maximum absorbance wavelength of Rho-Pro-Ala-Asn-OH was measured as it is the 
same compound that would be released upon cleavage of OM50 by legumain.  Figure 











































































































blank NU:UB 51 Rho-Pro-Ala-Asn-OH
Figure 2.33: UV-Vis absorption assay of Rho B-Pro-Ala-Asn-OH and NU:UB 51. Concentration: 20 
µM of NU:UB 51 and 5 µM of rho B-Pro-Ala-Asn- in legumain assay buffer (50 mM MES hydrate, 





The maximum absorbance wavelength of the fluorophore was determined at 562 nm and 
then this was used as the excitation wavelength for the following fluorescence 
spectroscopy assays. Additionally, as the efficiency of the FRET was dependent on the 
overlap between the emission of the fluorophore (rhodamine B) and the absorbance of 
the acceptor NU:UB 51, it was important to characterize the absorbance of NU:UB 51. 
The maximum absorbance wavelength for NU:UB 51 was at 569 nm. 
2.3.7.3 Fluorescence spectroscopy assays  
The emission of Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) has been established 
by fluorescence assay to ensure that  completely quenches the emission of Rho-Pro-Ala-
Asn-OH when excited at the maximum wavelength 562 nm, due to the overlap of the 
absorbance of NU:UB 51 with the emission of the rhodamine B. The emission range of 
Rho-Pro-Ala-Asn-OH was determined when excited at a wavelength of 562 nm and is 





Figure 2.34: Fluorescence intensity spectrum of Rho-Pro-Ala-Asn-OH. Concentration: 0.5 µM in 
legumain assay buffer (50 mM MES hydrate, 250 mM NACl, pH 5.0). Excitation wavelength: 562 
nm. Red arrow: maximum fluorescence intensity at 583 nm. 
Rho-Pro-Ala-Asn-OH gave a strong fluorescence emission which reached a maximum at 
583 nm as shown in Figure 2.34 (indicated by red arrow). This value was the wavelength 
at which fluorescence would be expected to increase with the incubation of OM50 with 
legumain following cleavage of OM50 by legumain. 
However, to determine whether or not there was a significant fluorescence emission by 
OM50 when compared with free fluorophore, the assay was carried out at a concentration 
of 0.5µM of OM50. The result indicates that OM50 emitted almost no fluorescence, as 
shown by a relative fluorescence intensity value of 3 (red line) when compared with the 



































Figure 2.35: Fluorescence emission spectrum of OM50 (red line) compared with Rho-Pro-Ala-Asn-
OH (blue line). Concentration 0.5µM each in legumain assay buffer. Excitation wavelength: 562 nm 
 
As a result, it was concluded that rhodamine B fluorophore is completely quenched by 
and OM50 has an extremely low emission level which once cleaved by legumain would 
release a rhodamine B labelled tripeptide (fluorescence compound) with maximum 
fluorescence emission at 583 nm, permitting the detection and localization of the activated 
protease (in vivo) and the concurrently released NU:UB 51, which would exert its 
therapeutic effects (in vivo).  
 
2.3.7.4 Incubation of OM50 with legumain 
Human recombinant legumain at 37oC in legumain assay buffer (50 mM MES hydrate, 
250 mM NACl, pH 5.0) was used to investigate the quenching of the fluorogenic prodrug 
(OM50) and restoration of rhodamine B fluorescence upon incubation with legumain.  The 
aim of this study was to indicate whether OM50 is a substrate for legumain or not. The 
ability of legumain to cleave at the C-terminal of asparagine will result in release of both 






Figure 2.36: The cleavage site of legumain at the C-terminal of asparagine 
 
The legumain was activated by incubation in activation buffer for 2 hours at 37oC and 
then it was diluted with legumain assay buffer (pH5). The fluorescence test was set for 2 
hours at 37oC to detect how much fluorescence was released over time. Figure 2.37 
shows the fluorescence emission spectra of the incubation of OM50 with activated 
legumain for 2 hours. The fluorescence emission increased gradually over the first 65 
minutes and then there was no further increase in fluorescence after 65 minutes which 
indicates that no more cleavage of OM50 was taking place. The results indicates that the 
fluorescence emission increased gradually over the first 65 minutes and then there was 
no further increase in fluorescence after 65 minutes which indicates that no more 





Figure 2.37: Cleavage of Prodrug OM50 by recombinant human legumain.  Variation in RFI 
(Relative Fluorescence Intensity) with time for OM50 [Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH)] 
upon incubation with legumain (40 ng) in legumain assay buffer (50 mM MES hydrate, 250 mM 
NACl, pH 5.0), 2 h. 
 
Fluorescence intensity increased with the time verifying that cleavage of OM50 was taking 
place by legumain. The relative fluorescence as shown in Figure 2.37 increased from 
~300 (RFI) at 0 hours to ~1569 at 65 minutes resulting in a 5-fold increase in fluorescence.  
 
 Cellular uptake and localization 
Confocal live cell imaging using a confocal microscope was performed to study the 
cellular uptake and localization of the prodrug Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) 
(OM50) and active agent Gly-APA-AQ(4,8-di-OH) (NU:UB 51) in live colon carcinoma 
cells (HCT-116) in the presence of MitoTracker green FM (fluorescent dye for 
mitochondrial staining) and LysoTracker green DND26 (fluorescent dye for lysosome 
staining). Figure 2.38 shows the cellular uptake of NU:UB 51 after 90 minutes of live cell 



































lysosomes. NU:UB 51 showed a clear staining HCT-116 cell line (panel A) and a clear 
yellow dots (panel C), which is the merge image for panel A (NU:UB 51) and B 
(MitoTracker Green FM and LysoTracker green DND26), confirming the colocalization of 




Figure 2.38: Localization of NU:UB 51 in HCT-116 cell.  NU:UB 51(5 µM) localized to the 
mitochondria and lysosome within 90 min as measured by live cell imaging. The localisation of 
NU:UB 51 in mitochondria shown in (i) (A) NU:UB 51 stained with(B) MitoTracker Green FM and (c) 
merged image. The localisation of NU:UB 51 in lysosomes shown in (ii) (A) NU:UB 51 stained with 
(B) LysoTracker Green DND26 and (c) merged image. Images were captured at 63 x magnification. 
 
However, Figure 2.39 shows that the prodrug OM50 was not taken up by the cells and 
localized outside the cells after 90 min of live cell imaging. There was no localization of 
the OM50 within the mitochondria or lysosome. OM50 showed a clear staining HCT-116 
cell line (panel A) and a clear red dots (panel C), which is the merge image for panel A 
(OM50) and B (LysoTracker green DND26), confirming that OM50 was not taken up by 
mitochondria or lysosome, indicating that OM50 localized extracellularly. In tumours, it 




surface of tumour cells (Guo et al., 2013; Haugen et al., 2015). Liu et al., 2012, design 
and synthesized a legumain prodrug αvβ3 inhibitor-NHAla-Ala-Asn-PABC-
monomethylauristatin E (MMAE), which is upon the cleavage by legumain, MMAE bound 
to cell surface glycoprotein integrin αvβ3 and induce cell death. They found that the 
prodrug was cleaved and activated by legumain on the cell surface and MMAE efficiency 
induced death of MDA-MB-435 human breast cancer (Liu et al., 2012).  Therefore, the 
overexpression of legumain extracellularly or on the cell surface would cleave the prodrug 
OM50 resulting in the release of cytotoxic NU:UB 51, which in turn could enter the cell 





Figure 2.39: live cell imaging of OM50 in HCT-116 cell lines stained with LysoTracker Green 
DND26. The colocalization of OM50 with LysoTracker Green shows the localization of OM50 (1 µM) 
outside the cell with no localization in the mitochondria and lysosome within 90 min as measured 
by live cell imaging. (A) OM50, (B) LysoTracker Green DND26 and (C) merged image. Images were 











The over expression of legumain in different types of cells, such as breast, colon and 
prostate cancers was used as a promising target for tumour activated prodrugs. The aim 
was to increase the drug selectivity and decrease the toxicity to the normal cells. The 
anthraquinone derivative Gly-APA-AQ(4,8-di-OH) (NU:UB 51) was used as the potent 
cytotoxic active agent and conjugated with legumain peptide substrate. The rhodamine B 
fluorophore was attached to the free amino group of the tripeptide legumain substrate 
(Pro-Ala-Asn) and the trityl protecting group was removed from the side chain of 
asparagine to afford the target fluorescently labeled prodrug Rho-Pro-Ala-Asn-Gly-APA-
AQ(4,8-di-OH) (OM50). 
In this project, two different synthetic strategies were adopted for the synthesis of the final 
target prodrug (OM50). The first route of synthesis of the target legumain substrate OM50 
was solution phase peptide synthesis. A bis-hydroxylated propyl spaced glycine 
conjugate NU:UB 51 was first synthesized and the tripeptide was built on to the free amino 
group of glycine. The final step of the synthesis was the conjugation of rhodamine B with 
the free amino group of tripeptide. A good yield of OM50 was achieved (0.04 g) by solution 
phase synthesis and the prodrug was purified by column chromatography. The synthesis 
of the target compound OM50 was successful and the structure of the purified product 
was confirmed by mass spectrometry. 
In a second approach, solid phase peptide synthesis was also considered. The tripeptide 
H2N-Pro-Ala-Asn(Trt)-OH was synthesized by SPPS. Rhodamine B was then reacted 
with the free amino group of the tripeptide, whilst still on resin. The rhodamine labelled 
tripeptide was cleaved from the resin and reacted with NU:UB 51. The synthesis of the 
target compound OM50 was successful and the structure of OM50 was confirmed by 
mass spectrometry. However, the purification of the target product from this method was 
difficult and unsuccessful and there was an unknown (highly fluorescent) impurity with the 
main compound which should be identified in a future study. Therefore, according to the 
results from both solid phase and solution phase methods, it was better to synthesise the 




The protection of the side chain of the asparagine, which should insert into the active site 
S1 pocket of legumain, was successful with no complications or byproducts such as the 
dehydration of the primary amide to a nitrile group. Therefore, the trityl group was the best 
choice as a protecting group of the asparagine side chain which was stable enough to 
withstand the coupling conditions and the action of the deprotecting agents such as 
piperidine, used for the removal of the Fmoc group. Mass spectrometry and TLC 
confirmed a very pure product and no evidence was found for byproducts from 
dehydration reaction of the asparagine side chain. In addition, the choice of protecting 
groups Fmoc and Boc group over other protecting groups was a good choice because 
the easier removal of these groups and easier chromatography due to their greater 
solubility over other groups. 
The UV-visible absorption and fluorescence spectroscopy assays confirmed that the 
chromophore NU:UB 51 quenches fluorescence emitted by the rhodamine B. The overlap 
of the acceptor’s (NU:UB 51) UV-visible absorption with the fluorescence emission 
spectrum of the rhodamine B was complete and the rationale design was valid and 
effective. Upon incubation of OM50 with recombinant human legumain there was an 
increase in fluorescence with time at an emission wavelength of 562 nm. This result gave 
a clear indication that OM50 was a good substrate for legumain because it clearly shows 
an increase in the fluorescence intensity upon incubation with recombinant human 
legumain with increasing time.  
In addition, in this study, although rhodamine B was used as a carrier to aid cell 
permeability and subcellular localisation, herein, the confocal study showed that NU:UB 
51 was not taken up at all into cells.. Also, the confocal studies showed clear localization 
of NU:UB 51 in both mitochondria and lysosomes. Therefore, cleavage of OM50 outside 
the cell by overexpressed legumain would result in release of the cytotoxic agent NU:UB 
51, which could then enter the cell and localise in lysosomes or mitochondria which in 
turn, potentially causing lysosomal disruption or  inhibition of both mitochondrial 



































 Synthesis of legumain targeted theranostic prodrug 
Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50)  
 
2.4.1.1 Synthesis of anthraquinone spacer compound APA-AQ(4,8-di-OH) 
(NU:UB 59) 
Leuco-1,4,5-trihydroxyanthraquinone (leuco-5-hydroxyquinizarin) (1 g, 3.87 mmol) was 
dissolved in CH2Cl2 (50 mL) and 1,3-diaminopropane (1 mL, 11.6 mmol) was added and 
heated at 40OC for 1.5 h. The product was then oxidized by aeration with the addition of 
triethylamine (Et3N, 0.5 mL). The product NU:UB 59 (Rf 0.43) was then isolated by 
chloroform/water solvent extraction [general method A] and the organic extracts were left 
overnight to dry. Yield 30%, 0.5 g. The crude product was then used for further reaction 
without further purification. 
TLC of the crude mixture (chloroform: methanol, 4:1): Rf 0.77 (green), 0.43 (purple) 
NU:UB 59, 0.90 (orange) 5-hydroxyquinizarin. 
 
2.4.1.2 Synthesis of Boc-Gly-APA-AQ(4,8-di-OH) (NU:UB 51-Boc) 
Boc-Gly-OH (0.42 g, 2.4 mmol) and PyBOP (1.248 g, 2.4 mmol) were dissolved in DMF 
(10 mL) and DIPEA (0.834 mL, 4.8 mmol) was added and allowed to react at rt for 15 
min. The coupling agent and amino acid were then added to NU:UB 59 (0.5 g, 1.6 mmol) 
in DMF (5 mL) and allowed to react for 1.5 h. The product NU:UB 51-Boc was isolated 
from DMF using chloroform/water solvent extraction [general method A]. NU:UB 51-Boc 
was washed with sodium bicarbonate to remove any acidic impurities and it was dried 
using sodium sulphate anhydrous. The product was then filtered and applied to a silica 
gel chromatography column using neat CH2Cl2 at the beginning and then the polarity of 




containing OM41 were filtered and evaporated to dryness. The crude product was then 
used for further reaction without solidification. 
TLC of NU:UB 51-Boc (chloroform: methanol, 4:1): Rf 0.53 (purple) NU:UB 51-Boc. 
 
2.4.1.3 Synthesis of Gly-APA-AQ(4,8-di-OH) [(NU:UB 51) 
The Boc-protected compound (OM41) was dissolved in trifluoroacetic acid (TFA) (5 mL) 
for 45 min. The solvent was evaporated and addition of diethyl ether (50 mL) gave a 
precipitate of NU:UB 51, which was filtered off and dried. Yield 45%, 0.25 g.  
TLC of NU:UB 51 (chloroform: methanol, 4:1) Rf 0.08 (purple) NU:UB 51. 
 
 Synthesis of Synthesis of prodrug OM50, Rho-Pro-Ala-
Asn-Gly-APA-AQ(4,8-di-OH), by solution phase 
peptide synthesis 
 
2.4.2.1 Synthesis of Fmoc-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM43) 
Fmoc-Asn(Trt)-OH (0.37 g, 0.62 mmol), PyBOP (0.312 g, 0.6 mmol) and HOBt (0.081 g, 
0.6 mol) were dissolved in DMF (10 mL) and DIPEA (0.398 mL, 2.3 mmol) was added 
and allowed to react for 15 min then added to NU:UB 51 (0.25 g, 0.5 mmol) in DMF (5 
mL) and was left at rt to react for 1.5 h. The product was separated from DMF using 
chloroform/water solvent extraction [general method A]. OM43 was applied to a silica gel 
chromatography column using neat chloroform initially and then more polar solvent 
chloroform: ethyl acetate + 5% methanol was used. OM43 was filtered and evaporated to 
dryness. The crude product was then used for further reaction without solidification. 
TLC of OM43 (chloroform: methanol, 4:1) Rf 0.6 (purple) OM43, 0.11 (blue) NU:UB 51  





2.4.2.2 Synthesis of Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM44) 
Piperidine in DMF (20% v/v) (10 ml) was added to OM43 to remove Fmoc group and 
allowed to react for 15 min. The reaction mixture was isolated using chloroform/water 
solvent extraction [general method A] and it was purified by silica gel column 
chromatography using neat chloroform to ensure that all Fmoc-piperidine was completely 
removed. The solvent was then changed to more polar solvent 4:1 chloroform: methanol 
+ 10% methanol. OM44 was filtered and dried under vacuum and ether was added to aid 
in solidification of OM44. Yield 54%, 0.20 g.  
TLC of OM44 (chloroform: methanol, 4:1) Rf 0.14 (purple) OM44. 
 
2.4.2.3 Synthesis of Fmoc-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM45) 
Fmoc-Ala-OH (0.15 g, 0.4 mmol), PyBOP (0.25 g, 0.4 mmol) and HOBt (0.067 g, 0.4 
mmol) was dissolved in DMF (10 mL) and DIPEA (0.211 mL, 1.5 mmol) was added. After 
15 min, Fmoc-Ala-OH and coupling agents was added to OM44 (0.20 g, 0.2 mmol) in 
DMF (5 mL) and allowed to react at rt for 1.5 h. OM45 was isolated using chloroform/water 
solvent extraction [general method A]. OM45 was filtered and the solvent was evaporated 
under vacuum. The crude product was then used for further reaction without solidification. 
 TLC of OM45 (chloroform: methanol, 4:1) Rf 0.48 (purple) OM45 
 
2.4.2.4 Synthesis of Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM46) 
Fmoc group was removed from OM45 by adding 20% piperidine in DMF (10 mL) and 
allowed to react for 15 min. OM46 was isolated with chloroform/water solvent extraction 
[general method A]. OM46 was filtered and concentrated to low volume before applied to 
silica gel column chromatography using neat chloroform initially and then 4:1 chloroform: 
methanol +10% methanol was used. After that, the solvents were filtered and evaporated 
to dryness. OM46 was precipitated by adding ether and the product was filtered and 




TLC of OM46 (chloroform: methanol, 4:1) Rf 0.15 (purple) OM46 
 
2.4.2.5 Synthesis of Fmoc-Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM47) 
Fmoc-Pro-OH (0.119 g, 0.3518 mmol) and PyClock (0.195 g, 0.3518 mmol) were 
dissolved in DMF (10 mL) and DIPEA (0.183 mL, 1.05 mmol) was added and allowed to 
react for 15 min at rt then added to OM46 (0.19 g, 0.234 mmol) in DMF (5 mL) and allowed 
to react for 1.5 h at rt. The reaction mixture was isolated from DMF using chloroform/water 
extraction [general method A]. The solvent was then evaporated under vacuum. The 
crude product was then used for further reaction without solidification. 
TLC of OM47 (chloroform: methanol, 4:1) Rf 0.53 (purple) OM47. 
 
2.4.2.6 Synthesis of Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM48) 
Piperidine in DMF (20% v/v) (10 mL) was added to remove Fmoc group and allowed to 
react for 15 min. The product was then isolated using chloroform/water solvent extraction 
[general method A] and it was purified by column chromatography using firstly neat 
CH2Cl2 to ensure that all Fmoc-piperidine was completely removed. After that, the solvent 
was changed to more polar solvent 4:1 CH2Cl2: ethyl acetate + 10% methanol. OM48 was 
then filtered and dried under vacuum and dietyl ether was added to aid in solidification. 
Yield 66%, 0.14 g. 
TLC of OM48 (chloroform: methanol, 9:1) Rf 0.17 (purple) OM48. 
 
2.4.2.7 Synthesis of Rho-Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM49) 
Rhodamine B (0.070 g, 0.14 mmol), PyClock (0.111 g, 0.2 mmol) were dissolved in DMF 
(10 mL) and DIPEA (0.088 mL, 0.508 mmol) was added and allowed to react for 15 min 
then added to OM48 (0.14 g, 0.15 mmol) in DMF (5 mL) and allowed to react for 1 h. The 
reaction mixture was separated from DMF using chloroform/water extraction [general 




gel column chromatography using 4:1 chloroform: ethyl acetate + 5% methanol. For the 
second column chromatography purification, 4:1 chloroform: ethyl acetate +5% methanol. 
However, the percentage of methanol was increased to 15% after all pink color 
(rhodamine B) has been removed. For third column chromatography purification, 9:1 
chloroform: methanol was used. The solvents were evaporated under vacuum. The crude 
product was then used for further reaction without solidification. 
TLC of OM49 (chloroform: methanol, 9:1) Rf 0.33 (purple) OM49.   
 
2.4.2.8 Synthesis of Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) 
Trifluoroacetic acid (TFA) (5 mL) was added to OM49 and allowed to react overnight at rt 
to remove Trityl group.  After that, the product was purified by silica gel column 
chromatography using 9:1 chloroform: methanol solvent system. The solvents were 
evaporated under vacuum and ether was added to precipitate OM50. The solid OM50 
was then filtered and collected. Yield 25%, 0.04 g.   
TLC of OM50 (chloroform: methanol 6:1) Rf 0.33 (purple) OM50. 
HRMS (ESI) (+) m/z: 1076.4855 (100%). Calculated for [C59H63N6O7]+ 1077.23; Found 
1076.4855 (M+H)+.  
 
 Synthesis of the target compound Rho-Pro-Ala-Asn-
Gly-APA-AQ(4,8-di-OH) (OM50) by solid phase peptide 
synthesis 
 
2.4.3.1 Resin swelling 
Fmoc-Asn(Trt)-Novasyn TGT (1 g, 0.3 mmol/g) was transferred to a solid phase peptide 
synthesis vessel, d CH2Cl2 (10 mL/g of resin) was added and was shaken for 1 h. CH2Cl2 




2.4.3.2 Fmoc deprotection  
Piperidine in DMF (20% v/v) (~10 mL/g of resin) was added to the resin and shaken for 
10 min each time (x2). The resin was washed with DMF three times. The successful 
removal of Fmoc group was indicated by red resin beads in colour test.  
 
2.4.3.3 Colour test 
A small number of resin beads were transferred to a small sample vial. Few drops of 
HZ22 (in DMF) was added to the resin and allowed the mixture to react at rt for 15 min. 
A few drops of CH2Cl2 were added to dilute the mixture. The mixture was then filtered 
using Whatman No. 1 filter paper and red beads were observed if there is a free amino 
group (after Fmoc deprotection) and clear beads if the amino group was protected by the 
Fmoc group.   
 
2.4.3.4 Peptide coupling and Fmoc deprotection addition of alanine residue 
Fmoc-Ala-OH (0.186 g, 0.6 mmol), PyClock (0.315 g, 0.57 mmol), HOBt (0.071 g, 0.57 
mmol) and DIPEA (0.312 mL, 1.8 mmol) were dissolved in DMF (10 mL). The solution 
was transferred to the SPPS vessel and shaken for 50 min. After 50 min, the solution was 
drained off and additional coupling agents and Fmoc-Ala-OH were added and shaken for 
another 50 min. The solution was drained off and was washed with DMF (3x5 mL). A 
positive color test was achieved (red beads). The Fmoc-Ala-Asn(Trt)-resin was then 
deprotected by adding 20% piperidine in DMF (10 mL) and ready for the coupling of next 
amino acid.  
 
2.4.3.5 Peptide coupling and Fmoc deprotection: addition of proline residue  
Fmoc-Pro-OH (0.2022 g, 0.6 mmol) was coupled to the Ala-Asn(Trt)-resin by the same 




2.4.3.6 Synthesis of Rho-Pro-Ala-Asn(Trt)-resin 
Rhodamine B (0.215 g, 0.448 mmol) and PyClock (0.249 g, 0.449 mmol) were dissolved 
in DMF (10 mL) and DIPEA (0.156 mL, 0.897 mmol) was added and then the solution 
was transferred to the SPPS vessel and shaken for 1 h. After 1 h, the solution was drained 
off and the same quantity of rhodamine B, PyClock and DIPEA were added and shaken 
for another 1 h. After that, the solution was drained off and the resin was washed 3 times 
with DMF and several times with CH2Cl2.  
 
2.4.3.7 Rho-Pro-Ala-Asn(Trt)-resin cleavage 
A 0.5% trifluoroacetic acid in 100 mL CH2Cl2 solution was prepared and 10 mL of the 
solution was added to the vessel, shaken and drained quickly to avoid the removal of 
Trityl group. This process was repeated until no pink color was coming out from the 
vessel. Triethylamine (base) was added to make the filtrates neutral. The filtrates were 
transferred into a round bottomed flask and evaporated to dryness under vacuum. Diethyl 
ether was added to precipitate the product, however, as the solvent does mix with diethyl 
ether therefore, 1,4-dioxane was added and then ether was added and it was left 
overnight at 4OC to precipitate the product. The product was then dried and collected. 
Yield 0.19 g.  
HRMS (ESI) (+) m/z: 967.4752 (55%). Calculated for [C59H63N6O7]+ 967.4753; Found 
967.4752 cation (+).  
 
2.4.3.8 Synthesis of Rho-Pro-Ala-Asn(Trt)-Gly-APA-AQ(4,8-di-OH) (OM49) 
Rho-Pro-Ala-Asn(Trt)-OH (0.156 g, 0.14 mmol) and HATU (0.053 g, 0.13 mmol) was 
dissolved in DMF (10 mL) and DIPEA (0.0754 mL, 0.43 mmol) was added and allowed to 
react at rt for 15 min. The solution was then added to NU:UB 51 (0.07 g, 0.145 mmol) in 
DMF (5mL) and allowed to react for 1 h. After 1 h, the product was isolated from DMF 
using chloroform/water solvent extraction [general method A]. The attempted purification 




ethyl acetate, 9:1 chloroform: methanol and 4:1 chloroform: ethyl acetate + 5% methanol 
Sequentially.  
TLC of OM49 (chloroform: methanol, 9:1) Rf 0.53 (purple) OM49, 0.46 (pink) Rho-Pro-
Ala-Asn(Trt)-OH 
 
2.4.3.9 Synthesis of Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) 
Trifluoroacetic acid (5 mL) was added to OM49 and it was left overnight at rt to remove 
Trityl group.  After that, the product was purified by silica gel column chromatography 
using 9:1 chloroform: methanol solvent system. The solvents were evaporated and ether 
was added to aid in solidification. The solid OM50 was then filtered and collected. The 
compound was dissolved in ethanol (100 L) and applied to a thick layer chromatography 
plate (20cm×20cm×0.1cm) and the plate was developed using chloroform: methanol, 4:1 
as the running solvent. The purple band was scraped from the plate and the product 
extracted into methanol, filtered, evaporated and dried.  
TLC of OM50 (chloroform: methanol, 9:1) Rf 0.24 (purple) OM50.  
HRMS (ESI) (+) m/z: 1076.4868 (87%). Calculated for [C59H66N9O11]+ 1077.23; Found 
1076.4868 (M+H)+.  
 
 UV-visible absorption assay 
 
2.4.4.1 Materials 
Legumain assay buffer: 50 mM MES hydrate (Sigma, M2933), 250 mM NaCl, pH 5.0; 
Gly-APA-AQ(4,8-di-OH) (NU:UB 51) and Rho-Pro-Ala-Asn-OH 1mg/mL stock in DMSO 





UV-visible absorption spectra of Rho-Pro-Ala-Asn-OH and a bis-hydroxylated propyl 
spaced glycine conjugate (NU:UB 51) was recorded on a DU 800 spectrophotometer, 3 
mL cuvettes. The final concentration of Rho-Pro-Ala-Asn-OH and NU:UB 51 was 20 µM 
in legumain assay buffer and the volume was 3000 µL. The blank legumain assay buffer 
was 3 mL. The wavelength scan was selected and the wavelength range was set between 
350.0 to 700.0 nm and scan speed was set at 1200 nm/min. 
 
 Fluorescence spectroscopy assay 
 
2.4.5.1 Materials 
Legumain assay buffer: 50 mM MES hydrate (Sigma, M2933), 250 mM NaCl, pH 5.0; 
Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) and Rho-Pro-Ala-Asn-OH 1 mg/mL 
stock in DMSO; 3 mL cuvettes.  
 
2.4.5.2 Methods  
Perkin Elmer LS50B luminescence spectrometer was used to measure the fluorescence 
spectra for OM50 and Rho-Pro-Ala-Asn-OH. The maximum excitation wavelength for 
Rho-Pro-Ala-Asn-OH was found to be at 562 nm. The emission was measured in the 
wavelength range between 570 nm and 700 nm; Ex slit: 5.5 nm, Em slit: 5.5 nm and scan 
speed 700 nm/min.  
A solution of Rho-Pro-Ala-Asn-OH concentration 100 µM was made from 1 mg/mL stock 
solution. 15 µL of this solution was mixed with 2985 µL of legumain assay buffer to 
produce a final solution of (3000 µL, 0.5 µM) in the cuvette. In addition, a solution of OM50 
concentration 100 µM was also prepared from 1 mg/mL stock solution and 15 µL of this 
solution was mixed with 2985 µL of assay buffer to produce a final product of (3000 µL, 




separately, however, fluorescence intensity measurements were plotted on the same 
graph to allow for more simplistic comparison between both of them.  
 
 Fluorescence spectroscopy assay of OM50 with 
recombinant human legumain 
 
2.4.6.1 Materials 
Activation buffer: 50 mM Sodium Acetate, 100 mM NaCl, pH 4.0; Recombinant human 
legumain (R&D systems, 2199-CY-010); Assay buffer: 50 mM MES hydrate (Sigma, 
M2933), 250 mM NaCl, pH 5.0; Substrate: Probe OM50, 1mg/mL stock in DMSO; 
Fluorophore: Rho-Pro-Ala-Asn-OH, 1mg/mL stock in DMSO then diluted to 100 µM in 




Activation buffer (100 µL) (pH 4) was added to recombinant human legumain (10 µg) and 
stored at -78OC. aliquot was incubated in a water bath for 2 h at 37OC then diluted to 1 
ng/µL in assay buffer (pH 5). 
 1 2 3 4 
E B B+R B+OM50 B+OM50+L 
F B B+R B+OM50      B+OM50+L 
G B B+R B+OM50 B+OM50+L 
Table 2.1: Arrangement on black 96-well plate for Fluorimetric Assay 
As shown in Table 2.1, in each well: 
E1-G1 100 µL assay buffer (B) 




E3-G3 98.8 µL assay buffer (B) + 1.2 µL 841 µM fluorogenic probe OM50 
E4-G4 58.9 µL assay buffer (B) + 1.2 µL 841 µM fluorogenic probe OM50 + 40 µL 1 ng/µL 
Legumain stock solution (L) 
The final concentrations in each well are: 10 µM of Rho-Pro-Ala-Asn-OH (E2-G2), 10 µM 
of OM50 (E3-G3 + E4-G4) and 40 ng of legumain (E4-G4). 
Emission spectra were recorded at 5 min intervals on a FluoStar Omega multi-mode 
Microplate Reader. The emission was measured in the wavelength range between 544 
nm and 590 nm. Fluorescence intensity measurements were plotted on the same graph 
to allow for more simplistic differentiation between them.  
 
 Confocal microscopy 
 
2.4.7.1 Materials  
HCT-116 (Human colon carcinoma), RPMI 1640 medium containing phenol red; sterile 
NaCl; 35 mm glass bottomed micro well dish (Ibidi/Thistle Scientific); compounds: Gly-
APA-AQ(4,8-di-OH) (NU:UB 51) and Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50). 
LysoTracker Green DND 26 probe and MitoTracker Green FM probe. Live cell imaging 
was performed using Zeiss LSM800 confocal laser scanning microscope with HCX PL 
APO lambda blue (63.0 x 1.4 oil objective). Lasers used were: diode (405 nm), Argon 
(458 nm, 488 nm and 514 nm), HeNe (543 nm), HeNe (543 nm), HeNe (594 nm) and 
HeNe (633 nm). 
 
2.4.7.2 Method 
Stock solutions of tested compounds (1 mg/mL) were prepared in DMSO. HCT-116 (2 x 
105) were seeded in 35 mm glass bottomed micro well dish and incubated for 24 h. Cells 
were washed with PBS x3. For the LysoTracker Green DND 26, a solution of dye (60 nM) 




medium was removed and the cells were washed with sterile NaCl. Then tested 
compound solution was applied to cell culture medium and were imaged live using a Zeiss 
LSM800 confocal laser scanning microscope. For MitoTracker Green FM, a solution of 
dye (50 nM) was added to the cell culture medium and incubated at 37oC for 20 min. After 
20 min the medium was removed and the cells were washed with sterile NaCl. Then 
tested compound solution was applied to cell culture medium and were imaged live using 
a Zeiss LSM800 confocal laser scanning microscope. Lens used was a 63.0 x 1.4 oil-





















































2.5 Structure library 
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All of the research and data presented in this thesis (Chapters 1 and 2) is focused on 
methods to improve drug selectivity for cancer cells by designing and developing novel 
chemotherapeutic agents that actively exploit phenotypic differences between cancer and 
healthy cells and which target features unique to the tumour microenvironment. If 
cytotoxic agents can be made to target cancer cells selectively, this will thereby reduce 
adverse side effects while improving therapeutic efficacy. One approach being used to 
achieve selectivity is to better control drug delivery by using appropriately designed drug 
delivery vehicles (Senapati et al., 2018). Alternatively, in this research project, to achieve 
selectivity, non-vehicle mediated approaches have been used to design new candidate 
drugs or prodrugs in the anthraquinone (anthracenedione) category of cytotoxics (the 
former to be directly imported into intracellular components of the cancer cell and the 
latter to be activated at the cancer cell surface). This chapter describes proven concepts 
that were achieved and summarizes the biological significance of the major research 
findings in relation to the primary objective of improving drug selectivity for cancer cells 
and collated structure-activity relationships drawn from the data. 
3.2 Proof of Concepts 
 
 Proof of Concept 1: selectivity for cancer cell 
mitochondria  
In this project, proof of concept has been demonstrated for selective localization of 
anticancer compounds inside the mitochondria of cancer cells, summarized as illustrated 
in proof of concept Figure 3.1 where novel aminoanthraquinone derivatives have been 




residues. Attaching these cationic residues has made compounds more lipophilic, as 
hypothesized, to improve entry to the cell by taking advantage of the reported high 
membrane potential of mitochondria compared with the plasma membrane (Constance & 
Lim, 2012).  The sub-cellular localization of novel compounds to the target mitochondria 
was shown by confocal microscopy studies (data in Chapter 1 section 1.3.9) 
 
 
Figure 3.1: Illustration of Proof of Concept for mitochondrial targeted drugs. A. Chemical 
synthesis of mitochondrial targeted drug; B. mitochondrial targeted drug and C. confocal image 
which shows the localization of a TPP conjugate drug in mitochondria. 
 
 Biological significance of mitochondrial targeting and 
mechanistic considerations. 
The failure of cancer patients to respond to specific therapeutic treatment can happen 
due to the fact that cancer cells become resistant to a single class of drugs by specific 
metabolism of a drug, loss of a cell surface receptor or transporter for a drug and 
modification by mutation of the specific target of a drug (Longo-Sorbello & Bertino, 2001). 
Also, cancer cells can develop resistance to different classes of drugs that have unrelated 




et al., 2001) and P-gp (drug efflux pump) is commonly involved in the development of 
MDR, overexpressed in the plasma membrane of cancer cells and can be found in 
subcellular regions including the lysosomes, mitochondria and nucleus (Roundhill & 
Burchill, 2012). However, the presence of P-gp is controversial; it has been reported that 
P-gp is not present in mitochondria (Paterson & Gottesman, 2007), but may simply be 
functionally inactive, therefore specific delivery of anticancer drugs to mitochondria could 
avoid drug resistance and consequently increase drug selectivity and efficacy.  
Considerable efforts have already been invested to develop mitochondria-targeted 
compounds to induce cancer cells apoptosis and bypass drug resistance mechanisms. 
Earlier reports have shown mitochondria-specific drug delivery can be achieved by direct 
chemical conjugation of selective anticancer agent with mitochondriotropic ligands, that 
have lipophilicity and delocalization of the positive charge properties such as 
triphenylphosphonium (TPP) (Han et al., 2014). It has been reported that the 
mitochondrial TPP-conjugates accumulate selectivity inside the mitochondria and induce 
cytotoxicity even in resistant cells. In the most closely related example to the work in this 
thesis, Han et al., 2014, conjugated the anthraquinone doxorubicin (DOX) with TPP and 
they studied the cellular distribution and cytotoxicity for both DOX and TPP-DOX 
conjugate. They found that the TPP-DOX conjugate accumulated inside the mitochondria 
compared with DOX alone, which was found to be localized in nucleus and cytoplasm. 
The TPP-DOX induced cytotoxicity in both cell lines MDA-MB-435/WT and DOX resistant 
MDA-MB-435/DOX. This indicates the ability of a TPP conjugate to escape the drug 
resistance and accumulate inside the mitochondria (Han et al., 2014). In addition, Millard 
et al., 2013, conjugated the non-anthraquinone chlorambucil with TPP. The results 
revealed that this TPP conjugate localized to cancer cell mitochondria where it acted on 
mtDNA to inhibit the cell cycle and induce cell apoptosis (Millard et al., 2013). In this 
program of research, anthraquinones (mitoxantrone analogues) were conjugated with 
TPP with the aim of achieving reaching the mitochondria (avoiding the nucleus) and 
similarly inducing apoptosis, which for the aminoanthraquinone class points to mtDNA or 
possibly mtDNA-topoisomerases as targets (given these are counterparts of their known 




In vitro studies revealed that attaching TPP made the anticancer drugs more lipophilic 
and gave the ability to bypass the lipid bilayer of cancer cells and accumulate inside the 
mitochondria. Also, the MTT assay for novel compounds was studied in both high 
resistance HCT-15 and low resistance MCF-7 cell lines, to screen for compounds that 
have the potential to circumvent P-gp drug resistance. The results showed the ability of 
TPP compounds to induce cytotoxicity in both cells lines compared with the unconjugated 
compounds, which suggests this strategy may be able to circumvent multidrug resistance 
in this series.  
Furthermore, lysosomes are another organelle inside the cell which offer an effective 
compartment for targeting anticancer drugs. Cancer cells are more vulnerable to 
lysosomal mediated cell death than normal cells which can be exploited in the design of 
new effective anticancer drugs that enhance lysosomal cell death for example, by 
inhibition of caspase dependent cell death (Halaby, 2019). However, lysosomes were 
suggested to play a significant role in MDR by sequestering protonated hydrophobic weak 
bases from their intracellular targeting site (Zhitomirsky & Assaraf, 2015). Therefore, this 
can be exploited by designing a weak base anticancer drug that can accumulate inside 
the lysosomes and alter its function which in turn could lead to cell death. Herein, OM22 
[TPP-EAE-AQ(4-OH)] was synthesised and found to be localised in lysosomes not in  the 
mitochondia even in the presence of an added lipophilic cation TPP, due to the presence 
of amine group in its side chain, which made OM22, a lipophilic amine (weak base) which 
was trapped or sequestered inside the acidic lysosomes. However, in vitro studies 
revealed that OM22 induced cytotoxicity at low concentration in both high resistance 
HCT-15 and low resistance MCF-7 cell lines. These properties may be due to the  ability 
of OM22 to avoid drug resistance by interfering with lysosome function and induce 
apoptosis. In preliminary apototic studies, OM22 exhibited prominent growth inhibition of 
HCT-116 and cells were shrunken and floating indicating that the cells were dead at all 
tested time points. Therefore, OM22 has the ability to localise inside the lysosomes and 
induce cell death. Groth-pedersen & Jäättelä, 2013  reported that induction of lysosomal 
membrane permeabilization is an effective way to kill resistant cancer cells and the 
enlarged lysosomal in cancer cells make them more vulnerable to cancer drugs compared 




combination of structural features of cationic groups and weakly-basic amine chains in 
OM22 is something that can be exploited further to design lysosomotropic agents and is 
considered worthy of expanding these studies to design more analogues in future. 
As lysosomes in cancer cells are more fragile than normal cells, they are more susceptible 
to lysosomal membrane permeabilization LMP. This fragility may stem in part from their 
high lysosomal iron content (Abok et al., 1983; Persson et al., 2003). Reactive oxygen 
species (ROS) generation can result in destabilisation of lysosomal membranes though 
lipid peroxidation (Persson, et al. 2003). ROS are aerobic respiration byproducts which 
are responsible for maintaining redox homeostasis in cells by antioxidant enzymes, 
reduced thiols and NADP(H) cofactors and it is essential for cancer cells survival and 
progression. Cancer cells exhibit higher metabolic rates and increased iron-containing 
proteins, which lead to the accumulation of iron in lysosomes, which in turn affords iron-
mediated sensitization to ROS and induction of LMP  (Halaby, 2015). Dharmaraja, 2017, 
reported that quinones based compounds such as mitoxantrone and doxorubicin have 
the ability to induce ROS. Therefore, elevating the ROS rates led to disruption of the LMP, 
resulting in release of acid hydrolases, specifically the cathepsins to the cytosol, then 
inducing cell apoptosis (Halaby, 2019). Therefore, the well-known mechanism for iron 
mediated ROS production by anthraquinones and anthracyclines could be a potential 
mechanism of cell death by the anthraquinones OM22 and NU:UB 51.  
Disruption of organelle membranes is a mechanism of cell death that can also apply to 
mitochondria (Via et al., 2014), with outer mitochondrial membrane (OMM) 
permeabilisation followed by release of proteins such as cytochrome C (essential for 
activation of the mitochondrial apoptotic pathway) (Riganti et al., 2013). As with lysosomal 
membrane permeability, generation of ROS have been found to play a role in OMM 
permeabilisation (Webster, 2013). Quinone containing compounds, for example β-
lapachone, induce enhanced ROS via mitochondrial enzyme mediated redox cycling  with 
ROS production leading to mitochondrial oxidative damage, membrane permeabilisation 
and apoptosis (Ma et al., 2015). This mechanism of cell kill could potentially also apply to 




Furthermore, it is known, for example, the triterpenoid betulinic acid triggers RSO 
mediated apoptosis and when conjugated to TPP resulted in a significant increase in 
cytotoxicity compared to unconjugated betulinic acid (Nedopekina et al., 2017). In addition 
to mitochondrial targeting, TPP conjugation to betulinic acid was also used to enhance 
bioavailability, a concept that also applies to many of the compounds synthesised in this 
research programme. For example, NU:UB 238, the aminobutanol anthraquinone 
precursor of SH1, is not taken up by cells and is completely inactive in vitro [and in vivo 
(unpublished data)]  however upon conjugation to TPP, results in compound SH1 with the 
ability to bind with DNA at high affinity and induce cytotoxicity in vitro  at low 
concentrations. In Addition, SH1 was found to be localized in mitochondria and induce 
cell morphological changes, whereas the NU:UB 238 has no ability to enter the cells 
Figure 3.4. 
Uptake of a mitochondrial targeted organometallic ruthenium doxorubicin complex 
(Imstepf et al., 2016) triggered apoptosis and disrupted mitochondrial membrane potential 
and also inhibited topoisomerase II; mechanisms of cell kill that incorporate these dual-
targeting features could also apply to the TPP conjugates such as SH1, OM30, OM31 
and OM32 and further research into these plausible mechanisms is required. 
 
 Proof of Concept 2: selective prodrug activation at the 
cancer cell surface 
In this research programme, a theranostic (therapeutic and diagnostic) prodrug Rho-Pro-
Ala-Asn-Gly-APA-AQ(4,8-di-OH) (OM50) was synthesized, where selectivity was 
achieved by exploiting the proteolytic activity of overexpressed legumain in the cancer 
cell microenvironment. Proof of concept Figure 3.2 illustrates how the cleavage of the 
prodrug OM50 by legumain at the directed cleavage site, resulted in the release of the 
cytotoxic agent, anthraquinone derivative NU:UB 51, accompanied by a large increase in 
rhodamine fluorescence. Confocal microscopy and live cell imaging using HCT-116 colon 




agent (data in Chapter 2 section 2.3.8) These properties make prodrug OM50 a good 
candidate for extracellular activation by secreted legumain.  
 
 
Figure 3.2: Illustration of Proof of Concept for the theranostic prodrug Rho-Pro-Ala-Asn-Gly-APA-
AQ(4,8-di-OH) (OM50) and showing legumain-mediated activation of the prodrug and 
simultaneous release of a rhodamine B-labelled peptide (fluorescent reporter of prodrug 
activation) and cytotoxic agent NU:UB 51 at the tumour cell.  
 
 Biological significance 
Cancer progression is not exclusively due to changes in cancer cells, but also includes 
the tumour microenvironment, which has a notable different character in in cancer cells 
compared with the environment surrounding normal cells. Tumour microenvironment is 
rich in proteolytic activity and it is acidic and hypoxic and includes a wide spectrum of 
proteases that include the cysteine endopeptidase legumain. The tumour 
microenvironment is a favourable environment for protease targeted alteration of 
prodrugs. Additionally, the cellular microenvironment has a role in tumourigenesis which 




specificities for peptide substrates provide a promising tool for designing prodrugs that 
are specifically activated by proteases (in this research, legumain) in the tumour 
microenvironment (Wu et al., 2006). In this programme of work which focused on the 
anthraquinone class of compounds, it was logical to test the combination of achieving 
selective targeting of an anthraquinone by prodrug conversion and extracellular 
activation. Therefore, a theranostic prodrug Rho-Pro-Ala-Asn-Gly-APA-AQ(4,8-di-OH) 
(OM50) was designed and synthesized in this project. The legumain-targeted prodrug 
OM50 employs a three component design which are a cytotoxic topoisomerase inhibitor 
(NU:UB 51) as the active agent and fluorescence quencher, a tripeptide Pro-Ala-Asn 
(substrate sequence) and rhodamine B (as latent fluorophore). In vitro assays were 
performed by incubation of OM50 with human recombinant legumain. Increase in the 
fluorescence intensity of rhodamine emission with time verified that cleavage of OM50 
was taking place by legumain at the predicted C-terminal of asparagine, resulting in the 
release of the active drug NU:UB 51 and rhodamine B-labelled peptide fragment, which 
in turn indicated prodrug activation.  
More cellular localization studies were performed for both OM50 and the active drug 
NU:UB 51 to find the preferred targeting location for both. The results indicated that the 
prodrug OM50 was localized outside the cells in the tumour microenvironment (where the 
legumain is secreted). However, the active drug NU:UB 51 was found to be localized in 
both mitochondria and lysosomes. It has been reported that NU:UB 51 has the ability to 
inhibit topoisomerase IIα and II β mediated decatenation and relaxation of DNA and it 
inhibits topoisomerase I mediated DNA-relaxation. NU:UB 51 produces a tumour volume 
reduction and significant growth delay in a colon tumour model, whereas mitoxantrone 
and doxorubicin produce a simple growth delay with no reduction in tumour volume 
(Mincher, 1999; Turnbull, 2003). Therefore, the new results confirmed the successful 
synthesis of the theranostic prodrug and its activation and these promising results could 
open a new field in the treatment of tumour cells by adding an extra layer of cancer cell 
selectivity by using a prodrug approach to  the anthraquinone class with known in vivo 
activity. These results are consistent with the findings of Løvsletten et al., 2014 who a 
synthesized a legumain-cleavable prodrugs Suc-Ala-Ala-Asn-Val-colchicine. They found 




active legumain and inactive, zymogen prolegumain) than SW620 cells expressing 
prolegumain only. 
 
3.3 Multiple uses of rhodamine B in this research 
Rhodamine B has been used in several different ways throughout this research 
programme and presented in each of chapters 1 and 2; as a delocalized lipophilic cation 
for selective mitochondrial targeting, as a capping group and as a fluorophore in 
theranostic applications Figure 3.3. Rhodamine B is a member of delocalized lipophilic 
cations and it has been used as a carrier for molecules targeting mitochondria because 
of preferential accumulation in this organelle and due to its lipophilic cationic properties 
(Muli et al., 2014). It has been reported that accumulation of rhodamine B conjugate dyes 
inside the cell (mitochondria) is higher than the unconjugated ones due directly to the 
delocalized positive charge of rhodamine B (Ngen et al., 2009). Therefore, rhodamine B 
was conjugated with anthraquinone derivatives for selective targeting to mitochondria. 
However, due to difficulty in purification and stability of rhodamine B conjugates, no 
further in vitro studies were carried out, and TPP conjugates remained the main focus.  
In addition, rhodamine B was used as a fluorescent probe and required some 
modifications such as reaction to form a tertiary amide and locked in the ring-open form 
as in Rho-Pro-OH, due to the sensitivity of ring-open rhodamine B to pH causing loss of 
fluorescence at low pH, whereas when reacted with Pro-OH the fluorescence emission 
remained constant over the measured pH range. Therefore, this technique was employed 
in the design of OM50 in which rhodamine B was used to label the N-terminus of Pro-Ala-
Asn (legumain substrate) and cytotoxic topoisomerase inhibitor NU:UB 51 was linked with 









Figure 3.3: Different uses of rhodamine B in this research 
 
3.4 Structure-activity relationships 
Confocal microscopy proved invaluable when determining subcellular localisation of the 
novel compounds, as summarised in Figure 3.4. These studies indicated that even small 
structural changes led to very marked alterations in the subcellular distribution of the TPP 
conjugates. The chemical structure plays an important role in localization and activity of 
targeting compounds. Shaul et al., (2013) studied the effect of anthracyclines structure 
on the cytotoxicity and the time required for these compounds to exert cytotoxic effects 
on tumor cells. Also the confocal studies indicated that structural differences led to 
differences in subcellular localization (Shaul et al., 2013). All of the TPP compounds 
containing hydrophobic polymethylene alkyl linkers (SH1, OM 30 and OM31) localised 
selectively in the mitochondria, with little or no evidence of lysosomal or nuclear 
accumulation. These observations proved the hypothesis that the novel TPP analogues 
of mitoxantrone can be delivered to and accumulate selectively in mitochondria of cancer 





Figure 3.4: Selective delivery of novel anticancer drugs that have been synthesised in this 
research. 
Although not for anticancer use, similar simple alkyl TPP cations were also used for 
selective delivery of Coenzyme Q and Vitamin E to mitochondria (Smith et al., 2003; Smith 
et al., 1999), In common with SH1, OM30 and OM31, MitoQ and MitoVitE selectively 
accumulated in mitochondria in vitro (Kelso et al., 2001; Smith et al., 2003) and are also 
low molecular weight lipophilic TPP conjugates. In addition to in vitro evaluation, Smith et 
al also carried out in vivo studies on MitoQ and MitoVitE in mice and found that not only 
could TPP deliver potentially therapeutic effective concentrations to mitochondria in vivo, 
the compounds were also able to cross the blood brain barrier (Smith et al., 2003). The 
favourable in vivo profile shown by MitoQ and MitoVitE offers promise for the future 
development of anthraquinone conjugates such as SH1, OM30 and OM31. 
In complete contrast to compounds with simple alkyl linked TPP cations, OM22, 
containing an ethyl-amino-ethyl linker localised selectively in lysosomes Figure 3.4, this 
is despite also containing a TPP delocalised cation. The only structural difference 
between OM22 and the compounds which did selectively target mitochondria [SH1, 
OM30, OM31 and OM32 (containing central oxygen in the linker)] is the presence of the 
secondary amino group in the side chain which appears to lead to ‘over-riding’ of the TPP 




This is rather surprising, as the literature confirms that TPP can be used to transport 
neutral, acid and basic cargos into mitochondria (Finichiu et al., 2013), although the rate 
of accumulation was slower for amine containing compounds. As TPP compounds are 
first accumulated from the extracellular matrix into the cytoplasm, if subsequent uptake 
into mitochondria is relatively slow, there may be competition between mitochondrial and 
lysosomal distribution for amine containing compounds. Although delocalised lipophilic 
cations preferentially accumulate in mitochondria (Guzman-villanueva et al., 2015; Reily 
et al., 2013), weakly basic lipophilic drugs with localised cationic charges are extensively 
sequestered in acidic lysosomes (Zhitomirsky & Assaraf, 2015).  
The observation that the compounds that accumulate in lysosomes are OM22 and NU:UB 
51 might be linked to the presence of the secondary and primary amino groups, 
respectively (they are both weakly basic lipophilic drugs with localised cationic charges). 
It is well known from the literature that weakly basic amine containing drugs diffuse 
through membranes at physiological pH via passive diffusion, once inside the lysosomes, 
the amine containing drugs become protonated and become trapped in lysosomes in their 
cationic state (Derendorf, 2020; Halaby, 2019).  
What is notable from the confocal studies is the absence of nuclear localisation for any of 
the novel anthraquinone compounds synthesised in this research programme. The 
principal mechanism of action for many anthraquinones and anthracyclines, including 
doxorubicin, is usually given as inhibition of DNA topoisomerases (Swift et al., 2006; 
Tacar et al., 2013). In fact, many anthraquinones have now been shown to also 
accumulate in other organelles such as lysosomes (Shaul et al., 2013) and this organelle 
is now proposed to contain additional targets for anthraquinones and anthracyclines 
(Kroemer & Jäättelä, 2005; Kwok & Richardson, 2004) which might also be targets for 
OM22 and NU:UB 51. As these are both cationic drugs, they have the potential to induce 
lysosomal membrane permeability (LMP) and cell death through the release of cathepsins 
into the cytosol (Fennelly & Amaravadi, 2017; Groth-pedersen & Jäättelä, 2013).  
Furthermore, regarding the prodrug aspects of this work, in the synthesis of the prodrug 
OM50, selection of the amino acid residues at the N- and C- terminal is a key point to be 




recognition and cleavage by legumain at the C-terminus (Stern et al., 2009) and proline 
was chosen for position P3 to maintain constant fluorescence once cleaved by legumain 
to lock the rhodamine B in a ring open form by linking it through a tertiary amide bond 
(Beija et al., 2009) Figure 3.4.  
In conclusion, by understanding of the tumour biology, structure-activity relationships and 
by development of specific carriers and/or designing more advanced features such as, 
prodrug and theranostic systems, have led to successful approaches to deliver 
anthraquinone chemotherapeutic agents selectively to the mitochondria or lysosomes of 
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3.6 Appendix  
 




6-(9,10-Dioxo-9,10-dihydroanthracen-1-ylamino)-hexanoic acid pentafluorophenyl ester 
 
HZ22 is an active O-pentafluorophenolate ester, which is a safer and simpler alternative 
to the use of the Kaiser colour test for the detection of a free primary or secondary amino 
group (by amide formation). HZ22 colour test has several advantages over the Kaiser test 
in that it gives a positive result with secondary amines (the Kaiser test does not) and 
avoids the use of extremely toxic potassium cyanide and other hazardous chemicals used 
in the Kaiser test. HZ22 is used to import red resin beads indicate a positive test, for a 
primary or secondary amine. However, resin beads remain clear (not red colour) when 
there are no residual amino groups present.  
 
 
